

Professor Chak-Sing Lau JP

MBChB (Dundee) MRCP (UK) MD (Honours) (Dundee)
FHKCP FHKAM (Medicine) FRCP (Edinburgh) FRCP (Glasgow) FRCP (London)

Chair and Daniel CK Yu Professor
Division of Rheumatology and Clinical Immunology
Department of Medicine
The University of Hong Kong

Chairperson
Department of Medicine
School of Clinical Medicine
Li Ka Shing Faculty of Medicine
The University of Hong Kong

Chief of Service
Department of Medicine
Queen Mary Hospital

Chairman
Board of the Li Ka Shing Faculty of Medicine
The University of Hong Kong

Immediate Past President
Hong Kong Academy of Medicine

PROFILE

Professor Chak Sing Lau

Chairperson, Department of Medicine
Chair & Daniel CK Yu Professor in Rheumatology and Clinical Immunology
The University of Hong Kong

Professor Chak Sing Lau is currently Chairperson of the Department of Medicine, School of Clinical Medicine, and Chairman of the Board of the Li Ka Shing Faculty of Medicine, the University of Hong Kong. He is also Chief of Service of the Queen Mary Hospital Department of Medicine.

Professor Lau graduated MBChB from the University of Dundee in 1985. In 1992, he joined the University of Hong Kong (HKU) as Lecturer in Medicine and successfully rose through the ranks to Senior Lecturer in 1997 and Professor in 2000. He returned to his Alma Mater in 2007 to become the first Chair of Rheumatology of the College of Medicine, Dentistry and Nursing Studies. In 2010, however, he began his second tenure at HKU as Chair Professor and later (2014) Daniel CK Yu Professor in Rheumatology and Clinical Immunology.

Within HKU Medicine, Professor Lau was Assistant Dean in Information Technology and Planning (2001-2004), Assistant Dean in Education and Student Affairs (2005-2007), Director of the Bau Institute of Medical and Health Sciences Education (2010-2018) and Associate Dean for Teaching & Learning (2013-2018). In 2016, he co-led the reform of the MBBS Curriculum incorporating a one-year enrichment experience for all medical students.

Professor Lau has been a major player in rheumatology in Hong Kong and beyond. Locally, he was President of the Hong Kong Society of Rheumatology (1997-2001) and Chairman of the Hong Kong College of Physicians Subspecialty Board in Rheumatology, Immunology & Allergy (2001-2007). In 2001, he founded the Hong Kong Arthritis & Rheumatism Foundation, the first and only local charity organisation that raises funds to support the psychosocial and therapeutic needs of patients with rheumatic diseases. Regionally, Professor Lau co-founded the Asian Congress on Autoimmunity, Huaxia Congress on the Management of Rheumatic Diseases and Ten Topics in Rheumatology in Asia. Notably, he was President of the Asia Pacific League of Rheumatology Associations (APLAR) between 2006-2008. In addition, Professor Lau led the development of the Region's first treatment recommendations for rheumatoid arthritis and axial spondyloarthritis. In 2011, he co-founded the multi-national, multi-centre Asia Pacific Lupus Collaboration. Beyond the Asia Pacific region, Professor Lau is a member of the Outcomes in Rheumatology (1999-2002), European Alliance of Associations for Rheumatology (EULAR) Task Force on Rheumatoid Arthritis Treatment Recommendations (2019) and EULAR Scientific Committee (since 2019). Further, he was selected as an Honorary Member of EULAR in 2022.

Between 2016-2020, Professor Lau was President of the Hong Kong Academy of Medicine, having served as Vice-President (Education and Examinations) in the previous 5 years. Professor Lau sits on numerous strategic committees and working groups of the Food and Health Bureau, Hospital Authority, Department of Health and the Medical Council of Hong Kong.

I. GENERAL INFORMATION

Personal Details

Name Chak-sing Lau

Sex Male

Marital Status Married to Kim with 1 son (Christopher) and 2 daughters (Christine and Emily)

Correspondence Room 410, Professorial Block
Queen Mary Hospital
102 Pokfulam Road
Hong Kong SAR
P.R. China
Tel: (852) 2255-3603
Tel: (852) 2255-3356 (direct)
Fax: (852) 2816-2863
e-mail: cslau@hku.hk

Education History

- 1967 – 1972** St. Francis of Assisi's Primary School, Hong Kong
- 1972 – 1978** St. Stephen's Church College, Hong Kong
- 1978 – 1980** College of Arts and Technology, Newcastle-upon-Tyne, England
- 1980 – 1985** MBChB (University of Dundee, Scotland)
- 1988 – 1993** MD (Honours) (University of Dundee, Scotland)

Employment History

- 08/1985 – 01/1986** House Physician, Walsgrave Hospital, Coventry, England
- 02/1986 – 07/1986** House Surgeon, North Tees General Hospital, Stockton-upon-Tees, England
- 08/1986 – 07/1988** Internal Medicine Rotation, Ninewells Hospital and Medical School, NHS Tayside, Dundee, Scotland
- 05/1992 – 06/1997** Assistant Professor (Lecturer)
Department of Medicine, University of Hong Kong, Hong Kong

- 09/1995 – 06/2007** Honorary Consultant Physician, Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong
- 07/1997 – 06/2007** Honorary Consultant in Medicine / Rheumatology, Department of
01/2010 – present Medicine, Queen Mary Hospital
- 07/1997 – 06/2000** Associate Professor, Department of Medicine, University of Hong Kong
- 07/2000 – 06/2007** Professor, Department of Medicine, University of Hong Kong
- 05/2001 – 02/2004** Assistant Dean, Information Technology & Planning, Li Ka Shing Faculty of Medicine, University of Hong Kong
- 02/2005 – 02/2007** Assistant Dean, Education and Student Affairs, Li Ka Shing Faculty of Medicine, University of Hong Kong
- 07/2007 – 12/2009** Chair of Rheumatology, Division of Medical Sciences, College of Medicine, Dentistry and Nursing Studies, University of Dundee, United Kingdom
- 01/2010 – present** Professor and Chair of Rheumatology and Clinical Immunology, Department of Medicine, University of Hong Kong
- 11/2010 – 11/2018** Director, Bau Institute of Medical and Health Sciences Education, Li Ka Shing Faculty of Medicine, University of Hong Kong
- 08/2013 – 07/2018** Associate Dean (Teaching and Learning), Li Ka Shing Faculty of Medicine, University of Hong Kong
- 12/2018 – present** Chief of Service, Department of Medicine, Queen Mary Hospital, Hong Kong
- 04/2019 – present** Chairperson, Department of Medicine, School of Clinical Medicine, University of Hong Kong
- 10/2019 – present** Chairman, Board of the Li Ka Shing Faculty of Medicine, University of Hong Kong
- 06/2019 – present** Chief of Specialty, General Medicine, Gleneagles Hospital Hong Kong
- 07/2020 – present** Clinical Stream Coordinator (Medical)
Hong Kong West Cluster

Postgraduate Qualifications and Honorary Fellowships

- 1988** Member of the Royal College of Physicians (UK)
- 1992** Fellow (International) of the American College of Rheumatology
- 1993** Doctor of Medicine with Honours (University of Dundee)
- 1993** Fellow of the Hong Kong College of Physicians
- 1993** Founding Fellow of the Hong Kong Academy of Medicine (Medicine)
- 1998** Fellow of the Royal College of Physicians of Edinburgh
- 1999** Fellow of the Royal College of Physicians and Surgeons of Glasgow
- 2001** Fellow of the Royal College of Physicians of London
- 2017** Honorary Fellow of the American College of Physicians
- 2017** Honorary Fellow of the Academy of Medicine, Singapore
- 2017** Honorary Fellow of the Singaporean College of Physicians
- 2017** Honorary Fellow of the Royal College of Physicians of Thailand
- 2018** Honorary Fellow, Academy of Medicine of Malaysia
- 2018** Honorary Fellow, Royal College of Physicians of Ireland
- 2021** Honorary Fellow, Hong Kong Academy of Medicine
- 2022** Honorary Member, European Alliance of Associations for Rheumatology (EULAR)

Visiting / Honorary Professorship

- 1995** Division of Rheumatology, University of California, Los Angeles, USA
- 1996** Division of Rheumatology, Renji Hospital, Shanghai Second Medical University, Shanghai, China
- 1996** Department of Rheumatology, People's Liberation Army Hospital, Beijing, China

- 1998** Department of Medicine, First Military Hospital, Guangzhou, China
- 2005** Division of Rheumatology & Immunology, Foshan First People's Hospital, Foshan, Guangdong, China
- 2016** Central South University, Changsha, China
- 2016** Peking Union Medical College, China
- 2018 - 2021** The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

Awards and Recognitions

- 1991** Registrars Research Prize, Royal College of Physicians and Surgeons of Glasgow
- 1996** Young Investigator Award, Department of Medicine, University of Hong Kong
- 1999** Best Scientific Research Paper Award, Hong Kong College of Physicians
- 2002** Faculty Teaching Medal, University of Hong Kong
- 2014** Outstanding Team: Hong Kong West Cluster cum Queen Mary Hospital (As clinical lead)
- 2016 - 2019** APLAR Center of Excellence for Research, Training and Education and Patient Care Award (As academic lead)
- 2018** Outstanding Community Service Award, Hang Seng-Regeneration Society
- 2018** Justice of the Peace, The Government of Hong Kong Special Administrative Region, China
- 2019** Teaching Innovation Award 2019, University of Hong Kong (As team lead)
Re-imagining Medical Education: An Enrichment Year in the Core MBBS Curriculum
(Other members: Dr Julie Y. Chen, Professor Gilberto K.K. Leung, Dr George L. Tipoe and Dr Gordon T.C. Wong of the Li Ka Shing Faculty of Medicine)
- 2021** Excellent Research Award, Health Research Symposium 2021
Project titled “Validation of a new definition of lupus low disease activity state (LLDAS): Clinical and management implications”
(Project No. 12132961)

II MEMBERSHIP OF ACADEMIC AND PROFESSIONAL ORGANISATIONS

Academic Organisations

- 1985 – 1992** *British Medical Association*
Member
- 1989 – 1992** *Scottish Society for Experimental Medicine*
Member
- 1989 – 1992** *Dundee Forum in Rheumatology*
Member
- 1988 – present** *Royal College of Physicians of Edinburgh*
Collegiate Member (1988 – 1998)
Fellow (1998 – present)
- 1988 – present** *Scottish Society for Rheumatology*
Member
- 1989 – 2004** *British Society for Haemostasis and Thrombosis*
Member
- 1989 – present** *British Society for Rheumatology*
Member
- 1992 – 1996** *American College of Angiology*
Fellow
- 1992 – present** *American College of Rheumatology*
Fellow (International)
- 1992 – 2018** *Asia-Pacific League of Associations for Rheumatology*
Member (1992 - present)
Deputy Secretary General (2000 – 2002)
Secretary General (2002 – 2004)
President-elect (2004 – 2006)
President (2006 – 2008)
Immediate Past President (2008 – 2010)
Chairman of the Education Committee (2012 – 2018)
Convener of the APLAR Treatment Recommendations Committee
(2015 – 2018)
- 1992 – present** *Hong Kong Society of Rheumatology*
Member (1992 – present)
Honorary Secretary and Council Member (1994 – 2005)
President (1997 – 2001)
Honorary Advisor (2005 – present)

- 1992 – 2000** *University Medical Doctors' Association, Hong Kong*
 Member (1992 – 1994)
 Honorary Treasurer (1994 – 1996)
 Vice-Chairman (1996 – 1997)
Chairman (1997 – 2000)
- 1992 – present** *Hong Kong College of Physicians*
 Fellow (1992 – present)
Chairman of Scientific Subcommittee (2004 – 2007)
 Council Member (2004 – 2007; 2010 – 2016)
Chairman of Examination Committee (2010 – 2016)
- 1992 – present** *Hong Kong Medical Association*
 Member
- 1993 – present** *Hong Kong Society for Immunology*
 Member
- 1993 – present** *Hong Kong Academy of Medicine*
 Founding Fellow (1993)
 Vice-President and **Chairman, Education Committee** (2011 – 2016)
President (2016 – 2020)
Chairman, Foundation Fund (2021-present)
- 1994 – 2017** *Subspecialty Board in Rheumatology/Immunology & Allergy, Hong Kong College of Physicians*
 Committee Member (1994 – 1996)
 Secretary (1996 – 2001)
Programme Director (1996 – 2007)
Chairman (June 2001 – 2007)
 Board Member (July 2011 – June 2017)
- 1994 – present** *Hong Kong Institution of Science*
 Member
- 1995 – 2001** *The Federation of Medical Societies of Hong Kong*
 Council member (1995 – 2001)
Chairman, Education Committee (1997 – 1999)
- 1997 – present** *The Hong Kong Society for Rehabilitation*
 Member (1997 – present)
 Honorary Advisor (2016 – 2022)
- 1998 – present** *Hong Kong-Guangzhou Rheumatology Study Group*
Co-founder
- 1999 – present** *Huaxia (China, Taiwan and Hong Kong) Congress on Diagnosis and Management of Rheumatic Diseases*

- 1999 – present** **Co-founding Chairman**
Royal College of Physicians and Surgeons of Glasgow qua physician
Fellow
- 1999 – 2000** *Asia-Pacific Arthritis and Rheumatism Council*
Chairman
- 1998 – 2001** *Conjoint Specialty Board in Geriatric Medicine / Rehabilitation*
Medicine, Hong Kong College of Physicians
Member (Rehabilitation Medicine)
- 1998 – 1999** *Medical Society, University of Hong Kong*
Honorary President
- 1999 – 2001** *Huaxia Education Council for Rheumatism and Arthritis*
Chairman (1999 – 2000)
Member (2000 – 2001)
- 1999 – 2002** *Outcome Measures in Rheumatology (OMERACT) Scientific Advisory*
Committee
Member
- 2001 – present** *Royal College of Physicians of London*
Fellow
- 2001 – present** *International Rheumatoid Arthritis Database*
Member of the Steering Committee
- 2005 – present** *Asian Congress of Autoimmunity*
Co-founding Chairman
- 2005 – 2007** *Hong Kong Specialist Medical Association*
Council Member
- 2006 – present** *Japan College of Rheumatology*
International Advisor
- 2006 – 2008** *International League of Associations for Rheumatology*
Council Member
- 2008 – present** *British Isles Lupus Assessment Group*
Member
- 2008 – 2014** *Ten Topics in Rheumatology in Asia*
Co-founding Chairman
- 2010 – 2012** *Stem Cell and Regenerative Medicine Consortium, Hong Kong*
Member

- 2011 – 2017** *Subcommittee in Clinical Pharmacology & Therapeutics, Hong Kong College of Physicians*
Subcommittee Member
- 2011 – present** *International Scientific Committee of Excellence in Rheumatology*
Member
- 2012 – 2013** *U21 Health Sciences Group*
Scientific Committee Member
- 2012 – present** *Asia Pacific Lupus Collaboration*
Co-founder and member of the Executive Committee
- 2015 – present** *The Hong Kong Institute of Allergy*
Council member
- 2016 – 2018** *SLE Special Interest Group of APLAR*
Convenor
- 2019** *European Alliance of Associations for Rheumatology Task Force on RA Management Recommendations*
Member
- 2019 - present** *European Alliance of Associations for Rheumatology Scientific Committee*
Co-opted Member
- 2019 - present** *Integrative Joint Organizational Platform, Hong Kong Association for Integration of Chinese-Western Medicine (IJOP)*
Adviser
- 2020 - present** *Management Committee of International Association of Medical Regulatory Authorities (IAMRA)*
Member
- 2021 - present** *Korean College of Rheumatology*
Fellow

Industry Consultancy

- 1998** Asia Pacific Arthritis Advisory Board
Merck
- 1998** Asia-Pacific Working Party on NSAID GI Toxicity: Epidemiology, Treatment, Prevention and New Developments in Anti-inflammatory Therapy
Boehringer Ingleheim, Merck Sharpe & Dohme and Searle
- 2004** Asia Pacific Advisory Board
Aspreva
- 2004** Zolendronate Multi-centre Studies
Novartis
- 2005** Data Management Committee, Centocor Golizulimab Multicentre Studies
Johnson & Johnson
- 2005** Asia Pacific Arthritis Advisory Board
Wyeth
- 2008** European SLE Expert Group
Wyeth
- 2010** ‘Treat to Target’ Advisory Board in Asia
Abbott
- 2010** Asia Pacific Advisory Board for Rheumatoid Arthritis
Roche
- 2010** Benlysta Asia Pacific Advisory Board
GlaxoSmithKline and Human Genome Sciences
- 2010** Asia Rheumatology Advocacy Workshop
Pfizer
- 2011** Asia Rheumatology Expert Advisory Council for Health (Asia REACH)
Pfizer
- 2011** Emerging Arthritis Therapies (EARTH) Asia Regional and Global Advisory Panel
Pfizer
- 2011** Fostamatinib in SLE Scientific Advisory Board
Astrazeneca

- 2012** Actemra Monotherapy Advisory Board
Roche
- 2012** Asia Pacific Rheumatoid Arthritis Pre-Approval Advisory Board
UCB
- 2013** AMG 557/MEDI5872 Clinical Research Advisory Board
Amgen
- 2014** Asia Autoimmune Advisory Board
Eli Lilly
- 2015** Hong Kong Inflammation & Immunology Advisory Board
Celegene
- 2016** T2T Global Summit
Abbvie
- 2018** CollAboRatE Coalition
Janssen
- 2021** Hong Kong Upadacitinib Advisory Board
Abbvie
- 2021** Asia-AFME Advisory Board
Pfizer

III. MEMBERSHIP OF EDITORIAL BOARDS

- 1995 – 1999** *Medicine International (Far East Edition)*
Member of the Editorial Advisory Board
- 1996 – 1999** *The Hong Kong Medical Diary*
Member of the Editorial Board
- 1997** *Medical Directory, The Federation of Medical Societies of Hong Kong*
Editor
- 1997 – present** *Medicine Digest*
Member of the Editorial Advisory Board
- 1999 – 2000** *Articulate, Asia Pacific Arthritis and Rheumatism Council*
Editor-in-Chief
- 2002 – present** *Clinical Rheumatology*
Member of the Editorial Board
- 2002 – present** *Inflammopharmacology*
Member of the Editorial Board
- 2004 – 2012** *International Journal of Rheumatic Diseases*
Editor-in-chief
- 2005 – present** *Internet Journal Rheuma21st.com*
Member of the Editorial Board
- 2006 – present** *Nature Reviews Rheumatology*
International Advisor
- 2009 – present** *Indonesian Journal of Rheumatology*
Member of the Editorial Board
- 2009 – present** *Lupus*
Member of the Editorial Board
- 2011 – present** *Arthritis Research and Therapy*
Member of the Commissioning Advisory Group
- 2013 – present** *Indian Journal of Rheumatology*
Member of the Editorial Board
- 2015 – 2018** *Rheumatology Practice and Research*
Editor-in-Chief

2015 – present *International Journal of Molecular Sciences*
Member of the Editorial Board

2021 – present *Rheumatology & Autoimmunity*
Advisory Editorial Board Member

2021 – present *Rheumatology and Immunology Research*
Member of the Editorial Board

IV. RESEARCH ACTIVITIES

Bibliometrics (March 2022)

Scopus h-index 56; **Total citations** 11,431;

Google h-index 68; **i10 index** 211; **Total citations** 16,853

Membership / as grant reviewer of major research funding bodies

- Since 2000** *Research Grants Council (University Grants Committee), Hong Kong*
Reviewer
- 2004** *Singapore Anti-tuberculosis Association (Singapore)*
Reviewer
- 2007 – 2008** *National Medical Research Council (Singapore)*
Reviewer
- Since 2008** *Medical Research Council (UK)*
Reviewer
- Since 2012** *Health and Medical Research Fund, Food and Health Bureau, Hong Kong SAR*
Member of the Referee Panel
Reviewer
- 2013** *Dutch Arthritis Association*
Reviewer
- 2015** *The Netherlands Organisation for Scientific Research*
Reviewer
- 2016 – 2021** *Expert Panel of Central Research Working Group (CRWG) for Hospital Authority*
Member
- Since 2017 – present** *Research Council (RC), Health and Medical Research Fund, Food and Health Bureau, Hong Kong SAR*
Member
- 2018** *The Dutch Organisation for Health Research and Development*
Reviewer

2019 - present *University Research Committee (URC)'s
URC Research Support and Grants Sub-Committee
Member
Conference, Fellowship and Other Travel Sub-Group
Member*

Research staff supervised

Assistant professor Dr Vera Chan (Current)

Post-doctoral fellows Dr Rong Fu (Dr Cheng Yu Tung Fellow 2004 – 2005)
Dr Ou Jin (Dr Cheng Yu Tung Fellow 2002 – 2003)
Dr Frankie Ko
Dr Ian KY Lam
Dr Michelle WM Li
Dr Feng Liu (Mrs. Ivy Wu Fellow 2002 – 2003)
Dr Xueyan Liu
Dr Mehran Rahmani
Dr Y Ren
Dr KK Tong
Dr Mallik Uzzwal (APLAR Fellow)
Dr Selena Yan
Dr Geng Yin (Visiting Clinical Research Fellow)

PhD candidates supervised

Mr Eddie WK Ip The role of monocyte-derived dendritic cells and mannose-binding lectin in innate immunity against apoptotic cells and candida albicans (2003)

Miss Eli MY Chu Arthritis impact measurement scales 2: Translation, validation, utilization in clinical studies and the development of a short form (2003)

Dr Ou Jin The role of peripheral dendritic cells in systemic lupus erythematosus (2007)

Dr Ying Jie Nie Defective dendritic cells and mesenchymal stromal cells in systemic lupus erythematosus and the potential of mesenchymal stromal cells as cell-therapy (2009)

Miss Selina Sheng Yan Plasmacytoid dendritic cells: Their functional abnormalities and regulatory mechanisms in the development of systemic lupus erythematosus (2013)

- Miss Haijing Wu** The generation of tolerogenic dendritic cells in systemic lupus erythematosus and study of their mechanisms of action and therapeutic application in a lupus mouse model (2013)
- Miss Gloria Gao** Cognition dysfunction and disease and non-disease associated factors in systemic lupus erythematosus: longitudinal perspectives (2015)
- Mr Ian KY Lam** Characterisation of expression and function of dectin-1 on monocyte-derived dendritic cells in patients with systemic lupus erythematosus (2015)
- Dr Christopher YH See** An investigation of medical student culture and attitudes towards e-learning in Hong Kong and the implications for medical education (2017)
- Miss Ada LY Yim** Dendritic cell abnormalities and their contributions in systemic lupus erythematosus (2017)
- Dr Alexander MH Leung** The utility of patient-based disease activity score for routine practice in rheumatoid arthritis (2018)
- Miss Jia Xin Chow** Regulation of inflammasome activation in systemic lupus erythematosus (Current)
- Miss Jie Ma** Dysregulation of neutrophils in systemic lupus erythematosus (Current)

MD candidates supervised

- Dr CC Mok** Gender, sex hormones and systemic lupus erythematosus (2002)
- Dr MY Mok** Endothelial dysfunction and vascular disease in systemic sclerosis (2011)
- Dr Anselm Mak** Major organ damage in systemic lupus erythematosus (2011)
- Dr Roger CM Ho** The relationship between systemic lupus erythematosus and psychiatric morbidity (2015)
- Dr Jason PY Cheung** Development of spinal stenosis: From bedside to bench (2019)
- Dr HY Chung** Improving spondyloarthritis management (2021)
- Dr Billy Lai** Neuropsychological comorbidities in patients with psoriatic arthritis (Current)

Dr Philip H Li Penicillin allergy (Current)

Dr H So Anti-MDA5 Syndrome (Current)

MPhil candidates supervised

Miss Eva YW Ho Effects of gandoderma lucidum on rheumatoid synovial fibroblasts (2003)

Miss Sushma Kavikondala Dendritic cell and B cell interactions in systemic lupus erythematosus (2007)

Mr Daniel TW Luk The role of dectin-1 expressing dendritic cells in the pathogenesis of systemic lupus erythematosus (2011)

Mr Christopher CP Lee Exploring chemokines and cytokines as biomarkers for lupus nephritis (2016)

MSc candidates supervised

Miss Susan Ma Expression of cytokine receptors on peripheral blood lymphocytes in rheumatoid arthritis (1998)

Mr Joseph Yeung Effects of triptolide and its analogues on the proliferation and IL-6 production of rheumatoid arthritis human synovial fibroblasts (2000)

MRes (Medicine) / MMedSc candidates supervised

Miss Christie SK Kam Detection of anti-nuclear antibody responses induced by dendritic cells that have captured dying cells in mouse models (2003)

Miss Rosie HY Fan Cost of systemic lupus erythematosus in Hong Kong (2005)

Dr Anselm Mak Adrenomedullin in systemic lupus erythematosus (2006)

Mr Alfred Lee Validation of a novel definition of low disease activity state in systemic lupus erythematosus (2016)

Mr Andy Ka Chun Kan Secondary Immunodeficiency in Hong Kong (Current)

Mr Gavin SY Sze Exploring the potential non-coding RNAs as biomarkers for systemic lupus erythematosus (Current)

Mr Siqi Wang The association of long non-coding RNA LINC02207 transcript variants with systemic lupus erythematosus (Current)

BSc dissertations supervised

Eric WY Kwong The immunology of lupus nephritis (1995)

CH Lo The immunology of rheumatoid arthritis (1995)

Miss Laura Thomson An investigation of microvascular endothelial function in patients with systemic lupus erythematosus (2009)

As examiner of the following post-graduate student theses / dissertations:

1. Miss Christa Ho (MSc Immunology, University of Hong Kong) – Effects of triptolide and its synthetic analogues on the functions of human lymphocytes (as internal examiner) (1997)
2. Mr TF Liu (PhD, University of Hong Kong) – Interleukin 12 and systemic lupus erythematosus (as internal examiner) (1998)
3. Mr Eddie Ip (MPhil, University of Hong Kong) – Mannose binding lectin gene polymorphism in systemic lupus erythematosus (as internal examiner) (1999)
4. Ms WH Ling (PhD, Chinese University of Hong Kong) – Anti-idiotypic antibody production to transgene-encoded antibody in mice (as external examiner) (1999)
5. Mr Joe Yeung (MSc Immunology) - Effects of triptolide on synovial cell interleukin-1 β induced IL-6 production and MAP Kinase activity (as internal examiner) (2000)
6. Miss KY Lee (MSc Immunology, University of Hong Kong) – Anti- β 2 glycoprotein I antibodies in systemic lupus erythematosus (as internal examiner) (2000)
7. Dr KP Leong (MD, National University of Singapore) – Anti-phospholipid antibody syndrome in Chinese patients with systemic lupus erythematosus (as external examiner) (2001)
8. Mrs EM Liu (PhD, University of Hong Kong) – The development of cord blood monocyte-derived dendritic cells (as internal examiner) (May 2002)
9. Dr KH Leong (MD, National University of Singapore) – Dyslipidemia in systemic lupus erythematosus (as external examiner) (July 2002)

10. Ms Eli Chu (PhD, University of Hong Kong) – Health assessment in Chinese arthritis patients (as internal examiner) (2003)
11. Mr KP Kong (MPhil, University of Hong Kong) – Association of PD-1 gene polymorphisms with systemic lupus erythematosus (as internal examiner) (2003)
12. Mr WP Chong (MPhil, University of Hong Kong) – Association of interleukin 10 promoter polymorphisms with systemic lupus erythematosus (as internal examiner) (Aug 2003)
13. Miss Irene YW Cheng (MPhil, University of Hong Kong) – Treatment of knee osteoarthritis with lyprinol in Chinese patients: A double-blind randomised, placebo-controlled trial (as internal examiner) (Aug 2003)
14. Ms H Guo (PhD, University of Hong Kong) – Effects of anti-DNA antibodies on pleural mesothelial cells: In vitro studies to explore the pathogenetic mechanism of pulmonary lupus (as internal examiner) (Aug 2003)
15. Miss Christy SK Kam (MMedSc, University of Hong Kong) – Detection of anti-nuclear antibody responses induced by dendritic cells that have captured dying cells in lupus and non-lupus mouse models (as internal examiner) (2004)
16. Dr MK Yiu (MMedSc, University of Hong Kong) – Effects on 0.1% olopatadine ophthalmic solution on tear histamine levels in the conjunctival allergen challenge model (as internal examiner) (2004)
17. Mr Eric KP Kong Pang (MPhil, University of Hong Kong) – Association of PD-1 gene polymorphisms with systemic lupus erythematosus (as internal examiner) (2005)
18. Mr M Liang (PhD, University of Hong Kong) – Induction and regulation of autoimmune responses by dendritic cells upon interaction with dying cell sin murine models (as internal examiner) (2005)
19. Mr HP Ng Pong (PhD, University of Hong Kong) – Development of murine model of autoimmune thyroiditis induced with homologous thyroid peroxidase and ascertainment of immune tolerance in transgenic mice that overexpress mTPO in the thymus (as internal examiner) (Jun 2005)
20. Dr SK Tin (PhD, National University of Singapore) – Novel disease severity factors in systemic lupus erythematosus: A profile of mannose binding lectin gene polymorphisms, nephrin autoantibodies and brain-reactive autoantibodies (as external examiner) (2005)
21. Ms ZM Zhang (PhD, University of Hong Kong) – The role of B cell activating factor in B cell development and autoimmunity (as internal examiner) (Oct 2006)

22. Mr KW Shek (MPhil, University of Hong Kong) – DNASE2, CR2, TYK2 genes polymorphisms in systemic lupus erythematosus (as internal examiner) (July 2007)
23. Miss HO Siu (MPhil, University of Hong Kong) – The role of interferon regulatory factor 5 gene polymorphisms in systemic lupus erythematosus (as internal examiner) (August 2007)
24. Miss CW Lit (PhD, The Chinese University of Hong Kong) – Systemic lupus erythematosus: From immunology to viral pathogenesis (as external examiner) (December 2007)
25. Mr WP Chong (PhD, University of Hong Kong) – Tolerogenic and inflammatory properties of natural killer cells after interaction with apoptotic cells and immunoglobulin G opsonised apoptotic cells (as external examiner) (January 2008)
26. Miss TY Chong (MPhil, Chinese University of Hong Kong) – Studies of toll-like receptors, intracellular signalling molecules, CD26, T helper 17 cells and B cell chemokine medical pathological mechanisms in systemic lupus erythematosus (as external examiner) (March 2008)
27. Dr Adelle Dawaon (MD, University of Dundee) – The epidemiology of left ventricular abnormalities in type 2 diabetes mellitus: Does BNP have a role in their detection? (as internal examiner) (May 2008)
28. Dr SL Lui (PhD, University of Hong Kong) – Therapeutic potential of rapamycin in renal parenchymal diseases – insights from murine models of lupus nephritis, adriamycin nephropathy, and renal ischaemia reperfusion injury (as external examiner) (2009)
29. Dr Bernat Galarraga (PhD, University of Dundee) – Effect of anti-rheumatic therapy, folic acid supplementation and allopurinol on surrogate markers of cardiovascular disease in rheumatoid arthritis (as internal examiner) (2009)
30. Mr Martin Li (PhD, The Chinese University of Hong Kong) – Genetic associations of rheumatoid arthritis in Chinese (as external examiner) (November 2010)
31. Mr M Lin (PhD, University of Hong Kong) – The critical role of toll-like receptor 4 in diabetic nephropathy (as internal examiner) (January 2011)
32. YK Chang (MRes[Med], University of Hong Kong) – Genetic susceptibility for systemic lupus erythematosus from genome-wide association studies – BANK1 as an example (as internal examiner) (June 2011)
33. Ms LV Fengjuan (PhD, University of Hong Kong) – Potential of bone marrow and umbilical cord derived mesenchymal stem cells in intervertebral disc repair (as internal examiner) (April 2012)

34. Miss M Yang (PhD, University of Hong Kong) – Role of regulatory B cells in autoimmune disease (as internal examiner) (June 2012)
35. Dr KH Chan (PhD, University of Hong Kong) – Clinical features, diagnosis and immunopathogenesis of neuromyelitis optica spectrum disorders (as internal examiner) (July 2012)
36. Miss A L Lim (Mphil, University of Hong Kong) – Shedding of kidney injury molecule-1 by kidney proximal tubular epithelial cells: The role of matrix metalloproteinase-3 (as internal examiner) (Oct 2012)
37. Mr L Shao (PhD, University of Hong Kong) – Study on the role of CD4⁺CD25⁺ regulatory T cells in acute and chronic graft-versus-host disease in murine models (as internal examiner) (Dec 2012)
38. Mr T Ren (PhD, National University of Singapore) – Functional brain imaging, cognitive dysfunction and anti-NR2 antibodies in patients with non-neuropsychiatric systemic lupus erythematosus (as external examiner) (Dec 2012)
39. Dr RF Chen (PhD, The University of Sydney) – Immune responses to Sm peptides in the diagnosis and monitoring of systemic lupus erythematosus (as external examiner) (April 2013)
40. Dr Elaine YN Cheung (MD, University of Hong Kong) – Osteoporosis in Hong Kong: Important issues in prevention, assessment and treatment (as internal examiner) (April 2015)
41. Dr YY Leung (MD, The Chinese University of Hong Kong) – The clinical importance and instruments for outcome measurement in psoriatic arthritis (as external examiner) (June 2016)
42. Dr Marco HK Ho (MD, University of Hong Kong) – Clinical care of food allergy and food anaphylaxis in children (2016)

V. PUBLICATIONS

Conference abstracts are not listed but can be made available upon request.

Original Articles

	<u>Journal impact factor</u>
1. M McLaren, <u>CS Lau</u> , CD Forbes, JJF Belch. Seasonal variation in fibrinolysis in patients with rheumatoid arthritis. Fibrinolysis 1990; (4) 2: 1161117.	0.5
2. CC Lang, <u>CS Lau</u> , JJF Belch, AD Struthers. Effect of atrial natriuretic factor on platelet function in whole blood ex-vivo in man. European Journal of Clinical Pharmacology 1990; 39: 589-591.	2.953
3. <u>CS Lau</u> , C Gallacher, P Ross, JJF Belch. Rheumatoid arthritis – snake oil or fish oil? Rheumatology (Oxford) 1991; 30: 72-73.	7.580
4. JJF Belch, <u>CS Lau</u> , W Shaw, M McLaren. Oxygen free radical generation following angioplasty for peripheral vascular disease. In: La Chirurgia Vascolare nella Comunità Economica Europea. Eds: D. Palombo, P. Brustia, Domenico Palombo, Valle D'Aosta 1991: 127-128.	-
5. <u>CS Lau</u> , M McLaren, A Saniabadi, N Scott, JJF Belch. The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis – a preliminary study. Clinical and Experimental Rheumatology 1991; 9(3): 271-273.	4.473
6. <u>CS Lau</u> , M McLaren, JJF Belch. Factor VIII von Willebrand Factor antigen levels correlate with symptom severity in patients with Raynaud's phenomenon. Rheumatology (Oxford) 1991; 30(6): 433-436.	7.580

7. CS Lau, F Khan, M McLaren, A Bancroft, M Walker, JFF Belch. 2.631
The effects of thromboxane receptor blockade on platelet aggregation and digital skin blood flow in patients with secondary Raynaud's syndrome.
Rheumatology International – Clinical and Experimental Investigation 1991; 11: 163-168.
8. CS Lau, N Scott, W Shaw, JFF Belch. 2.789
Increased activity of oxygen free radicals during reperfusion in patients with peripheral arterial disease undergoing percutaneous peripheral artery balloon angioplasty.
International Angiology 1991; 10: 244-246.
9. JFF Belch, CS Lau, CD Forbes. 4.965
Iloprost and risk of thrombo-embolism.
American Journal of Medicine 1991; 91(6): 666-667.
10. CC Lang, CS Lau, JJ Belch, AD Struthers. 4.335
The effect of atrial natriuretic factor on platelet function ex vivo in man
British Journal of Clinical Pharmacology 1991.
PMID: 2151320. DOI: [10.1007/BF00316102](https://doi.org/10.1007/BF00316102)
11. CS Lau, A O'Dowd, JFF Belch. 19.103
White blood cell activation in the Raynaud's phenomenon of systemic sclerosis and vibration induced white finger syndrome.
Annals of the Rheumatic Diseases 1992; 51: 249-252.
12. CS Lau, AB Bridges, A Muir, N Scott, A Bancroft, JFF Belch. 7.580
Further evidence of white cell activation in patients with Raynaud's phenomenon.
Rheumatology (Oxford) 1992; 31: 375-380.
PMID: 1312815. DOI: [10.1136/ard.51.2.249](https://doi.org/10.1136/ard.51.2.249)
13. CS Lau, AB Bridges, A Muir, N Scott, A Bancroft, JJ Belch. 7.580
Further evidence of increased polymorphonuclear cell activity in patients with Raynaud's phenomenon.
Rheumatology (Oxford) 1992; 31(6):375-80.
PMID: 1596699. DOI: [10.1093/rheumatology/31.6.375](https://doi.org/10.1093/rheumatology/31.6.375)
14. J Keys, P Beardon, CS Lau, CC Lang, DG McDevitt. 5.344
General practitioner use of non-steroidal anti-inflammatory drugs in Tayside and Fife regions.
Journal of the Royal Society of Medicine 1992; 85: 442-445.

15. AR Saniabadi, TC Fisher, CS Lau, A Bridges, J Taylor, JJF Belch, CD Forbes. 2.953
Dipyridamole increases human red cell deformability.
European Journal of Clinical Pharmacology 1992, 42(6): 651-654.
16. JJF Belch, P Ross, CS Lau, 7.58
Authors' reply.
Rheumatology, Nov 1992, 31(11), 789.
<https://doi.org/10.1093/rheumatology/31.11.789>
17. CS Lau, JJF Belch. 4.711
The in vitro free radical scavenging effects of tenidap, a dual
cyclo-oxygenase and 5-lipoxygenase inhibitor – a preliminary study.
Mediators of Inflammation 1993, 1(2): 141-143.
18. CS Lau, JJF Belch, R Madhok, H Cappell, A Herrick, 4.473
M Jayson, JM Thompson.
A randomised double-blind group comparative placebo controlled
study to assess the efficacy and tolerance of cicaprost, an oral
prostacyclin analogue, in the treatment of Raynaud's syndrome
secondary to systemic sclerosis.
Clinical and Experimental Rheumatology 1993; 11(1): 30-40.
19. CS Lau, M McLaren, M Walker, JJF Belch. 3.641
Increased whole blood platelet aggregation in patients with
Raynaud's phenomenon with or without systemic sclerosis.
Scandinavian Journal of Rheumatology 1993; 22: 97-101.
20. CS Lau, M McLaren, M Walker, JJF Belch. 19.103
Baseline plasma fibrinolysis and its correlation with clinical
manifestations in patients with Raynaud's phenomenon.
Annals of the Rheumatic Diseases 1993; 52: 443-448.
21. JJF Belch, M McLaren, CS Lau, AR Saniabadi, A Bancroft, 4.335
J McEwen, JM Thompson.
Cicaprost, an orally active prostacyclin analogue: its effects on
platelet aggregation and skin blood flow in normal volunteers.
British Journal of Clinical Pharmacology 1993; 35: 643-647.
22. CS Lau, KD Morley, JJF Belch. 7.580
Effects of Maxepa fish oil supplementation on non-steroidal anti-
inflammatory drug requirement in patients with mild rheumatoid
arthritis – a double blind placebo controlled study.
Rheumatology (Oxford) 1993; 32: 982-989.

23. CS Lau, M McLaren, J Hanslip, M Kerr, JJF Belch. 19.103
Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitis.
Annals of the Rheumatic Diseases 1993; 52: 643-649.
24. CS Lau. -
Haemostatic Abnormalities in Raynaud's phenomenon and the potential for treatment with manipulation of the arachidonic acid pathway. MD thesis.
University of Dundee, Scotland (1993)
25. BM Jones, CS Lau, RWS Wong. 2.815
CD5-positive and CD5-negative plaque-forming cells against poly-l-lysine-treated sheep erythrocytes in patients with systemic lupus erythematosus.
Autoimmunity 1994; 18: 189-194.
26. CS Lau, F Khan, P McCallum, JJF Belch. 3.619
Digital blood flow response to body warming, cooling and rewarming in patients with Raynaud's phenomenon.
Angiology 1995; 46(1): 1-10.
27. CS Lau, M McLaren, JJF Belch. 4.473
Effects of fish oil on plasma fibrinolysis in patients with mild rheumatoid arthritis.
Clinical and Experimental Rheumatology 1995; 13(1): 87-90.
28. CS Lau. -
Effects of fish oil on plasma fibrinolysis in rheumatoid arthritis.
Focus on Rheumatology 1995; 2(4): 88-89.
29. CC Mok, CS Lau, SP Poon. 7.580
Primary nocardial meningitis in systemic lupus erythematosus.
Rheumatology (Oxford) 1995; 34(2): 178-181.
30. CC Mok, YL Kwong, CS Lau. 19.103
Secondary acute myeloid leukaemia with 7q-complicating azathioprine treatment for rheumatoid arthritis.
Annals of the Rheumatic Diseases 1995; 54(2): 155-156.
31. CS Lau, AR Saniabadi, JJF Belch. 9.002
Reduced red blood cell deformability in patients with rheumatoid vasculitis: Improvement after in vitro treatment with dipyridamole.
Arthritis and Rheumatology 1995; 38(2): 248-253.

32. JF Belch, HA Capell, ED Cook, JDT Kirby, CS Lau, R Madhok, E Murphy, M Steinberg. 19.103
Oral iloprost as a treatment for Raynaud's syndrome. A double-blind multi-centre placebo controlled study. Annals of the Rheumatic Diseases 1995; 54: 197-200.
33. A Kung, CS Lau, PC Wu. 4.473
Graves' ophthalmopathy and relapsing polychondritis. Clinical and Experimental Rheumatology 1995; 13: 501-503.
34. WM Chan, M Ip, CS Lau, E Wang, WCG Peh. 3.415
Anti-Jo-1 syndrome presenting as cryptogenic organizing pneumonia. Respiratory Medicine 1995; 89: 639-641.
35. CC Mok, CS Lau. 1.876
Transverse myelitis and anti-phospholipid antibodies in mixed connective tissue disorders. Clinical Neurology and Neurosurgery 1995; 97(3): 259-260.
36. CS Lau, CC Mok and YET Chan 7.580
Assessing systemic lupus erythematosus activity using plasma factor VIII von Willebrand factor antigen Rheumatology (Oxford) 1995, 34(1):8.
37. CMY Ho, CS Lau, EYT Chan. -
Complement activation in systemic lupus erythematosus – a review. The Journal of Hong Kong Medical Technology Association 1996; 6: 51-55.
38. YL Lau, CS Lau, SY Chan, J Karlberg, MW Turner. 9.002
Mannose-binding protein in Chinese with systemic lupus erythematosus. Arthritis and Rheumatology 1996; 39 (4): 706-708.
39. CC Mok, CS Lau. 4.666
Dapsone syndrome in cutaneous lupus erythematosus. Journal of Rheumatology 1996; 23(4): 766-768.
40. CC Mok, CS Lau, CR Kumana. 7.580
Polymyalgia rheumatica as the rheumatological manifestation of myelodysplastic syndrome in a Chinese patient. Rheumatology (Oxford) 1996; 35(5): 496-497.

41. EYT Chan, CS Lau, H Zola. 3.411
Expression of IL-2R, IL-4R and IL-6R on peripheral blood lymphocytes in systemic lupus erythematosus: correlation with disease activity.
Journal of Clinical Pathology 1996; 49(8): 660-663.
42. CC Mok, CS Lau. 4.666
Lack of association between prolactin levels and clinical activity in patients with systemic lupus erythematosus.
Journal of Rheumatology 1996; 23(12): 2185-2186.
43. CC Mok and CS Lau 0.029
Management strategies for systemic lupus erythematosus.
Hong Kong Practitioner. 1996; 18: 475-480.
44. CC Mok, KY Yuen, CS Lau. 4.7
Nocardiosis in systemic lupus erythematosus.
Seminars in Arthritis and Rheumatism 1997; 26 (4): 675-683.
45. EYT Chan, JWM Lawton, AKW Lie, CS Lau. 5.306
Autoantibody formation after allogeneic bone marrow transplantation: correlation with the reconstitution of CD5⁺ B cells and occurrence of graft-versus-host disease.
Pathology 1997; 29: 184-188.
46. EYT Chan, SCW Ko, CS Lau. 2.31
Increased rate of apoptosis and decreased expression of bcl-2 protein in peripheral blood lymphocytes from patients with active systemic lupus erythematosus.
Asian Pacific Journal of Allergy and Immunology 1997; 15: 3-7.
47. CC Mok, CS Lau, PW Cheng, WY Ip. 3.641
Bilateral Kienbock's disease in systemic lupus erythematosus.
Scandinavian Journal of Rheumatology 1997; 26 (6): 485-487.
48. CC Mok, CS Lau, CF Tam. 7.580
Prolactin profile in a cohort of Chinese systemic lupus erythematosus patients.
Rheumatology (Oxford) 1997; (36)9: 986-989.
49. CC Mok, CS Lau. 2.454
Rheumatic manifestations of haematological malignant disorders.
International Journal of Rheumatic Diseases 1997; 1(2): 155-161.

50. CS Lau, JF Belch. 2.454
Lack of correlation between red cell membrane incorporation of essential fatty acids and disease activity and severity variables of rheumatoid arthritis.
International Journal of Rheumatic Diseases 1997;1(2): 88-91.
51. MY Mok, CS Lau. 4.473
Protein losing enteropathy and primary Sjögren's syndrome.
Clinical and Experimental Rheumatology 1997; 15 (6): 705.
52. WL Lim, KF Wong, CS Lau. 6.072
Parvovirus b19 infection in Hong Kong.
Journal of Infection, 1997, v. 35 n. 3, p. 247-249.
[http://dx.doi.org/10.1016/S0163-4453\(97\)92928-5](http://dx.doi.org/10.1016/S0163-4453(97)92928-5)
53. EYT Chan, OKH Ko, JWM Lawton, CS Lau. 2.07
Use of anti-ribosomal P antibodies in diagnosis of cerebral lupus: superiority of Western blotting over ELISA.
Hong Kong Medical Journal 1998; 4 (2): 145-150.
54. CC Mok, CS Lau, KY Yuen. 4.473
Cryptococcal meningitis presenting concurrently with systemic lupus erythematosus.
Clinical and Experimental Rheumatology 1998; 16 (2): 169-171.
55. KH Wong, JWM Lawton, SKL Cheng, SS Lee, CS Lau. 5.306
Measurement of anti-dsDNA – a comparative study of two ELISA and the Crithidia assay.
Pathology 1998 30: 57-61.
56. CC Mok, CS Lau, CTK Ho, KW Lee, MY Mok, RWS Wong. 3.641
Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus.
Scandinavian Journal of Rheumatology 1998; 27(5): 342-346.
[DOI: 10.1080/03009749850154357](https://doi.org/10.1080/03009749850154357)
57. CC Mok, CS Lau, EYT Chan, RWS Wong. 4.666
Acute transverse myelopathy in systemic lupus erythematosus – clinical presentation, treatment and outcome.
Journal of Rheumatology 1998; 25(3): 467-473.
58. CC Mok, CS Lau, RWS Wong. 9.002
Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
Arthritis and Rheumatology 1998; 41 (5): 831-837.

59. CC Mok, CS Lau, RW Wong. 4.666
Toxicities of dapsone in the treatment of cutaneous manifestations of rheumatic diseases.
Journal of Rheumatology 1998; 25(6): 1246-1247.
60. CC Mok, JS Lanchbury, DW Chan, CS Lau. 9.002
Interleukin-10 promoter polymorphisms in southern Chinese patients with systemic lupus erythematosus.
Arthritis and Rheumatology 1998; 41(6): 1090-1095.
61. CS Lau, KY Yuen, KH Chan, RWS Wong. 2.628
Lack of evidence of active lytic replication of Epstein-Barr and cytomegaloviruses in patients with systemic lupus erythematosus.
Chinese Medical Journal 1998; 111(7): 650-665.
62. CTK Ho, CC Mok, CS Lau, RWS Wong. 19.103
Late-onset systemic lupus erythematosus in southern Chinese.
Annals of the Rheumatic Diseases 1998; 57(7): 437-440.
63. CC Mok, CS Lau, RWS Wong. 7.580
Risk factors for avascular bone necrosis in systemic lupus erythematosus. Rheumatology (Oxford) 1998; 37 (8): 895-900.
64. CC Mok, RWS Wong, CS Lau. 2.911
Exacerbation of systemic lupus erythematosus by breast feeding.
Lupus 1998; 7 (8): 569-570.
65. WK Ip, SY Chan, CS Lau, YL Lau. 9.002
Association of systemic lupus erythematosus with promoter polymorphisms of mannose binding lectin gene.
Arthritis and Rheumatology 1998; 41 (9): 1663-1668.
66. CC Mok, CS Lau, RWS Wong. 4.666
Clinical characteristics, treatment, and outcome of adult onset Still's disease in southern Chinese.
Journal of Rheumatology 1998; 25 (12): 2345-2351.
67. CC Mok, CS Lau, KW Lee, RWS Wong. 4.666
Hyperprolactinaemia in males with systemic lupus erythematosus.
Journal of Rheumatology 1998; 25(12): 2357-2363.
68. CC Mok, RWS Wong and CS Lau. 7.580
Kienbock's disease in rheumatoid arthritis.
Rheumatology (Oxford) 1998; 37(7): 796-797.

69. CC Mok, CS Lau, RWS Wong. 10.668
Still's disease in an 80-year-old woman.
Age and Ageing 1998; 27: 407-409.
70. KC Lai, SK Lam, WM Hui, BCY Wong, CS Lau. 3.216
Helicobacter pylori eradication cannot prevent peptic ulcers
development in stable patients on long-term NSAIDs.
Digestion, 1998 85(3) 214.
71. CC Mok, CS Lau, JS Lanchbury. 9.002
Interleukin-10 promoter polymorphism and lupus nephritis: Reply.
Arthritis and Rheumatism Mar 1999, 42(3) 591-593.
72. CC Mok, RWS Wong, CS Lau. 9.002
Ovarian failure and flares of systemic lupus erythematosus.
Arthritis and Rheumatology 1999 Jun;42(6):1274-80
DOI: [10.1002/1529-0131\(199906\)42:6<1274:AID-ANR26>3.0.CO;2-B](https://doi.org/10.1002/1529-0131(199906)42:6<1274:AID-ANR26>3.0.CO;2-B)
73. MF Yuen, CS Lau, YL Lau, W Wong, C Cheng, CL Lai. 17.425
Mannose binding lectin gene mutations are associated with
progression of liver disease in chronic hepatitis B infection.
Hepatology 1999;29(4):1248-1251.
74. C Huynh, SL Ho, KY Fong, RTF Cheung, CC Mok, CS Lau. 2.177
Peripheral neuropathy in systemic lupus erythematosus.
Journal of Clinical Neurophysiology 1999 Mar 1;16 (2):164-168.
75. CC Mok, CS Lau, TM Chan, RWS Wong. 2.911
Clinical characteristics and outcome of southern Chinese males with
systemic lupus erythematosus.
Lupus 1999; 8(3): 188-196.
76. MY Mok, HF Tse, CS Lau. 2.911
Pulmonary hypertension secondary to systemic lupus
erythematosus: prolonged survival following treatment with
intermittent low dose iloprost.
Lupus 1999; 8(4): 328-331.
77. CC Mok, CS Lau, RWS Wong. 4.473
Acute lupus myelitis affecting the clonus medullaris.
Clinical and Experimental Rheumatology 1999; 17(1): 123-124.

78. CGO Baerwald, CC Mok, M Tikly, CS Lau, BP Wordsworth, B Ollier, GS Panayi, JS Lanchbury. 2.846
Distribution of corticotropin releasing hormone promoter polymorphism in different ethnic groups: Evidence for natural selection in human populations. Immunogenetics 1999; 49(10): 894-899.
79. KK Tong, D Yang, EYT Chan, PKY Chiu, KS Yau, CS Lau. 4.36
Downregulation of lymphocyte activity and human synovial fibroblast growth in rheumatoid arthritis by triptolide. Drug Development Research 1999; 47: 144-153.
80. CC Mok, RWS Wong, CS Lau. 8.860
Lupus nephritis in Southern Chinese patients: clinicopathologic findings and long term outcome. American Journal of Kidney Diseases 1999; 34(2): 315-323.
81. AWC Kung, TM Chan, CS Lau, RWS Wong, SSC Yeung. 7.580
Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: A randomised controlled trial comparing calcitriol and hormonal replacement therapy. Rheumatology (Oxford) 1999; 38(12): 1239-1244.
82. EYT Chan, TMY Mok, JWM Lawton, OKH Ko, L Ho, CS Lau. 2.31
Comparison of counter immunoelectrophoresis with immunoblotting for detection of anti-extractable nuclear antigen antibodies in systemic lupus erythematosus. Asian Pacific Journal of Allergy and Immunology 1999; 17: 275-279.
83. CC Mok, CTK Ho, CS Lau, RWS Wong. 2.454
Disease course and prognosis of postmenopausal onset systemic lupus erythematosus patients. International Journal of Rheumatic Diseases 1999; 3(2): 124-129.
84. GC Fong, RT Cheung, SL Ho, CS Lau. 9.91
Brainstem tuberculoma mimicking glaucoma. Neurology 1999; 53 (8): 1894-1895.
85. CC Mok, CS Lau, CTK Ho, RWS Wong. 3.641
Do flares of systemic lupus erythematosus decline after menopause? Scandinavian Journal of Rheumatology 1999; 28(6): 360-365.

86. CC Mok, WS Wong, CS Lau. -
Ovarian failure and cyclophosphamide treatment in systemic lupus erythematosus.
Mosby Yearbook of Rheumatology 1999
87. CS Lau, WT Wong. 4.39
Synthesis and structural characterisation of trinuclear and tetranuclear ruthenium clusters containing diyne ligands derived from 1,4-bis(1-hydroxycyclopentyl)-1,3-butadiyne.
Journal of Chemical Society, Dalton Transactions Aug 1999 (15); 2511-2519.
88. CS Lau, WT Wong. 4.39
Synthesis and structural characterisation of ruthenium carbonyl clusters containing acetylenic fluorene moieties derived from 9-ethynylfluorene-9-ol.
Journal of the Chemical Society, Dalton Transactions 1990; 4: pp.607-613.
<http://dx.doi.org/10.1039/A808240E>
89. CS Lau, WT Wong. 2.369
Synthesis, structural characterisation and electrochemistry of ruthenium carbonyl clusters derived from ferrocenyl(formyl)acetylene.
Journal of Organometallic Chemistry. Oct 1999, 588(1) 113-124.
[https://doi.org/10.1016/S0022-328X\(99\)00353-8](https://doi.org/10.1016/S0022-328X(99)00353-8)
90. MY Mok, RWS Wong, CS Lau. 2.911
Intestinal pseudo-obstruction in systemic lupus erythematosus – an uncommon but important clinical manifestation.
Lupus 2000; 9: 11-18.
91. CG Baerwald, CC Mok, M Tickly, CS Lau, BP Wordsworth, B Ollier, GS Panayi, JS Lanchbury. 1.372
Corticotropin releasing hormone (CRH) promoter polymorphisms in various ethnic groups of patients with rheumatoid arthritis.
Zeitschrift für Rheumatologie 2000 Feb;59(1):29-34.
DOI: 10.1007/s003930050002. PMID: 10769420.
<https://pubmed.ncbi.nlm.nih.gov/10769420/>
92. CC Mok, KW Lee, CTK Ho, CS Lau, RWS Wong. 7.580
A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population.
Rheumatology (Oxford) 2000; 39(4): 399-406.

93. BMY Cheung, CS Lau, RYH Leung, KK Tong, CR Kumana. 7.580
Plasma adrenomedullin level in systemic lupus erythematosus.
Rheumatology (Oxford) 2000;39(7):804-805.
94. MY Mok, WL Ng, MF Yuen, RWS Wong, CS Lau. 4.473
Safety of disease modifying anti-rheumatic agents in rheumatoid
arthritis patients with chronic viral hepatitis.
Clinical and Experimental Rheumatology 2000; 18 (3): 363-368.
95. CC Mok, WM Wong, TWH Shek, CTK Ho, CS Lau, CL Lai. 10.864
Cumulative hepatotoxicity induced by continuous low-dose
cyclophosphamide therapy.
The American Journal of Gastroenterology 2000; 95(3): 845-846.
96. WK Ip, YL Lau, SY Chan, CC Mok, D Chan, KK Tong, 9.002
CS Lau.
Mannose-binding lectin and rheumatoid arthritis in southern
Chinese.
Arthritis and Rheumatology 2000; 43 (8): 1679-1687.
97. JJY Sung, RI Russell, N Yeomans, FKL Chan, SL Chen, KM Fock, 4.029
KL Goh, P Kullavanijaya, K Kimura, CS Lau,
J Louw, J Sollano, G Triadialafalopulos, SD Xiao, P Brooks.
Non-steroidal anti-inflammatory drug toxicity in the upper
gastrointestinal tract.
Journal of Gastroenterology and Hepatology 2000; 15: G58-68.
98. CC Mok, CS Lau. 2.911
Profile of sex hormones in male patients with systemic lupus
erythematosus.
Lupus 2000; 9(4): 252-257.
99. I Lambrinoudaki, DTM Chan, CS Lau, RWS Wong, 4.666
SSC Yeung, AWC Kung.
Effect of calcitriol on bone mineral density in premenopausal
Chinese women taking chronic steroid therapy. A randomized,
double-blind, placebo-controlled study.
Journal of Rheumatology 2000; 27(7): 1759-1765.
100. TM Chan, FK Li, CSO Tang, RWS Wong, GX Fang, YL Ji, 91.245
CS Lau, AKM Wong, MKL Tong, KW Chan, and KN Lai, for the
Hong Kong – Guangzhou Nephrology Study Group.
Efficacy of Mycophenolate Mofetil in the treatment of patients
with diffuse proliferative lupus nephritis.
New England Journal of Medicine 2000; 343(16): 1156-1162.

101. WK Ip, YL Lau, SY Chan, CC Mok, D Chan, CS Lau. 9.002
Mannose-binding lectin and rheumatoid arthritis in southern Chinese.
Arthritis and Rheumatology 2000; 43(8): 1679-1687.
102. CC Mok, CS Lau, RWS Wong. 4.7
Use of exogenous estrogens in systemic lupus erythematosus.
Seminars in Arthritis and Rheumatism 2001; 30(6): 426-435.
103. TG Woodworth, DE Furst, V Strand, J Kempeni, H Fenner, 4.666
CS Lau, F Miller, R Day, J Lipani, P Brooks.
Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000; towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies.
Journal of Rheumatology 2001; 28(5): 1163-1169.
104. CC Mok, CT Ho, YP Siu, KW Chan, TH Kwan, CS Lau, 8.860
RW Wong, TC Au.
Treatment of diffuse proliferative lupus glomerulonephritis: A comparison of two cyclophosphamide-containing regimens.
American Journal of Kidney Diseases 2001; 38(2): 256-264.
105. F Huang, S Li, CS Lau, W Tsai. 0.10
Low dose methotrexate in the treatment of early ankylosing spondylitis.
Chinese Journal of New Drugs 2001; 10(9): 485-488.
106. CS Lau, CTK Ho, KW Lee, CC Mok, MY Mok, RWS Wong. -
Iloprost, a prostacyclin analogue, in the management of rheumatic disorders: an overview and a report on local experience.
Journal of Clinical Rheumatology and Immunology 2001; 1(1): 25-31.
107. CC Mok, CS Lau, RWS Wong. 4.666
Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus.
Journal of Rheumatology 2001; 28(4): 766-771.
108. CC Mok, CTK Ho, YP Siu, KW Chan, TH Kwan, CS Lau, RWS 8.86
Wong, TC Au.
Daily and nocturnal haemodialysis: How do they stack up?
American Journal of Kidney Diseases, 2001;38(2) 225-239.
<http://dx.doi.org/10.1053/ajkd.2001.26079>

109. CC Mok, CTK Ho, KW Chan, CS Lau, RWS Wong. 9.002
 Outcome and prognostic indicators of diffuse proliferative lupus
 glomerulonephritis treated with sequential oral cyclophosphamide
 and azathioprine.
 Arthritis and Rheumatology 2002; 46(4): 1003-1013.
110. PP Geusens, K Truitt, P Sfikakis, PL Zhao, L DeTora, 3.641
 S Shingo, CS Lau, A Kalla, G Tate.
 A placebo and active comparator-controlled trial of rofecoxib for
 the treatment of rheumatoid arthritis.
 Scandinavian Journal of Rheumatology 2002; 4: 230-238.
111. BP Tsao, RM Cantor, JM Grossman, SK Kim, N Strong, 9.002
CS Lau, CJ Chen, N Shen, EM Ginzler, R Goldstein,
 KC Kalunian, FC Arnett, DJ Wallace, BH Hahn.
 Linkage and interaction of loci on 1q23 and 16q12 may contribute
 to susceptibility to systemic lupus erythematosus.
 Arthritis and Rheumatology 2002; 46(11): 2928-2936.
112. CC Mok, TC Cheung, CT Ho, KW Lee, CS Lau, RW Wong. 4.666
 Behcet's disease in southern Chinese patients.
 Journal of Rheumatology 2002; 29(8): 1689-1693.
113. BP Tsao, JM Grossman, G Riemekasten, N Strong, J Kalsi, 9.002
 DJ Wallace, CJ Chen, CS Lau, EM Ginzler, R Goldstein,
 KC Kalunian, JB Harley, FC Arnett, BH Hahn, RM Cantor.
 Familiality and co-occurrence of clinical features of systemic
 lupus erythematosus.
 Arthritis and Rheumatology 2002; 46(10): 2678-2685.
114. MY Mok, Y Lo, DTM Chan, RWS Wong and CS Lau 9.002
 Efficacy of Isoniazid Chemoprophylaxis for Tuberculous Infection
 in Patients with systemic Lupus Erythematosus in an endemic
 area.
 Arthritis and Rheumatology 2002; 46 (9): pp.S60-60.
115. KC Lai, CS Lau, WY Ip, BC Wong, WM Hui, WH Hu, 8.171
 RW Hong, SK Lam.
 Effect of treatment of Helicobacter pylori on the prevention of
 gastroduodenal ulcers in patients receiving long term NSAIDs: a
 double-blind , placebo-controlled trial.
 Alimentary Pharmacology and Therapeutics 2003; 17(6): 799-805.

116. Y Ren, J Tang, MY Mok, AWK Chan, A Wu, CS Lau. 9.002
Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus.
Arthritis and Rheumatology 2003; 48(10): 2888-2897.
117. GC Ooi, MY Mok, KWT Tsang, Y Wong, PL Khong, 1.99
PCW Fung, S Chan, HF Tse, RWS Wong, WK Lam, CS Lau.
Interstitial lung disease in systemic sclerosis: A HRCT-clinical correlative study.
Acta Radiologica 2003; 44: 258-264.
118. CC Mok, CTK Ho, RWS Wong, CS Lau. 4.666
Damage accrual in southern Chinese patients with systemic lupus erythematosus.
Journal of Rheumatology 2003; 30(7): 1513-1519.
119. CC Mok, CS Lau, RWS Wong. 4.965
Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study.
American Journal of Medicine 2003; 115(1): 59-62.
120. CC Mok, CS Lau. 2.911
Lupus in Hong Kong Chinese.
Lupus 2003; 12(9): 717-722.
121. J Woo, E Lau, CS Lau, P Lee, J Zhang, T Kwok, C Chan, 9.002
P Chiu, KM Chan, A Chan, D Lam.
Socioeconomic impact of osteoarthritis in Hong Kong: Utilization of health and social services, and direct and indirect costs.
Arthritis and Rheumatology 2003; 49(4): 526-534.
122. DSS Kumar, CS Lau, WK Chan, D Yang, HY Cheung, F Chen, KD 5.037
Hyde.
Immunomodulatory compounds from Pestalotiopsis leucothes, an endophytic fungus from Tripterygium wilfordii.
Life Sciences Nov 2005; 78(2) 147-156.
123. AS McMillan, KCM Leung, MCM Wong, WK Leung, CS Lau, 3.837
TMY Mok.
Impact of Sjögren's syndrome on oral health-related quality of life in southern Chinese.
Journal of Oral Rehabilitation 2004; 31: 653-659.

124. CC Mok, KY Ying, CS Lau, CW Yim, WL Ng, RWS Wong, TC Au. 8.860
 Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: An open-label trial.
 American Journal of Kidney Diseases 2004; 43(2): 269-276.
125. MY Mok, DL Jack, CS Lau, DYT Fong, MW Turner, DA Isenberg, PM Lydyard. 2.911
 Antibodies to mannose binding lectin in patients with systemic lupus erythematosus.
 Lupus 2004; 13(7): 522 – 528.
126. WP Chong, WK Ip, CS Lau, TM Chan, L Padyukov, YL Lau. 7.580
 Common NOD2 polymorphisms in Hong Kong Chinese patients with systemic lupus erythematosus.
 Rheumatology (Oxford) 2004; 43(1): 104-105.
127. JC Ho, G Tipoe, L Zheng, TM Leung, KWT Tsang, DKY Shum, CS Lau, JCW Mak, WK Lam, MSM Ip. 3.415
 In vitro study of regulation of IL-6 production in bronchiectasis.
 Respiratory Medicine 2004; 98(4): 334-341.
128. EMY Chu, KY Chiu, RWS Wong, WM Tang, CS Lau. 9.002
 Translation and validation of arthritis impact measurement scales 2 into Chinese: CAIMS2.
 Arthritis and Rheumatology 2004; 51(1): 20-27.
129. CC Mok, KY Ying, S Tang, CY Leung, KW Lee, WL Ng, RWS Wong, CS Lau. 9.002
 Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
 Arthritis and Rheumatology 2004; 50(8): 2559-2568.
130. KCM Leung, AS McMillan, WK Leung, MCM Wong, CS Lau, TMY Mok. 2.512
 Oral Health condition and saliva flow in southern Chinese with Sjögren's syndrome.
 International Dental Journal 2004;54(3):159-165.
131. J Woo, E Lau, P Lee, T Kwok, CS Lau, C Chan, P Chiu, E Li, A Sham, D Lam. 4.666
 Impact of osteoarthritis on quality of life in a Hong Kong Chinese population.
 Journal of Rheumatology 2004; 31(12): 2433-2438.

132. WP Chong, WK Ip, WHS Wong, CS Lau, TM Chan, YL Lau. 2.676
 Association of interleukin-10 promoter polymorphisms with systemic lupus erythematosus.
Genes and Immunity 2004; 5(6): 484-492.
133. CR Kumana, GTY Cheung, CS Lau. 19.103
 Severe digital ischaemia treated with phosphodiesterase inhibitors.
Annals of the Rheumatic Diseases 2004;63(11):1522-1524.
134. MY Mok, PY Leung, TH Lao, Y Lo, TM Chan, WS Wong, CS Lau. 19.103
 Clinical predictors of fetal and maternal outcome in Chinese patients with systemic lupus erythematosus.
Annals of the Rheumatic Diseases 2004; 63(12): 1705-1706.
135. MY Mok, Y Lo, PY Leung, CS Lau. 4.666
 Pregnancy outcome in patients with adult onset Still's disease.
Journal of Rheumatology 2004; 31(11): 2307-2309.
136. SSD Kumar, HY Cheung, WK Chan, CS Lau, KD Hyde. 4.36
 In vitro studies of endophytic fungi from *Tripterygium wilfordii* with anti-proliferative activity on human peripheral blood monocular cells.
Journal of Ethnopharmacology 2004; 94: 295-300.
137. CS Lau, PKY Chiu, EMY Chu, IYW Cheng, WM Tang, RYK Man, GM Halpern. 0.538
 Treatment of knee osteoarthritis with Lyprinol®, lipid extract of the green-lipped mussel – A double-blind placebo-controlled study.
Progress in Nutrition 2004; 6(1): 17-31.
138. O Jin, LY Sun, CS Lau. 4.473
 Weber-Christian disease and pituitary dysfunction in a patient with polymyositis.
Clinical and Experimental Rheumatology 2004; 22(6): 792.
139. MY Mok, Y Lo, TM Chan, WS Wong, CS Lau. 4.666
 Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy.
Journal of Rheumatology 2005; 32: 609-615.
140. MY Mok, EY Chan, DY Fong, KF Leung, WS Wong, CS Lau. 4.666
 Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus.
Journal of Rheumatology 2005; 32: 622-628.

141. EKP Kong, L Prokunina-Olsson, WHS Wong, CS Lau,
TM Chan, M Alarcón-Riquelme, YL Lau. 9.002
A new haplotype of PDCD1 is associated with rheumatoid arthritis
in Hong Kong Chinese.
Arthritis and Rheumatology 2005; 52(4): 1058-1062.
142. O Jin, LY Sun, KX Zhou, XS Zhang, XB Feng, MY Mok,
CS Lau. 2.98
Lymphocyte apoptosis and macrophage function: correlation with
disease activity in systemic lupus erythematosus.
Clinical Rheumatology 2005; 24: 107-110.
143. MW Ng, CS Lau, TM Chan, WHS Wong, YL Lau. 7.580
Polymorphisms of the toll-like receptor 9 (TLR9) gene with
systemic lupus erythematosus in Chinese.
Rheumatology (Oxford) 2005;44(11);1456-1457.
144. SSD Kumar, CS Lau, JMF Wan, D Yang, KD Hyde. 5.037
Immunomodulatory compounds from pestalotiopsis leucothès, an
endophytic fungus from Tripterygium wilfordii.
Life Sciences 2005; 78(2): 147-156.
145. CWH Woo, RYK Man, YL Siow, PC Choy, EWY Wan,
CS Lau, K O. 3.396
Ganoderma lucidum inhibits inducible nitric oxide synthase
expression in macrophages.
Molecular and Cellular Biochemistry 2005; 275(1): 165-171.
146. MY Mok, SY Wong, TM Chan, WM Tang, WS Wong,
CS Lau. 2.911
Necrotizing fasciitis in rheumatic diseases.
Lupus 2006; 15(6): 380-383.
147. A Mak, BMY Cheung, CC Mok, R Leung, CS Lau. 7.580
Adrenomedullin: A potential disease activity marker and
suppressor of nephritis activity in systemic lupus erythematosus.
Rheumatology (Oxford) 2006; 45(10): 1266-1272.
148. CC Mok, KY Ying, WL Ng, KW Lee, CH To, CS Lau,
WS Wong, TC Au. 4.965
Long-term outcome of diffuse proliferative lupus glomerulonephritis
treated with cyclophosphamide.
American Journal of Medicine 2006;119(4):335-e25.

149. P Brooks, HY Kim, CS Lau. 2.454
 Anti-tumour necrosis factor- α : The dawn of a new era in the treatment of rheumatoid arthritis.
 International Journal of Rheumatic Diseases 2006;9(2): 103-104.
150. CS Lau, G Yin, MY Mok. 2.911
 Ethnic and geographical differences in systemic lupus erythematosus: An overview.
 Lupus, 2006, v. 15 n. 11, p. 715-719.
 PMID: 17153840. <http://dx.doi.org/10.1177/0961203306072311>
151. M Wong, CS Lau. 2.454
 Management of systemic lupus erythematosus: A brief update on recent advances.
 International Journal of Rheumatic Diseases, November 2006;9(4) 387-391.
<http://dx.doi.org/10.1111/j.1479-8077.2006.00246.x>
152. S Kavikondala, Y Nie and CS Lau 9.754
 Report on the Second Asia Autoimmunity Forum 3-5 March 2006, Hong Kong.
 Autoimmunity Reviews. Amsterdam, New York: Elsevier, 2006, 6(2), 115-118.
153. J X Zhang, J Woo, CS Lau, P Lee, P Chiu, D Lam. 4.667
 Effects of use of alternative therapies on quality of life and healthcare spending.
 The American Journal of Chinese Medicine. 2007; 35 (2): 183-193.
154. MY Mok, PL Tsang, YM Lam, Y lo, WS Wong, CS Lau. 2.911
 Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension.
 Lupus 2007; 16: 279-285.
155. MY Mok, S Wong, TM Chan, DYT Gong, WS Wong, CS Lau. 7.580
 Non-tuberculous mycobacterial infection in patients with systemic lupus erythematosus.
 Rheumatology (Oxford) 2007; 46(2): 280-284.
156. MY Mok, EY Chan, WS Wong, CS Lau. 19.103
 Intrathecal immunoglobulin production in patients with systemic lupus erythematosus with neuropsychiatric manifestations.
 Annals of the rheumatic diseases, 2007; 66(6), 846-847.
<http://dx.doi.org/10.1136/ard.2006.061069>

157. YW Ho, JS Yeung, PK Chiu, WM Tang, ZB Lin, RY Man, CS Lau. 3.396
 Ganoderma lucidum polysaccharide peptide reduced the production of proinflammatory cytokines in activated rheumatoid synovial fibroblast.
 Molecular and Cellular Biochemistry 2007; 301(1-2): 173-179.
158. EK Kong, WP Chong, WH Wong, CS Lau, TM Chan, PK Ng, YQ Song, W Mak, YL Lau. 7.580
 p21 gene polymorphisms in systemic lupus erythematosus.
 Rheumatology (Oxford) 2007; 46(2): 220-226.
159. MY Mok, BMY Cheung, Y Lo, RYH Leung, WS Wong, CS Lau. 4.666
 Elevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis.
 Journal of Rheumatology 2007; 34(11): 2224-2249.
 PMID: 17937467
160. LY Sun, KX Zhou, XB Feng, HY Zhang, XQ Ding, O Jin, LW Lu, CS Lau, YY Hou, LM Fan. 2.98
 Abnormal surface markers expression on bone marrow CD34+ cells and correlation with disease activity in patients with systemic lupus erythematosus.
 Clinical Rheumatology 2007; 26(12): 2073-2079.
161. MY Mok, PCW Fung, C Ooi, HF Tse, Y Wong, YM Lam, WS Wong, CS Lau. 2.98
 Serum nitric oxide metabolites and disease activity in patients with systemic sclerosis.
 Clinical Rheumatology 2007; 3: 315-322.
162. MY Mok, WK Ip, CS Lau, Y Lo, WHS Wong, YL Lau. 4.666
 Mannose-binding lectin and susceptibility to infection in Chinese patients with systemic lupus erythematosus.
 Journal of Rheumatology 2007; 34: 1270-1276.
163. CS Lau, PH Feng. 20.543
 Rheumatology without borders.
 Nature Reviews Rheumatology 2007; 3(6): 305.
<http://dx.doi.org/10.1038/ncprheum0509>

164. O Jin, S Kavikondala, L Sun, R Fu, MY Mok, A Chan, J Yeung, CS Lau.
Systemic lupus erythematosus patients have increased number of circulating plasmacytoid dendritic cells, but decreased myeloid dendritic cells with deficient CD83 expression.
Lupus 2008; 17(7): 654 – 662. 2.911
165. HO Siu, W Yang, CS Lau, TM Chan, RW Wong, WH Wong, YL Lau, ME Alarcon-Riquelme.
Association of a haplotype of IRF5 gene with systemic lupus erythematosus in Chinese.
Journal of Rheumatology 2008; 35(2): 360 – 362. 4.666
166. KCM Leung, AS McMillan, MCM Wong, WK Leung, MY Mok, CS Lau.
The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: A randomised double-blind, placebo-controlled crossover study.
Clinical Rheumatology, 2008, v. 27 n. 4, p. 429-436.
<http://dx.doi.org/10.1007/s10067-007-0723-x> 2.98
167. JF Belch, S McSwiggan, CS Lau.
Macrovascular disease in systemic sclerosis: The tip of an iceberg?
Rheumatology (Oxford) 2008; 47 (Suppl 5): 16-17. 7.580
168. WL Yang, P Ng, M Zhao, N Hirankarn, CS Lau, CC Mok, TM Chan, RWS Wong, KW Lee, MY Mok, SM Wong, Y Avihingsanon, TL Lee, MCK Ho, PPW Lee, WHS Wong, YL Lau.
Population differences in SLE susceptibility genes – STAT4 and BLK, but not PXX, are associated with systemic lupus erythematosus in Hong Kong Chinese.
Genes and Immunity 2009; 10 (3): 219 – 216. 2.676
169. WL Yang, MH Zhao, N Hirankarn, CS Lau, CC Mok, TM Chan, RWS Wong, KW Lee, MY Mok, SN Wong, Y Avihingsanon, IONG Ng, TL Lee, MHK Ho, PPW Lee, WHS Wong, PC Sham, YL Lau.
ITGAM is associated with disease susceptibility and renal nephritis of systemic lupus erythematosus in Hong Kong Chinese and Thai.
Human Molecular Genetics 2009; 18 (11): 2063-2070. 6.15

170. YK Chang, WL Yang, MH Zhao, CC Mok, TM Chan, RWS Wong, KW Lee, MY Mok, SN Wong, IOL Ng, TL Lee, MHK Ho, PPW Lee, WHS Wong, CS Lau, PC Sham, WL Lau. Association of BANK1 and TNFSF4 with systemic lupus erythematosus in Hong Kong Chinese. *Genes and Immunity* 2009; 10(5): 414-420. 2.676
171. A Mak, AAC Cheak, JYS Tan, HC Su, RCM Ho, CS Lau. Mycophenolate mofetil is as efficacious as, but safer than cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. *Rheumatology (Oxford)* 2009; 48(8): 944-952. 7.580
172. A Mak, RCM Ho, CS Lau. Clinical implications of neuropsychiatric systemic lupus erythematosus. *BJPsych Advances*, 2009;15(6), 451-458. <https://doi.org/10.1192/apt.bp.108.005785> 0.86
173. DM Reid, JP Deogelaer, K Saag, C Roux, CS Lau, JY Reginster, P Papanastasiou, A Ferreira, F Hartl, T Fashola, P Mesenbrink, PN Sambrook. Zoledronic Acid and Risedronate in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis (Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Trial): A Multicentre, Double-Blind, Double-Dummy, Randomized Controlled Trial. *Obstetrical and Gynecological Survey*; August 2009,64(8) 522-523. DOI: [10.1097/01.ogx.0000356937.03800.0f](https://doi.org/10.1097/01.ogx.0000356937.03800.0f) 2.347
174. DM Reid, JP Devogelaer, K Saag, C Roux, CS Lau, JY Reginster, P Papanastasiou, A Ferreira, F Hartl, T Fashola, P Mesenbrink, PN Sambrook. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomized controlled trial. *Lancet* 2009; 373(9671): 1253-1263. 79.321
175. MY Mok, S Chiu, Y Lo, HF Mak, WS Wong, PL Khong, CS Lau. Coronary atherosclerosis using computed tomography coronary angiography in patients with systemic sclerosis. *Scandinavian Journal of Rheumatology* 2009; 38(5): 381-385. 3.641

176. KH Yiu, S Wang, MY Mok, GC Ooi, PL Khong, KFH Mak, KF Lam, CS Lau, HF Tse. 4.666
 Pattern of arterial calcification in patients with systemic lupus erythematosus.
 Journal of Rheumatology 2009; 36(10): 2212-2217.
177. CH To, CC Mok, SS Tan, SK Ying, RW Wong, CS Lau. 2.911
 Prognostically distinct clinical patterns of systemic lupus erythematosus identified by cluster analysis.
 Lupus 2009; 18(14): 1267-1275.
178. S Wang, KH Yiu, MY Mok, GC Ooi, PL Khong, KF Mak, CP Lau, CS Lau, HF Tse. 8.986
 Prevalence and extent of calcification over aorta, coronary and carotid arteries in patients with rheumatoid arthritis.
 Journal of Internal Medicine 2009; 266(5): 445-452.
179. A Mak, MWL Cheung, RCM Ho, AAC Cheak, CS Lau. 2.246
 Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies.
 BMC Musculoskeletal Disorders, 2009, v. 10 n. 1.
<http://dx.doi.org/10.1186/1471-2474-10-113>
180. W Yang, N Shen, DQ Ye, Q Liu, Y Zhang, XX Qian, N Hirankarn, D Ying, HF Pan, CC Mok, TM Chan, RW Wong, KW Lee, MY Mok, SN Wong, AM Leung, XP Li, Y Avihingsanon, CM Wong, TL Lee, MH Ho, PP Lee, YK Chang, PH Li, RJ Li, L Zhang, WH Wong, IO Ng, CS Lau, PC Sham, YL Yan, Asian Lupus Genetics Consortium. 5.917
 Genome-Wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus.
 PLoS Genetics 2010; 6(2): e1000841.
181. YJ Nie, MY Mok, GCF Chan, A Chan, O Jin, S Kavikondala, AKW Lie, CS Lau. 5.156
 Phenotypic and functional abnormalities of bone marrow-derived dendritic cells in systemic lupus erythematosus.
 Arthritis Research and Therapy 2010;12(3):1-12.
182. O Jin, S Kavikondala, LY Sun, JR Gu, R Fu, MY Mok, A Chan, J Yeung, YJ Nie, CS Lau. 5.156
 Abnormalities in circulating plasmacytoid dendritic cells in patients with systemic lupus erythematosus.
 Arthritis Research and Therapy 2010; 12(4):1-11.

183. YJ Nie, CS Lau, AK Lie, GC Chan, MY Mok. 2.911
Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus.
Lupus 2010; 19(7): 850 – 859.
184. MY Mok, KH Yiu, CY Wong, J Qiuwaxi, WH Lai, WS Wong, HF Tse, CS Lau. 4.473
Low circulating level of CD133+KDR+cells in patients with systemic sclerosis.
Clinical and Experimental Rheumatology 2010; 28 (5 Suppl 62): S19-25.
185. KH Yiu, S Wan, MY Mok, GC Ooi, PL Khong, CP Lau, WH Lai, LY Wong, KF Lam, CS Lau, HF Tse. 4.666
Role of circulating endothelial progenitor cells in patients with rheumatoid arthritis with coronary calcification.
Journal of Rheumatology 2010; 37(3): 529 – 535.
186. R Cheung, TT Cheng, Y Dong, HY Lin, K Lai, CS Lau, H Feng, B Parsons. 2.454
Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis.
International Journal of Rheumatic Diseases 2010; 13(2): 151-157.
187. MY Mok, HJ Wu, Y Lo, CS Lau. 4.666
The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus.
Journal of Rheumatology 2010; 37(10): 2046-2052.
188. LK Chan, NG Patil, JY Chen, JC Lam, CS Lau, MS Ip. 3.65
Advantages of video trigger in problem-based learning.
Medical Teacher 2010; 32(9): 760-765.
189. MY Mok, SSH Chiu, Y Lo, HKF Mak, WS Wong, PL Khong, CS Lau 3.641
Coronary atherosclerosis using CT coronary angiogram in patients with systemic sclerosis. Rely letter to Editor.
Scandinavian Journal of Rheumatology 2010, 38(5), 381-385.
<http://dx.doi.org/10.3109/03009742.2010.489662>

190. AH Wong, GKS Woo, WY Lee, PKC Cheng, PCK Leung, WWL Lim, CS Lau. 2.327
 Comparison of laboratory diagnostic methods for measles infection and identification of measles virus genotypes in Hong Kong.
 Journal of Medical Virology, 2010, v.82 n. 10, p.1773-1781.
<http://dx.doi.org/10.1002/jmv.21888>
191. MY Mok, CS Lau, S Chiu, A Tso, Y Lo, LSC Law, KF Mak, WS Wong, PL Khong, KSL Lam. 9.002
 Systemic Sclerosis is an independent risk factor for increased coronary artery calcium deposition.
 Arthritis and Rheumatology 2011; 63(5): 1387-1395.
192. J Yang, W Yang, N Hirankarn, DQ Ye, Y Zhang, HF Pan, CC Mok, TM Chan, RW Wong, MY Mok, KW Lee, SN Wong, AM Leung, XP Li, Y Avihingsanon, P Rianthavorn, T Deekajorndej, K Suphapeeporn, V Shotelersuk, L Baum, P Kwan, TL Lee, MH Ho, PP Lee, WH Wong, S Zeng, J Zhang, CM Wong, IO Ng, MM Garcia-Barceló, SS Cherny, PK Tam, PC Sham, CS Lau, YL Lau. 6.15
 ELF1 is associated with systemic lupus erythematosus in Asian populations.
 Human Molecular Genetics 2011; 20(3): 601-607.
193. Y Zhang, W Yang, CC Mok, TM Chan, RW Wong, MY Mok, KW Lee, SN Wong, AM Leung, TL Lee, MH Ho, PP Lee, WH Wong, J Yang, J Zhang, CM Wong, IO Ng, MM Garcia-Barcelo, SS Cherny, PK Tam, PC Sham, CS Lau, YL Lau. 2.676
 Two missense variants in UHRF1BP1 are independently associated with systemic lupus erythematosus in Hong Kong Chinese.
 Genes and Immunity 2011; 12(3): 231-234.
194. HY Chung, CS Lau, KP Wu, WS Wong, MY Mok. 2.98
 Comparison of performance of the Assessment of Spondyloarthritis International Society, the European Spondyloarthropathy Study Group and the modified New York criteria in a cohort of Chinese patients with spondyloarthritis.
 Clinical Rheumatology 2011; 30(7): 947-953.
195. KH Yiu, S Wang, MY Mok, GC Ooi, PL Khong, CS Lau, HF Tse. 4.666
 Relationship between cardiac valvular and arterial calcification in patients with rheumatoid arthritis and systemic lupus erythematosus.
 Journal of Rheumatology 2011; 38(4): 621-627.

196. HY Chung, MY Mok, WS Wong, CS Lau. -
Improvement in diagnostic delay in spondyloarthritis patients over time but disease control is still inadequate.
Journal of Clinical Rheumatology and Immunology 2011 Dec; 11(2): 48-52.
197. PN Sambrook, C Roux, JP Devogelaer, K Saag, CS Lau, 4.398
JY Reginster, C Bucci-Rechtweg, G Su, DM Reid.
Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
Bone 2012; 50(1): 289-295.
<http://dx.doi.org/10.1016/j.bone.2011.12.006>
198. R Li, W Yang, J Zhang, N Hirankarn, HF Pan, CC Mok, 2.911
TM Chan, RW Wong, MY Mok, KW Lee, SN Wong,
AM Leung, XP Li, Y Avihingsanon, TL Lee, MH Ho, PP Lee,
WH Wong, CM Wong, IO Ng, J Yang, PH Li, Y Zhang,
L Zhang, W Li, L Baum, P Kwan, P Rianthavorn,
T Deekajoudej, K Suphapeetiporn, V Shotelersuk,
MM Garcia-Barceló, SS Cherny, PK Tam, PC Sham, CS Lau, N
Shen, YL Lau, DQ Ye.
Association of CD247 with systemic lupus erythematosus in Asian populations.
Lupus 2012; 21(1): 75-83.
199. KH Yiu, MY Mok, S Wang, GC Ooi, PL Khong, CS Lau, 4.473
HF Tse.
Prognostic role of coronary calcification in patients with rheumatoid arthritis and systemic lupus erythematosus.
Clinical and Experimental Rheumatology-Incl Supplements 2012;30(3):345-350.
200. C Roux, DM Reid, JP Devogelaer, K Saag, CS Lau, 4.507
JY Reginster, P. Papanastasiou, C BucciRechtweg, G Su,
PN Sambrook.
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Osteoporosis International 2012 Mar;23(3):1083-90.
PMID 21975559. DOI: [10.1007/s00198-011-1800-1](https://doi.org/10.1007/s00198-011-1800-1)
201. M Yang, J Deng, Y Liu, KH Ko, X Wang, Z Jiao, S Wang, 4.307
Z Hua, L Sun, G Srivastava, CS Lau, X Cao, L Lu.
IL-10-producing regulatory B10 cells ameliorate collagen-induced arthritis via suppressing Th17 cell generation.
The American Journal of Pathology 2012; 180(6): 2375-2385.

202. VS Chan, YJ Nie, N Shen, S Yan, MY Mok, CS Lau. 9.754
 Distinct roles of myeloid and plasmacytoid dendritic cells in systemic lupus erythematosus.
 Autoimmunity Reviews 2012; 11(12): 890-897.
<https://doi.org/10.1016/j.autrev.2012.03.004>
203. VS Chan, HL Tsang, R Tam, L Lu, CS Lau. 11.53
 B-cell Targeted Therapies in Systemic Lupus Erythematosus.
 Cellular and Molecular Immunology 2013;10(2):133-142.
<https://doi.org/10.1038/cmi.2012.64>
204. W Yang, H Tang, Y Zhang, X Tang, J Zhang, L Sun, J Yang, Y Cui, L Zhang, N Hirankarn, H Cheng, HF Pan, J Gao, TL Lee, Y Sheng, CS Lau, Y Li, TM Chan, X Yin, D Ying, Q Lu, AM Leung, X Zuo, X Chen, KL Tong, F Zhou, Q Diao, NK Tse, H Xie, CC Mok, F Hao, SN Wong, B Shi, KW Lee, Y Hui, MH Ho, B Liang, PP Lee, H Cui, Q Guo, BH Chung, X Pu, Q Liu, X Zhang, C Zhang, CY Chong, F Fang, RW Wong, Y Sun, MY Mok, XP Li, Y Avihingsanon, Z Zhai, P Rianthavorn, T Deekajorndej, K Suphapeetiporn, F Gao, V Shotelersuk, X Kang, SK Ying, L Zhang, WH Wong, D Zhu, SK Fung, F Zeng, WM Lai, CM Wong, IO Ng, MM Garcia-Barceló, SS Cherny, N Shen, PK Tam, PC Sham, DQ Ye, S Yang, X Zhang, YL Lau. 9
 Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians.
 The American Journal of Human Genetics – Cell 2013; 92(1): 41-51.
205. PH Li, WH Wong, TL Lee, CS Lau, TM Chan, AM Leung, KL Tong, NK Tse, CC Mok, SN Wong, KW Lee, MH Ho, PP Lee, CY Chong, RW Wong, MY Mok, SK Ying, SK Fung, WM Lai, W Yang, YL Lau. 7.580
 Relationship between autoantibody clustering and clinical subsets in SLE: cluster and association analyses in Hong Kong Chinese.
 Rheumatology (Oxford) 2013; 52(2): 337-345.
206. J Zhang, Y Zhang, L Zhang, J Yang, D Ying, S Zeng, TL Lee, CS Lau, TM Chan, AM Leung, CC Mok, SN Wong, KW Lee, MH Ho, PP Lee, BH Chung, CY Chong, RW Wong, MY Mok, WH Wong, YL Lau, W Yang. 1.46
 Epistatic Interaction between Genetic Variants in Susceptibility Gene ETS1 Correlates with IL-17 Levels in SLE Patients.
 Annals of Human Genetics 2013; 77(4): 344-350.

207. H Gill, S Liu, A Ip, F Loong, EY Lee, RY Leung, CS Lau, WK Ip, S Tam, YL Kwong. 10.047
 Unremitting pyrexia, pancytopenia, hepatosplenomegaly and extreme hyperferritinemia.
 American Journal of Hematology 2013; 88(7): 626-629.
208. SC Fagerholm, M MacPherson, MJ James, C Sevier-Guy, CS Lau. 2.911
 The CD11b-integrin (ITGAM) and systemic lupus erythematosus.
 Lupus 2013; 22(7): 657-663.
209. CC Mok, LS Tam, MH Leung, KY Ying, CH To, KL Lee, LY Ho, ML Yip, HS Tsui, TH Chan, KW Lee, EKM Li. 2.454
 Referral strategy for early recognition of axial spondyloarthritis: consensus recommendations from the Hong Kong Society of Rheumatology.
 International Journal of Rheumatic Diseases. 2013, 16(5): 500-8.
<http://dx.DOI.org/10.1111/1756-185X.12161>
210. HY Chung, CY Chan, HHL Tsang, YL Au, CS Lau. -
 The socio-economic impacts on household income, employment status, need for public assistance, and marriage opportunities in patients with Spondyloarthritis: A comparison with the Hong Kong population.
 Journal of Clinical Rheumatology and Immunology 2013;13: 39-46.
211. YLE Au, WSR Wong, MY Mok, HY Chung, E Chan, CS Lau. 2.98
 Disease activity assessment in ankylosing spondylitis in a Chinese cohort: BASDAI or ASDAS?
 Clinical Rheumatology 2014 Aug;33(8):1127-34.
[10.1007/s10067-014-2729-5](http://dx.DOI.org/10.1007/s10067-014-2729-5)
212. N Sharma, CS Lau, D Harbutt, G Morris, I Doherty. 2.610
 Evaluation of the flipped classroom at the Li Ka Shing Faculty of Medicine.
 MedEdPublish 2014; 3: 7.
<http://dx.DOI.org/10.15694/mep.2014.003.0007>
213. G Kwok, A Kan, RY Leung, S Tam, CS Lau and YL Kwong. 4.965
 Pyrexia, massive hepatomegaly, and extreme hyperferritinemia.
 American Journal of Medicine. 2014, 127(6): e13-e14.
<http://dx.DOI.org/10.1016/j.amjmed.2014.01.015>

214. J Zhang, Y Zhang, J Yang, L Zhang, L Sun, HF Pan, 6.15
 N Hirankarn, D Ying, S Zeng, TL Lee, CS Lau, TM Chan,
 AM Leung, CC Mok, SN Wong, KW Lee, MH Ho, PP Le,
 BH Chung, CY Chong, RW Wong, MY Mok, WH Wong,
 KL Tong, NK Tse, XP Li, Y Avihingsanon, P Rianthavorn,
 T Deekajorndej, K Suphapeetiporn, V Shotelersuk, SK Ying,
 SK Fung, WM Lai, MM Garcia-Barcelo, SS Cherny, PK Tam,
 Y Cui, PC Sham, S Tang, DQ Ye, XJ Zhang, YL Lau, W Yang.
 Three SNPs in chromosome 11q23.3 are independently associated
 with systemic lupus erythematosus in Asians.
 Human Molecular Genetics 2014; 23 (2): 524-533.
[10.1093/hmg/ddt424](https://doi.org/10.1093/hmg/ddt424)
215. N Sharma, CS Lau, I Dpherty, D Harbutt. 6.893
 Medical school pedagogy should be culture-dependent.
 Academic Medicine 2014 Feb ;89(1) :194. PMID: 24473566.
 DOI: [10.1097/ACM.000000000000118](https://doi.org/10.1097/ACM.000000000000118)
216. S Yan, YY Lok, LW Lu, CS Lau, VSF Chan. 6.303
 MicroRNA regulation in systemic lupus erythematosus
 pathogenesis.
 Immune Network 2014; 14(3):138-148.
<https://doi.org/10.4110/in.2014.14.3.138>
217. X Lin, K Rui, J Deng, J Tian, X Wang, S Wang, KH Ko, Z Jiao, 19.103
 VSF Chan, CS Lau, X Cao, L Lu.
 Th17 cells play a critical role in the development of experimental
 Sjögren’s syndrome.
 Annals of the Rheumatic Diseases 2015;74: 1302–1310.
 DOI: [10.1136/annrheumdis-2013-204584](https://doi.org/10.1136/annrheumdis-2013-204584)
218. N Sharma, CS Lau, I Doherty, D Harbutt. 3.65
 How we flipped the medical classroom.
 Medical Teacher 2015; 37 (4): 327-330.
 DOI: [10.3109/0142159X.2014.923821](https://doi.org/10.3109/0142159X.2014.923821)

219. Y Zhang, YF Wang, J Yang, J Zhang, L Sun, N Hirankarn, HF Pan, CS Lau, TM Chan, TL Lee, A Leung, CC Mok, L Zhang, JJ Shen, SN Wong, K Lee, MH Ho, PP Lee, BH Chung, CY Chong, RW Wong, MY Mok, WH Wong, KL Tong, NK Tse, XP Li, Y Avihingsanon, P Rianthavorn, T Deekajorndej, K Suphapeetiporn, V Shotelersuk, SK Ying, SK Fung, WM Lai, CM Wong, IO Ng, MM Garcia-Barcelo, SS Cherny, PK Tam, PC Sham, S Yang, DQ Ye, Y Cui, XJ Zhang, W Yang, YL Lau. 5.156
 Meta-analysis of two Chinese populations identifies an autoimmune disease risk allele in 22q11.21 as associated with systemic lupus erythematosus.
 Arthritis Research and Therapy 2015;17(1):1-9.
 DOI: [10.1186/s13075-015-0577-6](https://doi.org/10.1186/s13075-015-0577-6)
220. CS Lau, F Chia, A Harrison, TW Hsieh, R Jain, SM Jung, M Kishimoto, A Kumar, KP Leong, ZQ Li, JJ Lichauco, W Louthrenoo, SF Luo, P Nash, CT Ng, SH Park, BPP Suryana, P Suwannalal, LK Wijaya, K Yamamoto, Y Yang, SS Yeap. 2.454
 APLAR rheumatoid arthritis treatment recommendations.
 International Journal of Rheumatic Diseases 2015 ;18(7): 685-713.
<https://doi.org/10.1111/1756-185X.12754>
221. Y Zhang, J Zhang, J Yang, Y Wang, L Zhang, X Zuo, L Sun, HF Pan, N Hirankarn, T Wang, R Chen, D Ying, S Zeng, JJ Shen, TL Lee, CS Lau, TM Chan, AM Leung, CC Mok, SN Wong, KW Lee, MH Ho, PP Lee, BH Chung, CY Chong, RW Wong, MY Mok, WH Wong, KL Tong, NK Tse, XP Li, Y Avihingsanon, P Rianthavorn, T Deekajorndej, K Suphapeetiporn, V Shotelersuk, SK Ying, SK Fung, WM Lai, CM Wong, IO Ng, MM Garcia-Barcelo, SS Cherny, PK Tam, PC Sham, S Yang, DQ Ye, Y Cui, XJ Zhang, YL Lau, W Yang. 6.15
 Meta-analysis of GWAS on two Chinese populations followed by replication identifies novel genetic variants on the X chromosome associated with systemic lupus erythematosus.
 Human Molecular Genetics 2015; 24(1): 274-284.
 DOI: [10.1093/hmg/ddu429](https://doi.org/10.1093/hmg/ddu429)
222. RCY Tam, ALH Lee, WL Yang, CS Lau, VSF Chan. 5.542
 Systemic lupus erythematosus patients exhibit reduced expression of *CLEC16A* isoforms in peripheral leukocytes.
 International Journal of Molecular Sciences 2015; 16(7): 14428-14440.
<https://doi.org/10.3390/ijms160714428>

223. Y Chen, HY Chung, CT Zhao, A Wong, Z Zhen, HHL Tsang, CS Lau, HF Tse, KH Yiu. 7.580
 Left ventricular myocardial dysfunction and premature atherosclerosis in patients with axial Spondyloarthritis. Rheumatology (Oxford). 2015 Feb;54(2): 292-301. PMID: 25173350 DOI: [10.1093/rheumatology/keu337](https://doi.org/10.1093/rheumatology/keu337).
224. J Zhang, L Zhang, Y Zhang, J Yang, M Guo, L Sun, HF Pan, 9.002
 N Hirankarn, D Ying, S Zeng, TL Lee, CS Lau, TM Chan, AM Leung, CC Mok, SN Wong, KW Lee, MH Ho, PP Lee, BH Chung, CY Chong, RW Wong, MY Mok, WH Wong, KL Tong, NK Tse, XP Li, Y Avihingsanon, P Rianthavorn, T Deekajorndej, K Suphapeetiporn, V Shotelersuk, SK Ying, SK Fung, WM Lai, MM Garcia-Barceló, SS Cherny, PC Sham, Y Cui, S Yang, DQ Ye, XJ Zhang, YL Lau, W Yang.
 Gene-based meta-analysis of genome-wide association study identifies independent single-nucleotide polymorphisms in ANXA6 as being associated with systemic lupus erythematosus in Asian populations. Arthritis and Rheumatology 2015; 67(11): 2966-2977. DOI: [10.1002/art.39275](https://doi.org/10.1002/art.39275)
225. HJ Wu, Y Lo, D Luk, CS Lau, L Lu and MY Mok. 3.969
 Alternatively activated dendritic cells derived from systemic lupus erythematosus patients have tolerogenic phenotype and function. Clinical Immunology 2015; 156: 43-57. DOI: [10.1016/j.clim.2014.10.011](https://doi.org/10.1016/j.clim.2014.10.011)
226. YT Chan, HK Ho, CK Lai, CS Lau, YL Lau, 2.07
 TH Lee, TF Leung, WK Wong, YY Wu, for The Hong Kong Allergy Alliance.
 Allergy in Hong Kong: an unmet need in service provision and training. Hong Kong Medical Journal 2015; 21(1): 52-60. DOI: [10.12809/hkmj144410](https://doi.org/10.12809/hkmj144410)
227. K Franklyn, CS Lau, SV Navarra, W Louthrenoo, A Lateef, 19.103
 L Hamijoyo, CS Wahono, SL Chen, O Jin, S Morton, A Hoi, M Huq, M Nikpour, EF Morand. Asia-Pacific Lupus Collaboration. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Annals of the Rheumatic Diseases 2016; 75(9): 1615-1621. DOI: [10.1136/annrheumdis-2015-207726](https://doi.org/10.1136/annrheumdis-2015-207726)

228. JWH Leung, BWM Lau, VSF Chan, CS Lau, KF So. 2.406
 Abnormal increase of neuronal precursor cells and exacerbated neuroinflammation in the corpus callosum in murine model of systemic lupus erythematosus.
 Restorative Neurology and Neuroscience 2016; 34: 443-453.
 DOI: [10.3233/RNN-160638](https://doi.org/10.3233/RNN-160638)
229. AM Leung, D Farewell, CS Lau, EH Choy. 7.580
 Defining criteria for rheumatoid arthritis patient-derived disease activity score that correspond to Disease Activity Score 28 and Clinical Disease Activity Index based disease states and response criteria.
 Rheumatology (Oxford) 2016; 55(11): 1954-1958.
 DOI: [10.1093/rheumatology/kew279](https://doi.org/10.1093/rheumatology/kew279)
230. K Lim, M Chan, S Navarra, SA Haq, CS Lau. 2.98
 Development and implementation of models of care for musculoskeletal conditions in middle-income and low-income Asian countries. Best Practice and Research.
 Clinical Rheumatology 2016; 30(3): 398-419.
 DOI: [10.1016/j.berh.2016.08.007](https://doi.org/10.1016/j.berh.2016.08.007)
231. JY Chen, LY Wu, MYT Mok, JYJ Wu, KE Lintner, CM Wang, EK Chung, Y Yang, B Zhou, H Wang, DJ Yu, A Alhomosh, K Jones, CH Spencer, HN Nagaraja, YL Lau, CS Lau, YC Yu. 9.002
 Effects of complement C4 gene copy number variations, size dichotomy, and C4A deficiency on genetic risk and clinical presentation of systemic lupus erythematosus in East Asian populations.
 Arthritis and Rheumatology 2016, 68: 1442-1453.
 DOI: [10.1002/art.39589](https://doi.org/10.1002/art.39589)
232. Y Zhang, J Yang, J Zhang, L Sun, N Hirankarn, HF Pan, CS Lau, TM Chan, TL Lee, AM Leung, CC Mok, L Zhang, Y Wang, JJ Shen, SN Wong, KW Lee, MH Ho, PP Lee, BH Chung, CY Chong, RW Wong, MY Mok, WH Wong, KL Tong, NK Tse, XP Li, Y Avihingsanon, P Rianthavorn, T Deekajorndej, K Suphapeetiporn, V Shotelersuk, SK Ying, SK Fung, Lai WM, CM Wong, IO Ng, MM Garcia-Barcelo, SS Cherny, Y Cui, PC Sham, S Yang, DQ Ye, XJ Zhang, YL Lau, W Yang. 19.103
 Genome-wide search followed by replication reveals genetic interaction of CD80 and ALOX5AP associated with systemic lupus erythematosus in Asian populations.
 Annals of the Rheumatic Diseases 2016; 75(5): 891-898.
 DOI: [10.1136/annrheumdis-2014-206367](https://doi.org/10.1136/annrheumdis-2014-206367)

233. Z Wang, H Yin, CS Lau, Q Lu. 5.542
 Histone posttranslational modifications of CD4(+) T cell in autoimmune diseases.
 International Journal of Molecular Sciences 2016, 17: 1547.
 DOI: [10.3390/ijms17101547](https://doi.org/10.3390/ijms17101547)
234. S Yan, LY Yim, CY Tam, WK Chan, L Lu, CS Lau, VSF Chan. 5.542
 MicroRNA-155 mediates augmented CD40 expression in bone marrow derived plasmacytoid dendritic cells in symptomatic lupus-prone NZB/W F1 mice.
 International Journal of Molecular Sciences. 2016, 17: 1282.
 DOI: <https://doi.org/10.3390/ijms17081282>
235. Y Gao, EYY Lau, HY Wan, CS Lau, MYT Mok. 2.911
 Systemic lupus erythematosus patients with past neuropsychiatric involvement are associated with worse cognitive impairment: a longitudinal study.
 Lupus 2016, 25: 637-644.
 DOI: [10.1177/0961203315624022](https://doi.org/10.1177/0961203315624022)
236. X Huang, H Wu, H Qiu, H Yang, Y Deng, M Zhao, H Luo, X Zhou, Y Xie, V Chan, CS Lau, Q Lu. 3.969
 The expression of Bcl-6 in circulating follicular helper-like T cells positively correlates with the disease activity of systemic lupus erythematosus.
 Clinical Immunology 2016; 173: 161-170.
<https://doi.org/10.1016/j.clim.2016.10.017>
237. V Golder, R Kandane-Rathnayake, AY Hoi, M Huq, W Louthrenoo, Y An, ZG Li, SF Luo, S Sockalingam, CS Lau, MY Mok MY, A Lateef, K Franklyn, S Moron, ST Navarra, L Zamora, YJ Wu, L Hamijoyo, M Chan, S O'Neill, F Goldblatt, E Morand, M Nikpour; Asia-Pacific Lupus Collaboration. 5.156
 Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort.
 Arthritis Research and Therapy 2016; 18 (1): 1-9.
 DOI: [10.1186/s13075-016-1163-2](https://doi.org/10.1186/s13075-016-1163-2)
238. Q Zhang, S Ding, H Zhang, H Long, H Wu, M Zhao, V Chan, CS Lau, Q Lu. 6.551
 Increased Set1 binding at the promoter induces aberrant epigenetic alterations and up-regulates cyclic adenosine 5'-monophosphate response element modulator alpha in systemic lupus erythematosus.
 Clinical Epigenetics 2016; 24(8): 126.
 DOI: [10.1186/s13148-016-0294-2](https://doi.org/10.1186/s13148-016-0294-2)

239. KMK Ng, TT Cheung, CS Lau, HY Chung. -
 The role of magnetic resonance imaging in a patient with rheumatoid arthritis presented with lymphedema-like swelling: a case report. *Journal of Clinical Rheumatology and Immunology* Nov 2016. DOI:10.1515/hkbrd-2016-0007
240. CWS Chan, HHL Tsang, CS Lau, HY Chung. -
 Male smokers with HLA-B27 positivity, SI joints inflammation have more radiological damages and higher prevalence of AS while females have higher BASDAI scores: Observations from cluster analyses of a group of SpA patients. *Journal of Clinical Rheumatology and Immunology* 2016; 16(2): 42-47.
241. WY Yeung, CS Lau. -
 Mesenchymal Stem Cell Therapy for rheumatic diseases *Journal of Clinical Rheumatology and Immunology*, 2016; 16(1): 6-10.
<http://dx.doi.org/10.1515/hkbrd-2016-0002>
242. V Golder, M Huq, K Franklyn, A Calderone, A Lateef, CS Lau, ALH Lee, STV Navarra, T Godfrey, S Oon, AYB Hoi, EF Morand, M Nikpour. 4.7
 Does expert opinion match the operational definition of the lupus low disease activity state (LLDAS)? A case-based construct validity study. *Seminars in Arthritis and Rheumatism* 2017; 46, 798-803. DOI: [10.1016/j.semarthrit.2017.01.007](https://doi.org/10.1016/j.semarthrit.2017.01.007)
243. X Xu, SK Hui, MYT Mok, J Jiang, CS Lau, HKF Mak. 3.825
 Structural brain network reorganization in patients with neuropsychiatric systemic lupus erythematosus. *American Journal of Neuroradiology* 2017; 38 (1): 64-70. DOI: [10.3174/ajnr.A4947](https://doi.org/10.3174/ajnr.A4947)
244. V Golder, R Kandane-Rathnayake, AY Hoi, M Huq, 5.156
 W Louthrenoo, Y An, ZG Li, SF Luo, Z Sockalingam, CS Lau, MYT Mok M, A Lateef, K Franklyn, S Morton, ST Navarra, L Zamora, YJ Wu, L Hamijoyo, M Chan, S O'Neill, F Goldblatt, M Nikpour, EF Morand.
 Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. *Arthritis Research and Therapy* 2017; 19 (1): 62. DOI: [10.1186/s13075-017-1256-6](https://doi.org/10.1186/s13075-017-1256-6)

245. CY Chan, HHL Tsang, CS Lau, HY Chung. 2.454
Prevalence of depressive and anxiety disorders and validation of the Hospital Anxiety and Depression Scale as a screening tool in axial spondyloarthritis patients.
International Journal of Rheumatic Diseases. 2017 20(3):317-325.
PMID: 25293872. DOI: [10.1111/1756-185X.12456](https://doi.org/10.1111/1756-185X.12456)
246. HY Chung, X Xu, V Lau, G Ho, KL Lee, P Li, H Tsang, SK Kwok, CS Lau, CS Wong. 4.473
Comparing diffusion weighted imaging with clinical and blood parameters, and with short tau inversion recovery sequence in detecting spinal and sacroiliac joint inflammation in axial Spondyloarthritis.
Clinical and Experimental Rheumatology, 2017 Mar-Apr; 35(2):262-269.
PMID: 27908306
247. JH Liu, MY Ng, T Cheung, HY Chung, Y Chen, Z Zhen, Y Zou, KF Mak, PL Khong, CS Lau, HF Tse, KH Yiu. 2.98
Ten-year progression of coronary artery, carotid artery, and aortic calcification in patients with rheumatoid arthritis.
Clinical Rheumatology. 2017 Apr;36(4):807-816.
DOI: [10.1007/s10067-016-3536-y](https://doi.org/10.1007/s10067-016-3536-y). PMID: 28127640
248. Y Deng, Z Wang, C Chang, L Lu, CS Lau, Q Lu. 2.85
Th9 cells and IL9 in autoimmune disorders: Pathogenesis and therapeutic potentials.
Human Immunology 2017; 78: 120-128.
DOI: [10.1016/j.humimm.2016.12.010](https://doi.org/10.1016/j.humimm.2016.12.010)
249. KS Yeung, BHY Chung, S Choufani, MYT Mok, WL Wong, CCY MAK, W Yang, PPW Lee, WHS Wong, YA Chen, D Grafodatskaya, WSR Wong, CS Lau, DTM Chan, R Weksberg, YL Lau, JC Crispin. 3.24
Genome-wide DNA methylation analysis of Chinese patients with systemic lupus erythematosus identified hypomethylation in genes related to the type I interferon pathway.
PLoS One 2017;12:e0169553
DOI: [10.1371/journal.pone.0169553](https://doi.org/10.1371/journal.pone.0169553)
250. CS Lau, A Gibofsky, N Damjanov, S Lula, L Marshall, H Jones, P Emery. 2.631
Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review.
Rheumatology International 2017; 37 (11): 362-372.
DOI: [10.1007/s00296-017-3780-8](https://doi.org/10.1007/s00296-017-3780-8)

251. PH Li, KL Ko, CTK Ho, LL Lau, RKY Tsang, TT Cheung, WK Leung, CS Lau. 2.07
 Immunoglobulin G4-related disease in Hong Kong: clinical features, treatment practices, and its association with multisystem disease. Hong Kong Medical Journal 2017; 23 (5): 446-453. DOI: [10.12809/hkmj176229](https://doi.org/10.12809/hkmj176229)
252. CY Tam, WMM Li, YP Gao, YT Pang, S Yan, W Ge, CS Lau, VSF Chan. 3.905
 Human CLEC16A regulates autophagy through modulating mTOR activity. Experimental Cell Research 2017; 352(2): 304-312. <https://doi.org/10.1016/j.yexcr.2017.02.017>
253. LK Chan, FJA Ganotice, FKY Wong, CS Lau, SM Bridges, 2.372
 CHY Chan, NK Chan, WLP Chan, H Chen, JY Chen, KPJ Chu, CC Ho, JMC Ho, TP Lam, SF Lam, Q Li, J Shen, JA Tanner, WYW Tso, AKC Wong, GTC Wong, JYH Wong, NS Wong, AJ Worsley, LK Yu, TP Yum.
 Implementation of an interprofessional team-based learning program involving seven undergraduate health and social care programs from two universities, and students' evaluation of their readiness for interprofessional learning. BMC Medical Education. 2017; 17. <http://dx.DOI.org/10.1186/s12909-017-1046-5>
254. H Qiu, H Wu, VSF Chan, CS Lau, Q Lu. 2.815
 Transcriptional and epigenetic regulation of follicular T-helper cells and their role in autoimmunity. Autoimmunity 2017; 50: 71-81. <https://doi.org/10.1080/08916934.2017.1284821>
255. TH Lee, TF Leung, G Wong, M Ho, JR Duque, PH Li, CS Lau, WF Lam, A Wu, E Chan, C Lai, YL Lau. 2.31
 The unmet provision of allergy services in Hong Kong impairs capability for allergy prevention – implications for the Asia Pacific region. Asian Pacific Journal of Allergy and Immunology 2017 Dec. DOI: [10.12932/AP-250817-0150](https://doi.org/10.12932/AP-250817-0150)
256. PH Li and CS Lau 2.454
 Lupus in the far east: a modern epidemic. International Journal of Rheumatic Diseases 2017; 20: 523-525. <http://dx.doi.org/10.1111/1756-185X.13115>

257. D Huang, YY Cheng, PH Chan, J Hai, KH Yiu, HF Tse, KL Wong, K Fan, YW Li, WL Ng, CW Yim, CJ Wong, LS Tam, PCH Wong, CY Wong, CH Ho, AMH Leung, CC Mok, H Lam, CS Lau, T Cheung, C Ho, SWY Law, EW Chan, LX Yin, WS Yue, TM Mok, MA Evora, SW Siu. Rationale and design of the screening of pulmonary hypertension in systemic lupus erythematosus (SOPHIE) study. *European Respiratory Journal Open Research* 2018; 4(1): pii: 00135-2017.
DOI: [10.1183/23120541.00135-2017](https://doi.org/10.1183/23120541.00135-2017) 1.0
258. PH Li, TJ Watts, MS Lui, CS Lau, HY Chung. Recall Urticaria in Adalimumab Hypersensitivity. *Journal of Allergy and Clinical Immunology: In Practice*. May-Jun 2018; 6(3):1032-1033.
DOI: [10.1016/j.jaip.2017.10.031](https://doi.org/10.1016/j.jaip.2017.10.031) 8.861
259. DY Chen, CS Lau, B Elzorkany, PN Hsu, S Praprotnik, R Vasilescu, L Marshall, L Llamado. Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature. *International Journal of Rheumatic Diseases*. 2018 Feb; 21(2): 362-372.
DOI: [10.1111/1756-185X.13238](https://doi.org/10.1111/1756-185X.13238) 2.454
260. EY Au, WK Ip, CS Lau, YT Chan. Evaluation of a multiplex flow immunoassay versus conventional assays in detecting autoantibodies in systemic lupus erythematosus. *Hong Kong Medical Journal*. 2018 Jun;24(3):261-269.
DOI: [10.12809/hkmj177007](https://doi.org/10.12809/hkmj177007) 2.07
261. EYL Au, JS Rosa Duque, CS Lau, E Chan. A patient with anaphylaxis to diphenhydramine without cross-reactivity to loratidine. *Journal of Allergy and Clinical Immunology: In Practice* 2018; 6(3): 1061-1063.
DOI: [10.1016/j.jaip.2017.10.032](https://doi.org/10.1016/j.jaip.2017.10.032) 8.861
262. CWS Chan, HHL Tsang, PH Li, KH Lee, CS Lau, PYS Wong, HY Chung. Diffusion-weighted imaging versus short tau inversion recovery sequence: Usefulness in detection of active sacroiliitis and early diagnosis of axial spondyloarthritis. *PLoS One* 2018 Aug 7;13(8):e0201040.
DOI: [10.1371/journal.pone.0201040](https://doi.org/10.1371/journal.pone.0201040) 3.24

263. PH Li, PP Lee, SL Fung, CS Lau, YL Lu. 2.07
Chronic mucocutaneous candidiasis-more than just skin deep.
Hong Kong Medical Journal 2018 Aug 24(4) 423-425.
DOI: [10.12809/hkmj166048](https://doi.org/10.12809/hkmj166048)
264. IKY Lam, JX Chow, CS Lau, VSF Chan. 8.679
MicroRNA-mediated immune regulation in rheumatic diseases.
Cancer Letters 2018 Sept 1, 431:201-212.
DOI: [10.1016/j.canlet.2018.05.044](https://doi.org/10.1016/j.canlet.2018.05.044)
265. H Wu, W Liao, Q Li, H Long, H Yin, M Zhao, V Chan, 9.754
CS Lau, Q Lu
Pathogenic role of tissue-resident memory T cells in autoimmune
diseases.
Autoimmunity reviews. 2018 Sep 1;17(9):906-11.
<https://doi.org/10.1016/j.autrev.2018.03.014>
266. SPY Wong, CC Mok, CS Lau, ML Yip, LS Tam, KY Ying, 2.631
WL Ng, KH Ng, MH Leung, STY Lee, TC Hung, V Lee, C Yu,
PCH Wong, CK Sung, T Lee, E Kun.
Clinical presentation, treatment and outcome of Takayasu's arteritis
in southern Chinese: a multi-center retrospective study.
Rheumatology International 2018 Dec; 38(12): 2263-2270.
DOI: [10.1007/s00296-018-4150-x](https://doi.org/10.1007/s00296-018-4150-x)
267. KS Yeung, TL Lee, MY Mok, CCY Mak, W Yang, 4.528
PCY Chong, PPW Lee, MHK Ho, S Choufani, CS Lau, YL Lau, R
Weksberg, BHY Chung.
Cell lineage-specific genome-wide DNA methylation analysis of
patients with paediatric-onset systemic lupus erythematosus.
Epigenetics 2019 Feb 26.
<https://doi.org/10.1080/15592294.2019.1585176>
268. R Kandan-Rathnayake, V Golder, W Louthrenoo, SF Luo, 2.454
YJ Jan Wu, Z Li, Y An, A Lateef, S Sockalingam, SV Navarra,
L Zamora, L Hamijovo, Y Katsumata, M Harigai, M Chan,
S O'Neill, F Goldblatt, Y Hao, Z Zhang, J Al-Saleh,
M Khamashta, T Takeuchi, Y Tanaka, SC Bae, CS Lau, A Hoi,
M Nikpour, EF Morand.
Development of the Asia Pacific Lupus Collaboration cohort.
International Journal of Rheumatic Diseases 2019 Mar; 22(3): 425-
433.
DOI: [10.1111/1756-185X.13431](https://doi.org/10.1111/1756-185X.13431). PMID: 30398013

269. CWS Chan, HY Chung, CS Lau, HLH Tsang. 2.454
 Spontaneous pneumomediastinum in a dermatomyositis patient with anti-melanoma differentiation-associated gene-5 antibody and interstitial lung disease despite an initial response to immunosuppressant.
 International Journal of Rheumatic Diseases 2019 Mar; 22(3): 521-524. DOI: [10.1111/1756-185X.13112](https://doi.org/10.1111/1756-185X.13112)
270. KH Lee, HY Chung, XP Xu, V Lau, CS Lau. 11.105
 Apparent diffusion coefficient as an imaging biomarker for spinal disease activity in axial spondyloarthritis.
 Radiology 2019 Apr;29(1):121-128.
 PMID: 30720403. <http://dx.doi.org/10.1148/radiol.2019180960>
271. TP Lam, KS Sun, HY Chan, CS Lau, KF Lam, R Sanson-Fisher 3.364
 Perceptions of Chinese towards dementia in Hong Kong – diagnosis, symptoms and impacts.
 International Journal of Environmental Research and Public Health 2019; 16(1), 128.
<http://www.mdpi.com/1660-4601/16/1/128>
272. LS Tam, JCC Wei, A Aggarwal, HJ Baek, PP Cheung, 2.454
 P Chiowchanwisawakit, L Dans, J Gu, N Hagino, M Kishimoto, HM Reyes, S Soroosh, S Stebbings, S Whittle, SS Yeap, CS Lau.
 2018 APLAR axial spondyloarthritis treatment recommendations.
 International Journal of Rheumatic Diseases 2019; 22: 340-356.
 DOI: [10.1111/1756-185X.13510](https://doi.org/10.1111/1756-185X.13510)
273. CS Lau, F Chia, L Dans, A Harrison, TY Hsieh, R Jain, 2.454
 SM Jung, M Kishimoto, A Kumar, KP Leong, Z Li, JJ Lichauco, W Louthrenoo, SF Luo, R Mu, P Nash, CT Ng, B Suryana, LK Wijaya, SS Yeap.
 2018 Update of the APLAR recommendations for treatment of rheumatoid arthritis.
 International Journal of Rheumatic Diseases 2019; 22(3):357-375.
<http://dx.doi.org/10.1111/1756-185x.13513>
274. HY Chung, RSW Yiu, SCW Chan, KH Lee, CS Lau. 2.91
 Fatty corner lesions in T1-weighted magnetic resonance imaging as an alternative to sacroiliitis for diagnosis of axial spondyloarthritis.
 BMC Rheumatology. 2019 May 30; 3: 17.
 PMID: 31161154. <https://doi.org/10.1186/s41927-019-0068-5>

275. YH Chan, MC Ngai, Y Chen, MZ Wu, YJ Yu, Z Zhen, K Lai, T Cheung, LM Ho, HY Chung, CS Lau, HF Tse, KH Yiu 5.501
Cumulative rheumatic inflammation modulates the bone-vascular axis and risk of coronary calcification. Journal of the American Heart Association 2019 Jun;4;8(11) : e011540.
PMID :31130038. DOI: [10.1161/JAHA.118.011540](https://doi.org/10.1161/JAHA.118.011540)
276. HHL Tsang, JPY Cheung, CKH Wong, PWH Cheung, CS Lau, HY Chung 5.156
Psychometric validation of the EuroQoL 5-dimension (EQ-5D) questionnaire in patients with spondyloarthritis. Arthritis Research & Therapy 2019 ; 21:41.
PMID: 30700326. DOI: [10.1186/s13075-019-1826-x/](https://doi.org/10.1186/s13075-019-1826-x/)
277. HY Chung, ETF Chui, KH Lee, HHLTsang, SCW Chan, CS Lau. 5.117
ASDAS is associated with both the extent and intensity of DW-MRI spinal inflammation in active axial spondyloarthritis. RMD Open. 2019 Aug 6;5(2): e001008.
PMID: 31452930. DOI: [10.1136/rmdopen-2019-001008](https://doi.org/10.1136/rmdopen-2019-001008)
278. PH Li, LQC Siew, I Thomas, TJ Watts, KL Ue, K Rutkowski, CS Lau. 4.084
Beta-lactam allergy in Chinese patients and factors predicting genuine allergy. World Allergy Organization Journal 2019 Aug 12(8):100048.
<https://doi.org/10.1016/j.waojou.2019.100048>
279. LY Yim, CS Lau, VSF Chan 5.542
Heightened TLR7/9-induced IL-10 and CXCL13 production with dysregulated NF- κ B activation in CD11chiCD11b+ dendritic cells in NZB/W F1 mice. International Journal Molecular Sciences. 2019 Sep 19; 20(18). pii: E4639.
<https://www.mdpi.com/1422-0067/20/18/4639>
280. YH Chan, MC Ngai, Y Chen, MZ Wu, YJ Yu, Z Zhen, K Lai, T Cheung, LM Ho, HY Chung, CS Lau, CP Lau, HF Tse, KH Yiu. 1.468
Osteogenic circulating endothelial progenitor cells are linked to electrocardiographic conduction abnormalities in rheumatic patients Annals of Noninvasive Electrocardiology 2019; 24(5): e12651.
DOI: [10.1111/anec.12651](https://doi.org/10.1111/anec.12651)

281. PH Li, TJ Watts, HY Chung, CS Lau. 8.861
 Fixed drug eruption to biologics and role of lesional patch testing
 Journal of Allergy and Clinical Immunology. In Practice 2019
 Sep-Oct;7(7):2398-2399.
 DOI: [10.1016/j.jaip.2019.06.028](https://doi.org/10.1016/j.jaip.2019.06.028)
282. PH Li, HY Chung, CS Wong, HHL Tsang, VWH Lau, G Ho, -
 X XU, CS Lau, KY Ma
 Fatty corner lesions in T1-weighted magnetic resonance imaging
 as an alternative to sacroiliitis for diagnosis of axial
 spondyloarthritis.
 Journal of Clinical Rheumatology and Immunology 2019; 19(1):1-
 8.
 DOI: [10.1142/S2661341719500019](https://doi.org/10.1142/S2661341719500019)
283. R Kandane-Rathnayake, JR Kent, W Louthrenoo, SF Luo, 2.911
 YJ Wu, A Lateef, V Golder, S Sockalingam, SA Navarra,
 L Zamora, L Hamijoyo, Y Katsumata, M Harigai, M Chan,
 S O'Neill, F Goldblatt, CS Lau, A Hoi, M Nikpour, E Morand.
 Longitudinal associations of active renal disease with irreversible
 organ damage accrual in systemic lupus erythematosus.
 Lupus. 2019 Dec;28(14):1669-1677.
 DOI: [10.1177/0961203319887799](https://doi.org/10.1177/0961203319887799)
284. PH Li, HY Chung, CS Wong, HHL Tsang, VWH Lau, G Ho, -
 X XU, CS Lau, and KY Ma
 The association between age and clinical and radiological activity in
 axial spondyloarthritis
 Journal of Clinical Rheumatology and Immunology. 2019, 1-8
<http://dx.doi.org/10.1142/S2661341719500019>
285. LS Tam, CS Lau -
 Authors reply to comment on axial SpA recommendations
 International Journal of Rheumatic Diseases. 2019, 22, 1346-1347.
<http://dx.doi.org/10.1111/1756-185X.13643>
286. YLE Au, CS Lau, K Lam and YTE Chan 1.858
 Perioperative anaphylaxis and investigations: a local study in Hong
 Kong.
 Singapore Medical Journal. 2019,61(4): 200-205.
<http://dx.doi.org/10.11622/smedj.2019156>

287. SCT Wong, WS Li, AHY Ng, CS Lau, HY Chung 2.454
 Risk of cutaneous herpes zoster in patients with spondyloarthritis treated with conventional and biologic disease modifying anti-rheumatic drugs.
 International Journal of Rheumatic Diseases 2020;23:189-196.
 PMID: 31489783. DOI: [10.1111/1756-185X.13694](https://doi.org/10.1111/1756-185X.13694)
288. PH Li, I Thomas, JC Wong, K Rutkowski, CS Lau. -
 Differences in omega-5-gliadin allergy: East versus West.
 Asia Pacific Allergy 2020 Jan 26;10(1): e5.
<https://doi.org/10.5415/apallergy.2020.10.e5>
289. OM Wong, HHL Tsang, SCW Chan, KH Lee, PH Li, CS Lau, HY Chung. 3.517
 Clinical associations of uveitis in axial spondyloarthritis group and ankylosing spondylitis group: Do they represent the same disease?
 Journal of Clinical Rheumatology. 2020 Jan; 26(1): 1-6.
 DOI: [10.1097/RHU.0000000000000869](https://doi.org/10.1097/RHU.0000000000000869). PMID:30028807
290. PH Li, HHH Yeung, CS Lau, EYL Au. 8.48
 Prevalence, incidence, and sensitization profile of β -lactam antibiotic allergy in Hong Kong.
 JAMA Network Open. 2020 May 1;3(5): e204199.
 DOI: [10.1001/jamanetworkopen.2020.4199](https://doi.org/10.1001/jamanetworkopen.2020.4199)
291. IF Hung, KC Lung, EY Tso, R Liu, TW Chung, MY Chu, YY Ng, J Lo, J Chan, AR Tam, HP Shum, V Chan, AK Wu, KM Sin, WS Leung, WL Law, DC Lung, S Sin, P Yeung, CC Yip, RR Zhang, AY Fung, EY Yan, KH Leung, JD Ip, AW Chu, WM Chan, AC Ng, R Lee, K Fung, A Yeung, TC Wu, JW Chan, WW Yan, WM Chan, JF Chan, AK Lie, OT Tsang, VC Cheng, TL Que, CS Lau, KH Chan, KK To, KY Yuen. 79.321
 Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
 The Lancet 2020 May 30;395(10238):1695-1704.
 DOI: [10.1016/S0140-6736\(20\)31042-4](https://doi.org/10.1016/S0140-6736(20)31042-4)
292. TT Chung, HJ Ko, CS Lau and HY Chung. 2.631
 A retrospective study on the risk of tuberculosis in patients with rheumatoid arthritis.
 Rheumatology International 2020; Jun;40(6):983-990.
<https://doi.org/10.1007/s00296-020-04583-8>

293. P Li, CS Lau. -
Efficacy and safety of vaccinations in systemic lupus erythematosus.
Journal of Clinical Rheumatology and Immunology 2020; 1-7.
DOI.org/10.1142/S2661341720300037
294. PH Li, WWY Wong, ENY Leung, CS Lau, E Au. 6.161
Novel pathogenic mutations identified in the first Chinese pedigree
of complete C6 deficiency.
Clinical & Translational Immunology 2020; 9: e1148.
DOI: [10.1002/cti2.1148](https://doi.org/10.1002/cti2.1148)
295. K Pile, R Norager, M Skillecorn, KA Gibson, S Elderton, 2.454
W Favorito, Zhanguo Li, R Mu, H Nakahara, M Kishimoto,
S Hirata, Y Kaneko, CS Lau, LS Tam, YH Chen, P Chen,
B Wahking, D Furtner.
Elevating the role of carers in rheumatoid arthritis management in the
Asia-Pacific region
International Journal of Rheumatic Diseases 2020;23(7):898-910.
DOI: [10.1111/1756-185X.13893](https://doi.org/10.1111/1756-185X.13893)
296. F Liu, H Chen, T Chen, CS Lau, FX Yu, K Chen, HP Chen, 2.911
RS Pan, GC Chan, XY Zhang, YJ Nie.
Immunotherapeutic effects of allogeneic mesenchymal stem cells on
systemic lupus erythematosus.
Lupus. 2020 Jul;29(8):872-883.
DOI: [10.1177/0961203320928419](https://doi.org/10.1177/0961203320928419)
297. MH Leung, EHS Choy, CS Lau 4.7
Cumulative patient-based disease activity monitoring in rheumatoid
arthritis - predicts sustained remission, flare and treatment escalation.
Seminars in Arthritis and Rheumatism. 2020 Aug;50(4):749-758.
DOI: [10.1016/j.semarthrit.2020.03.010](https://doi.org/10.1016/j.semarthrit.2020.03.010)
298. PH Li, HH Yeung, CS Lau, EY Au. 8.861
Expicient allergy and importance of complete allergy histories.
Journal of Allergy and Clinical Immunology: In Practice 2020; 8:
2122 – 2123.

299. J Cho, R Kandane-Rathnayake, W Louthrenoo, A Hoi, 2.454
 V Golder, YH Chen, SF Luo, YJ Wu, L Hamijoyo, CS Lau,
 S Navarra, L Zamora, M Tee, A Flora Jr, ZG Li, Y An,
 S Sockalingam, Y Katsumata, M Harigai, Y Hao, Z Zhang,
 J Kikuchi, T Takeuchi, D Basnayake, F Goldblatt, M Chan, KPL
 Ng, SC Bae, S Oon, S O'Neill, K Gibson, S Kumar,
 AHN Law, N Tugnet, Y Tanaka, M Nikpour, E Morand,
 A Lateef.
 COVID-19 infection in patients with systemic lupus
 erythematosus: Data from the Asia Pacific Lupus Collaboration.
 International Journal of Rheumatic Diseases. 2020
 Aug;23(9):1255-1257.
 DOI: [10.1111/1756-185X.13937](https://doi.org/10.1111/1756-185X.13937). PMID: 32841510
300. ETF Chui, HHL Tsang, KH Lee, CS Lau, CH Wong, 7.580
 HY Chung.
 MRI inflammation of facet and costovertebral joints is associated
 with restricted spinal mobility and worsened functional status.
 Rheumatology (Oxford). 2020 Sep 1;59(9):2591-2602.
 PMID:32003811. DOI: [10.1093/rheumatology/kez649](https://doi.org/10.1093/rheumatology/kez649)
301. MF Tsoi, MH Chung, MY Cheung, CS Lau, TT Cheung. 5.156
 Epidemiology of gout in Hong Kong: a population-based study from
 2006 to 2016" (ARRT-D-19-00849R2).
 Arthritis Research & Therapy 2020 Sep 4;22(1):204.
 DOI: [10.1186/s13075-020-02299-5](https://doi.org/10.1186/s13075-020-02299-5)
302. IF Hung, VC Cheng, X Li, AR Tam, DL Hung, KH Chiu, 79.321
 CC Yip, JP Cai, DT Ho, SC Wong, SS Leung, MY Chu,
 MO Tang, JH Chen, RW Poon, AY Fung, RR Zhang, EY Yan, LL
 Chen, CY Choi, KH Leung, TW Chung, SH Lam, TP Lam,
 JF Chan, KH Chan, TC Wu, PL Ho, JW Chan, CS Lau, KK To, KY
 Yuen.
 SARS-CoV-2 shedding and seroconversion among
 passengers quarantined after disembarking a cruise ship: A case
 series.
 The Lancet Infectious Diseases 2020 Sep;20(9):1051-1060.
 DOI: [10.1016/S1473-3099\(20\)30364-9](https://doi.org/10.1016/S1473-3099(20)30364-9)
303. DYH Yap, CH Tam, S Yung, S Wong, CSO Tang, TMY Mok, 5.992
 CKY Yuen, MKM Ma, CS Lau, TM Chan.
 Pharmacokinetics and pharmacogenomics of mycophenolic acid
 and its clinical correlations in maintenance immunosuppression for
 lupus nephritis.
 Nephrology Dialysis and Transplantation 2020; 35: 810-818. DOI:
[10.1093/ndt/gfy284](https://doi.org/10.1093/ndt/gfy284)

304. PH Li, JCY Wong, CS Lau. 2.07
 Importance of allergological evaluation and skin testing for severe cutaneous adverse reactions: a case report.
 Hong Kong Medical Journal. 2020 Oct;26(5):444-445.
 DOI: [10.12809/hkmj198263](https://doi.org/10.12809/hkmj198263)
305. APP Ng, WY Chin, EYF Wan, J Chen, CS Lau. 2.692
 Prevalence and severity of burnout in Hong Kong doctors up to 20 years post-graduation: Across-sectional study.
 BMJ Open. 2020 Oct 27;10(10): e040178.
 DOI: [10.1136/bmjopen-2020-040178](https://doi.org/10.1136/bmjopen-2020-040178)
306. SCW Chan, WWY Yeung, JCY Wong, ESH Chui, MSH Lee, HY Chung, TT Cheung, CS Lau, PH Li. 3.706
 Prevalence and Impact of Reported Drug Allergies among Rheumatology Patients.
 Diagnostics (Basel). 2020 Nov 9;10(11):918.
 PMID: 33182278. <https://www.mdpi.com/2075-4418/10/11/918>
307. Y Chen, YH Chan, HY Chung, MZ Wu, YJ Yu, KL Pi, CS Lau, HF Tse, KH Yiu. 2.98
 Cardiovascular events prediction by left ventricular longitudinal strain and serum high-sensitivity troponin I in patients with axial spondyloarthritis.
 Clinical Rheumatology 2020 Nov; 39(11):3373-3382.
 DOI: [10.1007/s10067-020-05112-5](https://doi.org/10.1007/s10067-020-05112-5)
308. PH Li, ASY Leung, RMY Li, TF Leung, CS Lau, GWK Wong. 5.871
 Increasing incidence of anaphylaxis in Hong Kong from 2009 to 2019-discrepancies of anaphylaxis care between adult and paediatric patients.
 Clinical and Translational Allergy. 2020 Nov 19;10(1):51.
 DOI: [10.1186/s13601-020-00355-6](https://doi.org/10.1186/s13601-020-00355-6)
309. SCW Chan, PH Li, KH Lee, HHL Tsang, CS Lau, HY Chung. 5.346
 Diagnostic utility of whole spine and thoracic spine MRI corner inflammatory lesions in axial spondyloarthritis.
 Therapeutic Advances in Musculoskeletal Disease. 2020 Nov 24;12:1759720X20973922.
 PMID:33281954. DOI: [10.1177/1759720X20973922](https://doi.org/10.1177/1759720X20973922)
310. NC Ciang, SCW Chan, CS Lau, ETF Chiu, HY Chung. 2.246
 Risk of tuberculosis in patients with spondyloarthritis: data from a centralized electronic database in Hong Kong.
 BMC Musculoskeletal Disorders. 2020 Dec 10;21(1):832.
 DOI: [10.1186/s12891-020-03855-5](https://doi.org/10.1186/s12891-020-03855-5). PMID: 33302934

311. MY Ng, EYF Wan, HYF Wong, ST Leung, JCY Lee, TW Chin, CSY Lo, MM Lui, EHT Chan, AH Fong, SY Fung, OH Ching, KW Chiu, TWH Chung, V Vardhanbhuti, HYS Lam, KKW To, JLF Chiu, TPW Lam, PL Khong, RWT Liu, JWM Chan, AKL Wu, KC Lung, IFN Hung, CS Lau, MD Kuo, MS Ip. 3.623
Development and validation of risk prediction models for COVID-19 positivity in a hospital setting.
International Journal of Infectious Diseases 2020 Dec;101: 74-82.
DOI: [10.1016/j.ijid.2020.09.022](https://doi.org/10.1016/j.ijid.2020.09.022)
312. TYM Leung, YLA Chan, EWY Chan, KY CHAN, SLC Chui, BJ Cowling, L GAO, M GE, FNI Hung, MSM Ip, P Ip, GKK Lau, CS Lau, KW Lau, WK Leung, X Li, H Luo, KKCM Man, WSV NG, DCW Siu, YFE Wan, YKW Wing, SCMW Wong, KHTW Wong and ICK Wong 5.842
Short- and potential long-term adverse health outcomes of COVID-19: A rapid review.
Emerging Microbes & Infections. 2020,9(1): 2190-2199.
<http://dx.doi.org/10.1080/22221751.2020.1825914>
313. CS Lau, YH Chen, K Lim, M de Longueville, C Arendt, K Winthrop. 2.98
Tuberculosis and viral hepatitis in patients treated with certolizumab pegol in Asia-Pacific countries and worldwide: real-world and clinical trial data (vol 63 pg 931,2020).
Clinical Rheumatology 2021; 40(3) pp.867-875.
DOI: [10.1007/s10067-020-05356-1](https://doi.org/10.1007/s10067-020-05356-1)
314. JCY Wong, EYL Au, HHH Yeung, CS Lau, PH Li. 5.764
Piperacillin-tazobactam allergies: An exception to usual penicillin allergy.
Allergy, Asthma & Immunology Research 2021 Mar;13(2):284-294.
<https://doi.org/10.4168/aair.2021.13.2.284>
315. TL Lai, CK Au, HY Chung, MC Leung, WL Ng, CS Lau. 2.454
Fatigue in psoriatic arthritis: Is it related to disease activity?
International Journal of Rheumatic Diseases 2021 Mar;24(3):418-425.
PMID: 33506651. DOI: [10.1111/1756-185X.14069](https://doi.org/10.1111/1756-185X.14069)
316. J Chen J, WY Chin, A Tiwari, J Wong, ICK Wong, A Worsley, Y Feng, MH Sham, JPYTsang, CS Lau. -
Validation of the perceived stress scale (PSS-10) in medical and health sciences students in Hong Kong.
The Asia Pacific Scholar (TAPS) 2021 May 4: 6(2): 31-37.
DOI: [10.29060/TAPS.2021-6-2/OA2328](https://doi.org/10.29060/TAPS.2021-6-2/OA2328)

317. YF Wang, Y Zhang, Z Lin, H Zhang, TY Wang, Y Cao, DL Morris, Y Sheng, X Yin, SL Zhong, X Gu, Y Lei, J He, Q Wu, JJ Shen, J Yang, TH Lam, JH Lin, ZM Mai, M Guo, Y Tang, Y Chen, Q Song, B Ban, CC Mok, Y Cui, L Lu, N Shen, PC. Sham, CS Lau, DK Smith, TJ Vyse, X Zhang, YL Lau, W Yang. 14.92
 Identification of 38 novel loci for systemic lupus erythematosus and genetic heterogeneity between ancestral groups.
 Nature Communications 2021;12;772.
 DOI: [10.1038/s41467-021-21049-y](https://doi.org/10.1038/s41467-021-21049-y)
318. SK Kwok, LM Tang, HL Tsang, HY Chung, MH Chung, CT Ho, CS Lau, TT Cheung. 4.794
 Nurse-led consultations for patients with rheumatoid arthritis at low disease activity– a randomized non-inferiority trial.
 Arthritis Care and Research (Hoboken) 2021 May 10. P
 MID: 33973407. DOI: [10.1002/acr.24625](https://doi.org/10.1002/acr.24625)
319. HHL Tsang, CKH Wong, PWH Cheung, CS Lau, HY Chung, JPY Cheung. 2.246
 Responsiveness of the EuroQoL 5-Dimension (EQ-5D) questionnaire in patients with spondyloarthritis.
 BMC Musculoskeletal Disorders 2021; May 14;22(1):439.
 DOI: [10.1186/s12891-021-04315-4](https://doi.org/10.1186/s12891-021-04315-4). PMID:33990193
320. J Ma, IK Lam, CS Lau, VS Chan. 6.600
 Elevated interleukin-18 receptor accessory protein mediates enhancement in reactive oxygen species production in neutrophils of systemic lupus erythematosus patients.
 Cells. 2021 May;10(5):964.
 DOI: <https://doi.org/10.3390/cells10050964>
321. PH Li, HY Chung, CS Lau. 2.07
 Epidemiology and outcomes of geriatric and non-geriatric patients with drug allergy labels in Hong Kong.
 Hong Kong Medical Journal 2021 Jun;27(3):192-197.
 DOI: [10.12809/hkmj208716](https://doi.org/10.12809/hkmj208716). PMID:34168086

322. R Kandane-Rathnayake, W Louthrenoo, SF Luo, YJJ Wu, YH Chen, V Golder, A Lateefm J Cho, SV Navarra, Leonid Zamora, L Hamijoyo, S Sockalingam, A Yuan, A Li, R Montes, S Oon, Y Katsumata, M Harigai, Y Hao, Z Zhang, M Chan, J Kikuchi, T Takeuchi, F Goldblatt, S O'Neill, SC Bae, CS Lau, A Hoi, CS Karyekar, M Nikpour, EF Morand, Asia-Pacific Lupus Collaboration.
Patterns of medication use in systemic lupus erythematosus – A multi-centre cohort study.
Arthritis Care and Research 2021 Jul 1.
DOI: [10.1002/acr.24740](https://doi.org/10.1002/acr.24740). PMID 34197023 4.794
323. HY Chung, SCW Chan, ETF Chui, T Yau, CS Lau. Malignancies in spondyloarthritis with and without concomitant psoriasis, and the effect of disease modifying anti-rheumatic drugs.
Clinical and Experimental Rheumatology 2021 Jul 24. PMID: 34369368 4.473
324. SCW Chan, CK Teo, PH Li, KK Lau, CS Lau, HY Chung.
Cardiovascular risk in patients with spondyloarthritis and association with anti-TNF drugs.
Therapeutic Advances in Musculoskeletal Disease 2021 Jul 27;13:1759720X211032444. PMID:34377159.
DOI: [10.1177/1759720X211032444](https://doi.org/10.1177/1759720X211032444) 5.346
325. Q Lu, H Long, S Chow, S Hidayat, R Danarti, Y Listiawan, D Deng, Q Guo, H Fang, J Tao, M Zhao, L Xiang, N Che, F Li, H Zhao, CS Lau, FC Ip, KM Ho, AC Paliza, C Vicheth, K Godse, S Cho, CS Seow, Y Miyachi, TH Khang, R Ungpakorn, H Galadari, R Shah, K Yang, Y Zhou, C Selmi, AH Sawalha, X Zhang, Y Chen, CS Lin.
Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus.
Journal of Autoimmunity 2021 Sep; 123:102707.
DOI: [10.1016/j.jaut.2021.102707](https://doi.org/10.1016/j.jaut.2021.102707). PMID: 34364171 7.094
326. APP Ng, WY Chin, EYF Wan, J Chen, CS Lau.
Prevalence of depression and suicide ideation in Hong Kong doctors: A cross-sectional study.
Scientific Reports 2021 Sep 11(1), pp1-11.
<https://doi.org/10.1038/s41598-021-98668-4> 4.379

327. KYH Kwan, LWY Chan, PW Cheng, GKK Leung, CS Lau. 2.07
 Burnout and well-being in young doctors in Hong Kong: a territory-wide cross-sectional survey.
 Hong Kong Medical Journal 2021 Oct;27(5):330-337.
 DOI: [10.12809/hkmj219610](https://doi.org/10.12809/hkmj219610). PMID: 34607972
328. R Kandane-Rathnayake, W Louthrenoo, V Golder, SF Luo, 7.580
 YJ Wu, A Lateef, J Cho, Z Li, Y An, L Hamijoyo, S Navarra,
 L Zamora, Y Katsumata, M Harigai, S Sockalingam, M Chan, YH
 Chen, S O'Neill, F Goldblatt, Y Hao, Z Zhang, J Kikuchi,
 T Takeuchi, CS Lau, M Nikpour, E Morand, A Hoi.
 Asia Pacific Lupus Collaboration. Independent associations of
 lymphopenia and neutropenia in patients with systemic lupus
 erythematosus: A longitudinal, multinational study. Rheumatology
 (Oxford). 2021 Nov 3;60(11):5185-5193.
 DOI: [10.1093/rheumatology/keab217](https://doi.org/10.1093/rheumatology/keab217). PMID: 33693676
329. V Chiang, WS Mok, KC Chan, WY Leung, TK Ho, YL Au, 4.084
CS Lau, TH Lee, H Li.
 Experience of the first 1127 COVID-19 Vaccine Allergy Safety
 patients in Hong Kong – clinical outcomes, barriers to vaccination
 and urgency for reform.
 World Allergy Organization Journal 2021 Dec, 100622.
<https://doi.org/10.1016/j.waojou.2021.100622>
330. SCW Chan, CS Lau. -
 Systemic lupus erythematosus and immunodeficiency.
 Rheumatology and Immunology Research Dec 2021 2(3), pp.131-
 138.
<https://doi.org/10.2478/rir-2021-0019>
331. X Li, X Tong, WYW Yeung, K Peng, SHH Yum, SLC Chui, TTF 19.103
 Lai, YFE Wan, CKH Wong, EWY Chan, CS Lau. and ICK Wong
 Two-dose Covid-19 vaccination and possible arthritis flare among
 patients with rheumatoid arthritis in Hong Kong.
 Annals of the Rheumatic Diseases. 2021
<http://dx.doi.org/10.1136/annrheumdis-2021-221571>
332. CHP Lee, PNP Yeung, SY Y Pang, CLD Lam and CS Lau 2.07
 Successfully conducting an objective structured clinical examination
 with real patients during the COVID-19 pandemic.
 Hong Kong Medical Journal. 2021.
<http://dx.doi.org/10.12809/hkmj208839>

333. CS Lau 2.07
 Can COVID-19 vaccines stop the pandemic?
 Hong Kong Medical Journal. 2021, 27, 84-85
<http://dx.doi.org/10.12809/hkmj215116>
334. SCW Chan, HY Chung, CS Lau, PH Li. 3.888
 Epidemiology, mortality and effectiveness of prophylaxis for
 Pneumocystis jiroveci pneumonia among rheumatic patients: a
 territory-wide study.
 Annals of Clinical Microbiology and Antimicrobials. 2021, 20.
<http://dx.doi.org/10.1186/s12941-021-00483-2>
335. PH Li, SCW Chan, CS Lau, MTY Seto, HY Chung. 3.517
 Conventional and biologic disease-modifying antirheumatic drugs
 are not associated with increase in or progression of cervical
 neoplasia among patients with spondyloarthritis.
 Journal of Clinical Rheumatology. Jan 2022; 28(1); e63-e68.
 PMID:33105316. DOI: 10.1097/RHU.0000000000001590
336. HY Chung, SCW Chan, KH Lee, HHL Tsang, LL Ng, CS Lau. 2.454
 Both ASDAS and ADC are associated with spinal mobility in active
 axial spondyloarthritis: A comparison between early and later
 disease.
 International Journal of Rheumatic Diseases. (Epub 2022 Jan 12)
 DOI: 10.1111/1756-185X.14278
337. TL Lai, CK Au, HY Chung, CS Lau. 2.454
 Depression in psoriatic arthritis: Related to socio-demographics,
 comorbid loads or disease activity?
 International Journal of Rheumatic Diseases 2022 (Epub Feb 2022)
 DOI: 10.1111/1756-185X.14298
338. H So, J So, TTO Lam, VTL Wong, R Ho, WL Li, CS Lau, LS Tam. 4.47
 Seasonal effect on disease onset and presentation in anti-MDA 5
 positive dermatomyositis.
 Frontiers in Medicine (Rheumatology) (Accepted for publication)
339. KM Chow, C Ahn, I Dittmer, DK Au, I Cheung, YL Cheng, 5.299
CS Lau, DTK Yeung, P Li.
 Introducing incentives and reducing disincentives in enhancing
 deceased organ donation and transplantation
 Special issue on Kidney donation and transplantation: Ethics and
 controversies.
 Seminars in Nephrology (Accepted for publication)

340. J So, H So, VTL Wong, R Ho, TY Wu, P Ching, H Wong, LHP Tam, C Ho, TTO Lam, YK Chung, WL Li, CH To, CS Lau, CC Mok, LS Tam 7.580
 Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis
 Rheumatology (Oxford) 2022 (in press)
 DOI: 10.1093/rheumatology/keac094/6528340
341. H So, J So, T Lam, VTL Wong, R Ho, WL Li, CS Lau, LS Tam. 9.002
 Performance of the 2017 EULAR/ACR classification criteria in anti-MDA5 associated idiopathic inflammatory myopathy.
 Arthritis and Rheumatology 2022 (Accepted for publication)
342. DHY Yap, PH Li, C Tang, BYF So, LPY Kwan, GCW Lau, CS Lau and TM Chan. 4.164
 Long-Term Results of Triple Immunosuppression with Tacrolimus Added to Mycophenolate and Corticosteroids in the Treatment of Lupus Nephritis.
 Kidney International Reports 2022; 7: 516-525
 DOI: 10.1016/j.ekir.2021.12.005
343. R Kandane-Rathnayake; W Louthrenoo; A Hoi; SF Luo; YJJ Wu; YH Chen; J Cho; A Lateef; L Hamijoyo; SV Navarra; L Zamora; S Sockalingam; Y An; Z Li; Y Katsumata; M Harigai; Y Hao; Z Zhang; J Kikuchi; T Takeuchi; BMDB Basnayake; M Chan; KPL Ng; N Tugnet; S Kumar; S Oon; F Goldblatt; S O'Neill; K Gibson; N Ohkubo; Y Tanaka; SC Bae; CS Lau; M Nikpour; V Golder; EF Morand 5.156
 Not at target': Prevalence and consequences of inadequate disease control in systemic lupus erythematosus - A multinational observational cohort study
 Arthritis Research & Therapy 2022 (accepted for publication)

Review Articles, Invited Editorials and Book Chapters**Review articles and invited editorials**

- | | | |
|------|--|------|
| 344. | <u>CS Lau</u> , JJF Belch.
Raynaud's phenomenon – a vasospastic disorder.
Current Practice in Surgery 1991; 3(3): 170-175. | - |
| 345. | <u>CS Lau</u> .
Antiphospholipid syndrome.
Vascular Medicine Review 1994; 5(1): 33-45. | - |
| 346. | <u>CS Lau</u> .
WF shows promise as SLE disease activity marker.
Rheumatology News International 1995; 23 (6): 6. | - |
| 347. | MY Mok, <u>CS Lau</u> .
Drug therapy in rheumatoid arthritis.
Hong Kong Medical Journal 1996; 18(7): 353-358. | 2.07 |
| 348. | CC Mok, <u>CS Lau</u> .
Management strategies of systemic lupus erythematosus.
Hong Kong Medical Journal 1996; 18(9): 475-480. | 2.07 |
| 349. | <u>CS Lau</u> .
What scope for improving cost effectiveness of NSAIDs –
comments from Hong Kong.
Drugs and Therapy Perspectives 1996; 8(9): 15. | 0.17 |
| 350. | MY Mok, <u>CS Lau</u> .
Drug therapy in rheumatoid arthritis.
Medicine Digest 1997; 15 (6): 15-21. | - |
| 351. | <u>CS Lau</u> .
Management of rheumatic diseases: Hong Kong perspectives.
Medicine Digest June 1997; 19-20. | - |
| 352. | CTK Ho, <u>CS Lau</u> .
Intralesional steroid injections – general considerations.
The Hong Kong Medical Journal 1997; 19 (8): 425-429. | 2.07 |
| 353. | KW Lee, <u>CS Lau</u> .
Regional steroid injections – Intra-articular injections.
The Hong Kong Medical Journal 1997; 19 (9): 482-489. | 2.07 |

354. CS Lau, MY Mok. 2.07
Corticosteroid injections for common soft tissue rheumatism.
The Hong Kong Practitioner 1997;19(10): 535-545.
355. CC Mok, CS Lau, RWS Wong. 2.454
Estrogens and systemic lupus erythematosus.
International Journal of Rheumatic Diseases 1998; 2 (2): 113-118.
356. CS Lau, B Vargas, W Louthreeno, MY Mok, P Wordsworth, NC Zheng. 0.648
Features of spondyloarthritis around the world.
Rheumatic Disease Clinics of North America 1998; 24 (4): 753-770.
357. CS Lau, MY Mok. 56.272
Lupus in Asia. Editorial.
JAMA 1998 14 (2): 5-7.
358. CC Mok, CS Lau, CTK Ho, KW Lee, MY Mok, RWS Wong. -
HRT in systemic lupus erythematosus.
Menopause Digest 1999; 3: 28-29.
359. MY Mok, CS Lau. 2.454
Atherosclerosis and systemic lupus erythematosus.
International Journal of Rheumatic Diseases 1999; 3 (2): 138-141.
360. CS Lau, SL Chen. 2.454
Report on the First Hua Xia Congress on Diagnosis and Management of Rheumatic Diseases.
International Journal of Rheumatic Diseases 1999; 3 (2): 148.
361. CS Lau, EWK Ip, CC Mok, Y Ren, D Chan, SY Chan, YL Lau. 2.454
Mannose binding lectin and autoimmune disease.
International Journal of Rheumatic Diseases 2001; 4(1): 17-20.
362. CS Lau. 2.454
Writing the manuscript: From beginning to the end.
International Journal of Rheumatic Diseases 2001
363. CS Lau. -
Selective cyclo-oxygenase-2 inhibition: an answer to non-steroidal anti-inflammatory drug treatment for chronic arthritis?
Journal of Clinical Rheumatology and Immunology 2002; 2(2): 58-64.

364. CS Lau. -
Soft tissue rheumatism.
Journal of Clinical Rheumatology and Immunology 2002; 2
(Suppl): 25-28.
365. CC Mok, CS Lau. 3.411
Pathogenesis of systemic lupus erythematosus.
Journal of Clinical Pathology 2003; 56(7): 481-490.
366. KK Lee, CS Lau. -
Early diagnosis and treatment of rheumatoid arthritis.
Hong Kong Doctors' Union Bulletins on Self Study CME Series
(2003)
367. CS Lau. 2.454
Who's afraid of the big bad wolf? Fifth Tay Chong Hai Lecture
of the National Arthritis Foundation of Singapore.
International Journal of Rheumatologic Diseases. 2004; May;
7(1): 83-89.
368. CS Lau. -
An overview of the pathogenesis and treatment of pulmonary
hypertension: Part 1.
Journal of Clinical Rheumatology and Immunology 2004; 4(1):
19-25.
369. CS Lau. -
An overview of the pathogenesis and treatment of pulmonary
hypertension: Part 2.
Journal of Clinical Rheumatology and Immunology 2004; 4(2):
50-53.
370. CS Lau. 2.454
International Journal of Rheumatic Diseases: where do we go
from here?
International Journal of Rheumatic Diseases 2005; 8(1): 1-2.
371. CS Lau. 2.454
Developing rheumatology in the Asia-Pacific region: It starts
with our medical students.
International Journal of Rheumatic Diseases 2005; 8(2): 67-68.
372. CS Lau. -
Recent advances in the management of systemic lupus
erythematosus.
Synapse (Hong Kong College of Physicians) 2005; 2: 87-91.

373. CS Lau. 2.454
Lupus in Asia: How much do we know?
International Journal of Rheumatic Diseases 2006; 9(4): 313-314.
374. CS Lau. 2.454
One year on: How have we done so far?
International Journal of Rheumatic Diseases 2006; 9(1): 1.
375. AN Malaviya, CS Lau, RR Singh. 79.321
The Lancet's chronic disease series.
Lancet 2006; Feb 18;367 (9510): 563.
[https://doi.org/10.1016/S0140-6736\(06\)68212-3](https://doi.org/10.1016/S0140-6736(06)68212-3)
376. CS Lau. 4.666
Collateral benefits of fish oil therapy for rheumatoid arthritis.
Journal of Rheumatology. 2006 Oct;33(10):1931-1933.
PMID: 17014011
377. CS Lau. 2.454
President's message.
International Journal of Rheumatic Diseases, 2007;10 (1)1-2.
<http://dx.doi.org/10.1111/j.1479-8077.2007.00264.x>
378. CS Lau. 2.454
The future of APLAR.
International Journal of Rheumatic Diseases 2007; 10(3): 173.
379. CS Lau. -
Shaping the health of Hong Kong: 120 years of achievements.
Distributed by the Hong Kong University Press 2007
380. CS Lau, H-Y Kim, K Nishioka. 20.543
Rheumatology in the Asia Pacific: Challenges and opportunities.
Nature Reviews Rheumatology 2007; 3(3): 119.
381. CS Lau. 2.454
APLAR Rheumatology Congresses: Change for the better.
International Journal of Rheumatic Diseases 2007; 9(3): 107.
382. SL Chen, CS Lau. -
Atlas of lupus erythematosus.
Shanghai Century Publishing 2007

383. CS Lau. -
Seasons greetings.
International Journal of Rheumatic Diseases, 2007; 10(4) 263.
<http://dx.doi.org/10.1111/j.1479-8077.2007.00313.x>
384. CS Lau and PH Feng. 2.454
An international journal from the Asia-Pacific: An evolution.
International Journal of Rheumatic Diseases 2008; 11: 1-3.
<http://dx.doi.org/10.1111/j.1756-185X.2008.00341.x>
385. CS Lau. 2.454
Ten topics in rheumatology in Asia: A brief report.
International Journal of Rheumatic Diseases 2009; 12(1): 5-6.
386. CS Lau, A Mak. 20.543
The socioeconomic burden of SLE.
Nature Reviews Rheumatology 2009; 5(7): 400-404.
387. MY Mok, CS Lau. 20.543
The burden and measurement of cardiovascular disease in
systemic sclerosis (SSc)
Nature Reviews Rheumatology 2010; 6(7): 430-434.
<http://dx.doi.org/10.1038/nrrheum.2010.65>
388. CS Lau. 2.454
The International Journal of Rheumatic Diseases – a journal in
evolution.
International Journal of Rheumatic Diseases 2010; 13(3): 187-
188.
389. CS Lau. 2.911
Why another issue on lupus in Asia?
Lupus 2010; 19(12): 1361.
390. CS Lau. 2.454
A landmark for the journal.
International Journal of Rheumatic Diseases. 2010;13 (1):1-2.
<http://dx.doi.org/10.1111/j.1756-185X.2009.01459.x>
391. KH Yiu, HF Tse, MY Mok, CS Lau. 20.543
Ethnic difference in the cardiovascular risk in rheumatic
disease: Focus on Asians.
Nature Reviews Rheumatology 2011; 7(10): 609-618.
PMID:21912432. DOI: 10.1038/nrrheum.2011.126

392. CS Lau, T Cheung. 4.666
Should clinicians start measuring flow mediated dilation response in patients with systemic lupus erythematosus? Journal of Rheumatology 2011; 38(7): 1231-1233.
393. K Lim, CS Lau. 2.454
Perception is everything: OA is exciting. International Journal of Rheumatic Diseases 2011;14(2):111-112.
394. ES Vista, CS Lau. 2.454
What about supplements for osteoarthritis? A critical and evidenced-based review. International Journal of Rheumatic Diseases 2011; 14(2): 152-158.
395. HL Tsang, HY Chung, MY Mok, CS Lau. -
Kinase Inhibitors for the Treatment of Rheumatoid Arthritis. Journal of Clinical Rheumatology and Immunology 2012; 12: 43-49.
396. A Mak, DA Isenberg, CS Lau. 20.543
Global trends, potential mechanisms and early detection of organ damage in SLE. Nature Reviews Rheumatology 2013; 9(5): 301-10.
DOI: <http://dx.doi.org/10.1038/nrrheum.2012.208>
397. CS Lau, P Li. 20.543
Epidemiology: The effects of AIDS on the prevalence of rheumatic diseases. Nature Reviews Rheumatology 2017; 13 (1): 8-10.
DOI: [10.1038/nrrheum.2016.196](https://doi.org/10.1038/nrrheum.2016.196)
398. Q Li, H Wu, W Liao, M Zhao, V Chan, L Li, M Zheng, G Chen, J Zhang, CS Lau, Q Lu. 7.094
A comprehensive review of immune-mediated dermatopathology in systemic lupus erythematosus. Journal of Autoimmunity 2018; 93: 1-15.
<https://doi.org/10.1016/j.jaut.2018.07.007>
399. D Li and CS Lau 5.386
Combating COVID-19: East meets West British Journal of General Practice 2020; 70 (696): e442-e443.
DOI: [10.3399/bjgp20X710753](https://doi.org/10.3399/bjgp20X710753). Print 2020 Jul

400. PH Li, CS Lau 2.454
A comprehensive review of immune-mediated dermatopathology in systemic lupus erythematosus. International Journal of Rheumatic Diseases. 2017 May;20(5):523-525. DOI: [10.1111/1756-185X.13115](https://doi.org/10.1111/1756-185X.13115)
401. YE Chee, CS Lau. 2.07
Patient blood management: the solution to a double-edged sword? Hong Kong Medical Journal. 2020 Aug; 26(4):280-282. DOI: [10.12809/hkmj205104](https://doi.org/10.12809/hkmj205104)
402. IL Mak, EYF Wan, T Kwan, T Wong, W Woo, J Lee, EWY Chan, EPH Choi, CSL Chui, MSM Ip, CS Lau, KK Lau, MSF Lee, ICK Wong, EYT Yu, CLK Lam 21.98
The spill-over impact of the novel coronavirus-19 pandemic on medical care and disease outcomes in non-communicable diseases: a narrative review
Public Health Reviews 2022 (accepted for publication)

Book Chapters

403. CS Lau, JF Belch. -
Diseases of joints and bones. In: A colour atlas and text of clinical medicine. Eds: CD Forbes and WF Jackson. Wolfe Publishing 1993; 121-160.
404. CS Lau, RWS Wong. -
Achievements in Rheumatology. In: Achievements in medicine (1985 – 1995). Ed: YL Yu. University of Hong Kong 1995; 162-170.
405. CS Lau, CC Mok. -
Pathogenesis of systemic lupus erythematosus. In: Textbook of rheumatology. Ed: M Zhang. Beijing 2004; 865-885.
406. CS Lau, C Ho, MY Mok, WS Wong. -
Rheumatology short cases. In: Problem based medical case management. Eds. Lau CP, Chen MZ, Kumana CR, Lai CL, Lai KN, Lam KSL, Lam WK. Hong Kong University Press 2005; 237-250.

407. CS Lau, C Ho, MY Mok, WS Wong. -
Rheumatology - long cases. In: Problem based medical case
management. Eds. Lau CP, Chen MZ, Kumana CR, Lai CL,
Lai KN, Lam KSL, Lam WK. Hong Kong University Press
2005; 251-260.
408. CS Lau. -
Sjögren's Syndrome in China. In: Sjögren's Syndrome.
Springer Science+Business Media 2011.

VI. INVITED LECTURES

Invited Lectures at major Meetings /Conferences

Plenary and keynote lectures

1. Novel therapies for rheumatoid arthritis. The 5th National Rheumatology Congress of the Chinese Rheumatology Association, Beijing, China, September 1996
2. Ankylosing spondylitis in Hong Kong. Beijing Symposium on Ankylosing Spondylitis, Beijing, China, November 1996
3. Quality of life in systemic lupus erythematosus in Hong Kong. Asian Clinical Trials Conference, Hong Kong, October 1998
4. Treatment of difficult systemic lupus erythematosus in Hong Kong. First Joint Hong Kong-Guangzhou Rheumatology Symposium, Guangzhou, December 1998
5. Features of spondyloarthropathies around the world. 1st Hua Xia Congress on Diagnosis and Management of Rheumatic Diseases, Shanghai, China, April 1999
6. Perspectives on NSAID gastropathy in Asia – A New Era in the Management of Pain and Osteoarthritis. Korean Orthopaedic Association, Jeju Island, Korea, October 2000
7. Immunopathogenesis of systemic lupus erythematosus. Taiwan Rheumatology Association, Taipei, May 2001
8. Management of systemic lupus erythematosus. 5th Huaxia Education Council on Rheumatism & Arthritis (HECRA), Hualien, Taiwan, May 2001
9. Immunopathogenesis of systemic lupus erythematosus. International League of Associations for Rheumatology, Edmonton, Canada, August 2001
10. Pathogenesis of systemic lupus erythematosus. 1st Shanghai Symposium on Rheumatology, Shanghai, September 2002
11. Use of mycophenolate mofetil in the treatment of lupus nephritis. Asia-Pacific Forum on New Therapies in Rheumatic Diseases, Singapore, October 2002
12. Treatment of difficult lupus nephritis. 9th Annual Scientific Meeting, Chinese Rheumatology Association, Chengdu, China, November 2003
13. Novel therapies for osteoarthritis. 6th Malaysia/Singapore Workshop in Rheumatology, Penang, Malaysia, July 2004
14. Pathogenesis of SLE “Defective apoptotic cell clearance and systemic lupus erythematosus”. 11th APLAR Bi-annual Congress, Jeju Island, Korea, 11-16 September 2004

15. Osteoarthritis in Asia. National Arthritis Foundation of Singapore Annual Scientific Meeting, Singapore, November, 2004
16. Defects in the clearance of apoptotic cells in systemic lupus erythematosus. 2nd Huaxia Congress on the Management of Rheumatic Diseases, Taipei, December, 2004
17. The role of dendritic cells in the pathogenesis of systemic lupus erythematosus. 4th Guangzhou Rheumatology Association Annual Scientific Meeting, Guangzhou, China, August 2005
18. Treatment of common arthritis and rheumatic disorders: Western medicine perspectives. International Conference & Exhibition of the Modernisation of Chinese Medicine & Health Products (ICMCM), Hong Kong, August 2005
19. Dendritic cells: their role in the pathogenesis of systemic lupus erythematosus. 5th International Symposium on Rheumatic Diseases, Seoul, Korea, December 2005
20. Immunopathogenesis of systemic lupus erythematosus. Korean Rheumatology Association Annual Scientific Meeting, Seoul, Korea, May 2006
21. An overview of the treatment of systemic lupus erythematosus. Asia Pacific League of Associations for Rheumatology Congress, Kuala Lumpur, August 2006
22. Dendritic cells: their role in the pathogenesis of systemic lupus erythematosus. Asia Pacific League of Associations for Rheumatology Congress, Kuala Lumpur, August 2006
23. Abnormal Plasmacytoid Dendritic Cell Activity in Systemic Lupus Erythematosus. The American College of Rheumatology Annual Scientific Meeting 10-15 Nov 2006, Washington, DC USA 2006.
24. Dendritic Cells (DCs): Culprits of B-cell Hyper-responsiveness in Lupus. The 2006 ACR/ARHP Annual Scientific Meeting, Washington, DC., 10-15 November 2006. In Conference Proceedings, 2006, v. 54 n. 9, abstract no. 1075
25. Cost of Mild Systemic Lupus Erythematosus in Hong Kong. The 2006 ACR/ARHP Annual Scientific Meeting, Washington, DC., 10-15 November 2006. In Conference Proceedings, 2006, v. 54 n. 9, abstract no.1198.
26. Functional Abnormalities of Myeloid Dendritic Cells in Systemic Lupus Erythematosus. The American College of Rheumatology Annual Scientific Meeting 10-15 Nov 2006, Washington, DC USA.
27. Plasmacytoid-Dendritic Cell Induced T Cell Proliferation and Activation: A Potential Role in the Pathogenesis of Rheumatoid Arthritis. The American College of Rheumatology Annual Scientific Meeting 10-15 Nov 2006, Washington, DC USA 2006.

28. Polymorphisms of Tumour Suppressor P53 Gene with Systemic Lupus Erythematosus in Hong Kong Chinese Patients. 11th Research Postgraduate Symposium, Hong Kong, 7 December 2006.
29. Innate immunity and systemic lupus erythematosus. 8th International Congress on SLE, Shanghai, China, May 2007
30. Anti- β 2 glycoprotein I antibodies facilitate phagocytosis of apoptotic neutrophils in patients with systemic lupus erythematosus. The 12th Medical Research Conference (MRC 2007), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, 2007.
31. Association of Interferon Regulatory Factor 5 (IRF5) polymorphisms with systemic lupus erythematosus (SLE). The 2007 Conference of the European Society of Human Genetics (ESHG), Nice, France, 16-19 June 2007. In European Journal of Human Genetics, 2007, v. 15 suppl. 1, p. 279, abstract P1109
32. Immunopathogenesis of systemic lupus erythematosus. Australian Rheumatology Association Annual Scientific Meeting, Sydney, Australia, June 2007
33. Cooperation and collaboration in Asia. Nature Asia, Yokohama, Japan, June 2007
34. COX-2 inhibitors – anti –inflammation, and gastrointestinal and cardiovascular side-effects: A balancing act. Huaxia Congress on the Diagnosis and Management of Rheumatic Diseases, Hong Kong, December 2007
35. Elevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis. The 13th Medical Research Conference (MRC 2008), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, 19 January 2008.
36. Immunosuppressive effects of human mesenchymal stem cells on systemic lupus erythematosus (SLE) T- and B- cells. Annals of the Rheumatic Diseases, 2008; v.67 suppl. 2, p.350.
37. The pathogenic role of plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis & Rheumatism, 2008, v.58, p.1461: S707
38. Systemic lupus erythematosus: What have we learned from this condition? Scottish Society for Experimental medicine, Dundee, May 2008
39. Autoimmunity for the Clinicians. Ten Topics in Rheumatology, Singapore, July 2008
40. Burden of musculoskeletal disease in the Asia Pacific. 13th APLAR Congress, Yokohama, Japan, September 2008
41. Update on the development of osteoarthritis and rheumatoid treatment in Asia. Risk Management in OA/RA Treatment Summit, Beijing, China, October 2008

42. Cardiovascular thrombosis and autoimmune diseases. 26th Annual Scientific Meeting of the Rheumatology Association, ROC, Tainan, Taiwan, December 2008
43. Higher coronary artery calcification in systemic sclerosis despite lower rate of conventional cardiovascular risk factors. The 4th International Symposium on Healthy Aging (ISHA 2009), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, 7-8 March 2009.
44. The pathogenic role of dendritic cells in systemic lupus erythematosus. 4th Asian Congress of Autoimmunity, Singapore, September 2009
45. Asymptomatic hyperuricaemia. Bangladesh Society for Rheumatology Annual Scientific Meeting, Dhaka, Bangladesh, October 2009
46. Preventing organ damage and improving quality of life in systemic lupus erythematosus. Second Ten Topics in Rheumatology in Asia, Manila, Philippines, October 2009
47. Empowering people with arthritis through innovation, engagement and collaboration: A clinician's perspective. Hong Kong Society for Rehabilitation 50th Anniversary Scientific Meeting, Hong Kong, January 2010
48. Excellence in medicine and rheumatology in Hong Kong: Enter the Dragon. 14th Congress of Asia Pacific League of Associations for Rheumatology (APLAR), Hong Kong, July 2010
49. Use of biological therapies in the Asian Pacific region. 14th Congress of Asia Pacific League of Associations for Rheumatology (APLAR), Hong Kong, July 2010
50. Foxp3 mRNA expression on DC subsets in patients of systemic lupus erythematosus. The 14th Congress of Asia Pacific League of Associations for Rheumatology, Hong Kong, China, 11-15 July 2010. DOI: <http://dx.doi.org/10.1111/j.1756-185X.2010.01492.x>
51. 1 α , 25-Dihydroxyvitamin D3 suppresses differentiation, maturation and activation of dendritic cells from patients with systemic lupus erythematosus. Congress of Asia Pacific League of Associations for Rheumatology, Hong Kong, China 11-15 July, 2010.
52. IL-6 in Autoimmune Disease – A New Paradigm. Ten Topics in Rheumatology Asia, Singapore, August 2010
53. Fitness-to-Practice: Where are we today? 6th Congress of the Asian Medical Education Association (AMEA), Kuala Lumpur, Malaysia, March 2011
54. Dendritic cells and autoimmunity. 11th International Workshop on Autoantibodies and Autoimmunity (IWAA), Shanghai, China, May 2011

55. Problem based learning: Experience from the University of Hong Kong. East-West Alliance Conference, Shantou, China, May 2011
56. Development of an undergraduate curriculum for systemic lupus erythematosus: a questionnaire-based study. *Annals of Rheumatic Diseases* 2011.
57. Role of functional neuroimaging in neuropsychiatric (NP) systemic lupus erythematosus (SLE) - a combined study of diffusion tensor imaging (DTI) and MR spectroscopy (MRS) at 3 Tesla magnetic resonance imaging. American Society of Neuroradiology 49th Annual Meeting 2011.
58. Are patients with systemic lupus erythematosus and other connective tissue diseases at increased risk of cardiovascular events? First International Rheumatology and Cardiology Focus on inflammation: A shared concern, Prato, Italy, June 2011
59. Assessment of autonomic function in patients with history of neuropsychiatric lupus. 17th Research Postgraduate Symposium, RPS 2012.
60. Lupus monocyte-derived dendritic cells treated with 1 α , 25-dihydroxyvitamin D3 and dexamethasone are tolerogenic and induce IL-10 producing regulatory T cells. 17th Research Postgraduate Symposium, RPS 2012.
61. The pathogenic role of dendritic cells in systemic lupus erythematosus. The Chinese Rheumatology Association Annual Scientific Meeting, Kunming, China, May 2012
62. The situation of AS management and patient self-help groups in Hong Kong. The International Symposium of Ankylosing Spondylitis, Guangzhou, China, Sept 2012
63. Update on the Immunopathogenesis of SLE. The 15th Congress of Asia Pacific League of Associations for Rheumatology, Advancing Rheumatology in the Asian Pacific Region, Jordan, September 2012
64. Lupus in Asia: State of affairs and future directions. Asian Lupus Summit, Manila, Philippines, November 2012
65. Systemic lupus erythematosus in Asia: State of the art. Annual Meeting of Thai Rheumatism Association (TRA), Huahin, Thailand, March 2013
66. Impact of SLE in Asia Pacific – effect of Asian and indigenous ethnicity. Asia-Pacific Lupus Experts Awareness Programme (LEAP) meeting, Melbourne, Australia, April 2013
67. Lupus monocyte-derived dendritic cells treated with 1 α ,25-dihydroxyvitamin D3 and dexamethasone are tolerogenic and induce IL-10 producing regulatory T cells. European League Against Rheumatism Congress, Madrid, Spain, June 12-15, 2013.
68. Lupus research in Asia - Seizing the opportunity. The International Symposium for Rheumatic Disease in Asia, Japan, August 2013 (Keynote Lecture)

69. Unmet needs and challenges in treatment of systemic lupus erythematosus. 14th Singapore Society of Rheumatology – Malaysian Society of Rheumatology Workshops in Rheumatology, Singapore, September 2013
70. Pathogenesis of systemic lupus erythematosus. Korean Association of Immunology Annual Meeting, Seoul, Korea, November 2013
71. Lupus in Asia: Unmet needs. 2nd Asian Lupus Summit and the Lupus Academy, Cebu, the Philippines, April 2014
72. APLAR RA treatment recommendation. 16th APLAR Congress, Cebu, Philippines, April 2014
73. APLAR treatment recommendations for rheumatoid arthritis. 17th Asia Pacific League of Associations for Rheumatology Congress, Chennai, India, September 2015
74. Tribute to the late Professor PH Feng. LUPUS 2017 and Asian Congress of Autoimmunity 2017, Melbourne, Australia March 2017 (Keynote Lecture)
75. Perspectives from Hong Kong: Training the future physician. Training of specialists: are we on the right track symposium. 51st Singapore-Malaysia Congress of Medicine, Singapore, July 2017
76. Flipping the classroom in medical education. 2017 SKKU-SOM International Symposium on Medical Education, Seoul, November, 2017
77. State of the art lecture: Future of rheumatology in Asia. 22nd Annual International Conference, Pakistan Society for Rheumatology, Lahore, Pakistan, April 2018
78. State of the art lecture: Revised RA treatment recommendation. 22nd Annual International Conference, Pakistan Society for Rheumatology, Lahore, Pakistan, April 2018
79. Recent progress in the treatment of systemic lupus erythematosus. 23 Annual Scientific Meeting China Rheumatology Association, Fuzhou, China, May 2018
80. Patient advocacy. Hong Kong Arthritis & Rheumatism Foundation Patient Conference, Hong Kong, August 2018
81. APLAR update on rheumatoid arthritis treatment. 10th International Forum on Rheumatoid Arthritis, Beijing, September 2018
82. Status of postgraduate medical training in Hong Kong. The Best Practice in Postgraduate Medical Education, Shenzhen, December 2018
83. IgG4 – it's everywhere! Philippine Rheumatology Association (PRA) Annual Meeting 2019, SMX Convention Center, Lanang, Davao City, Philippines, 7-9 March 2019

84. Disruptions in medicine. The Inaugural Ceremony of the Macao Academy of Medicine, Macau, 13 July 2019

Other invited lectures

85. Advances in research in rheumatoid arthritis. Arthritis Care Annual Meeting, Dundee, UK, November 1989
86. Conditions associated with Raynaud's phenomenon. Raynaud's Association Meeting, Dundee, October 1989
87. Raynaud's phenomenon: its aetiology, clinical features and management. One day workshop in peripheral vascular diseases, National Society for Chiropractic, Kirkcaldy, UK, March 1991
88. SLE in Hong Kong Chinese. Symposium for Lupus Association, Singapore, October 1993
89. Management of rheumatoid arthritis. Topics in Rheumatic Diseases, Hong Kong Society of Rheumatology, Hong Kong, March 1994
90. Management of easy rheumatoid arthritis. Seminars in Rheumatology, Macau Association of general Practitioners, Macau, May 1994
91. Rheumatoid arthritis – Medical therapeutic aspects. Workshop on Rheumatoid Arthritis, Hong Kong Orthopaedic Association, Hong Kong, June 1994
92. Immuno-modulatory therapy for rheumatoid arthritis. 21st World Congress of Medical Technology, Hong Kong, July 1994
93. Systemic lupus erythematosus in Hong Kong. 120th Anniversary Celebration, Hospital Conde de Sao Januario, Macau, November 1994
94. Autoimmune diseases and recurrent pregnancy loss. Postgraduate Study Day, University Department of Obstetrics and Gynaecology, University of Hong Kong, Hong Kong, February 1995
95. Diagnosis and management of common autoimmune diseases. Pamela Youde Nethersole East Hospital, Chai Wan, Hong Kong, September 1995
96. Mannose binding protein: a new genetic risk factor of systemic lupus erythematosus? Rheumatology Research Meeting, Division of Rheumatology, Department of Medicine, University of California, Los Angeles, USA, October 1995
97. Systemic lupus erythematosus: Hong Kong experience. Rheumatology Grand Round, Division of Rheumatology, Department of Medicine, University of California, Los Angeles, USA, October 1995

98. Genetic predisposition of systemic lupus erythematosus. Specialty Laboratories, California, Los Angeles, USA, November 1995
99. Preliminary experience of bronchiolitis obliterans with organising pneumonia (BOOP) in Hong Kong. 4th Congress of the Asian Pacific Society of Respiriology, Beijing, China 1996.
100. Development of rheumatology in Hong Kong. Division of Rheumatology, Renji Hospital, Shanghai Second Medical University, Shanghai, China, January 1996
101. Mannose binding protein in Southern Chinese patients with systemic lupus erythematosus. Division of Rheumatology, Renji Hospital, Shanghai Second Medical University, Shanghai, China, January 1996
102. Research in rheumatology. Medical Research Conference, Department of Medicine, University of Hong Kong, Hong Kong, March 1996
103. Molecular pathology of autoimmune diseases. Pamela Youde Nethersole East Hospital, Chai Wan, Hong Kong, October 1996
104. Neurological manifestations of rheumatic disorders. Topics in Rheumatic Diseases, Hong Kong Society of Rheumatology Annual Scientific Meeting, Hong Kong, October 1996
105. Rehabilitation in rheumatoid arthritis and systemic lupus erythematosus. Institute of Advanced Nursing Studies, Hong Kong, November 1996
106. Systemic lupus erythematosus – clinical and therapeutic perspectives. Department of Medicine, Ruttonjee Hospital, Hong Kong, December 1996
107. The detection and clinical significance of autoantibodies in autoimmune diseases. Hong Kong Medical Technology Association, Hong Kong, January 1997
108. The role of T cells in the pathogenesis of autoimmune rheumatic diseases. Medical Research Conference, Department of Medicine, University of Hong Kong, Hong Kong, January 1997
109. Immunological intervention in autoimmunity. “Recent Development in Hospital Practice” in celebration of the 110th Anniversary of the Faculty of Medicine of University of Hong Kong and the 60th Anniversary of Queen Mary Hospital, Hong Kong, May 1997
110. Asia Lupus Study Workshop – Hong Kong Experience. 19th International League Against Rheumatism Congress of Rheumatology, Singapore, June 1997

111. Research in systemic lupus erythematosus in Hong Kong. Department of Medicine, Ninewells Hospital and Medical Schools, University of Dundee, Dundee, UK, August 1997
112. The use of steroid in rheumatoid arthritis. Hong Kong Society of Rheumatology Annual Scientific Meeting, Hong Kong, October 1997
113. Rheumatic disease and their medical treatment. Department of Rehabilitation Sciences, Hong Kong Polytechnic University, Hong Kong, November 1997
114. Use of anti-ribosomal P antibody in diagnosis of cerebral lupus: superiority of western blotting over elisa. 2nd Medical Research Conference (MRC 1997), Hong Kong, China, January 1997
115. T-Lymphocyte activity in autoimmune diseases, 2nd Medical Research Conference (MRC 1997), Hong Kong, China, 25-26 January, 1997
116. Peripheral lymphocyte apoptosis and bcl-2 expression in systemic lupus erythematosus: correlation with disease activity. 2nd Medical Research Conference (MRC 1997), Hong Kong, China 25-26 January, 1997
117. Increase in mutation of codon 54 of mannose-binding protein in Chinese HBsAg cirrhotics with spontaneous bacterial peritonitis. The 1997 Digestive Disease Week and the 97th Annual Meeting of the American Gastroenterological Association (AGA), Washington DC, USA, 11-14 May 1997
118. In vitro characterisation of immunosuppressive activity of triptolide. The 2nd Medical Research Conference (MRC 1997), Hong Kong, China, 25-26 January 1997.
119. Dysfunctional allele of the mannose binding protein gene in rheumatoid arthritis – a preliminary study. The 2nd Medical Research Conference (MRC 1997), Hong Kong, China, 25-26 January 1997
120. Novel immunomodulatory therapies for rheumatoid arthritis. Department of Rheumatology, First Military Hospital, Guangzhou, January 1998
121. Arthritis and Rheumatism. Department of Orthopaedic Surgery, Duchess of Kent Children's Hospital, Hong Kong, July 1998
122. Clinical presentation and treatment of common rheumatic diseases. The Pharmaceutical Society of Hong Kong, Hong Kong, September 1998
123. Treatment of difficult rheumatoid arthritis. Pamela Youde Nethersole East Hospital, Chai Wan, Hong Kong, October 1998
124. Treatment of common rheumatic disorders in Hong Kong. Department of Rehabilitation Sciences, Hong Kong Polytechnic University, Hong Kong, November 1998

125. Current trends in drug treatment in rheumatoid arthritis. Association of Private Orthopaedic Surgeons, Hong Kong, January 1999
126. The diagnosis and management of rheumatoid arthritis. Hong Kong Baptist University, Hong Kong, March 1999
127. Update on the treatment of rheumatoid arthritis. Hong Kong College of Physicians, Hong Kong, May 1999
128. Modern trends in drug treatment in rheumatoid arthritis. Union Hospital CME Programme. Union Hospital, Shatin, Hong Kong, June 1999
129. New therapies for Arthritis. Quality Health Care CME programme, Hong Kong, October 1999
130. Diagnosis of common arthritis. Associacao Dos Medicos De Macau Da Faculdade De Medicina Da Universidade Jinan, Macau, November 1999
131. Advances in the treatment of chronic arthritis. Associacao Dos Medicos De Macau Da Faculdade De Medicina Da Universidade Jinan, Macau, November 1999
132. Novel therapy for rheumatoid arthritis. Hong Kong Sanatorium and Hospital CME for Physicians Programme, Hong Kong, November 1999
133. Advances in the treatment of rheumatoid arthritis. Hong Kong College of Family Physicians, Hong Kong, December 1999
134. Advances in arthritis treatment. Associacao Chinesa dos Profissionais de Medicina de Macau, Macau, February 2000
135. An overview of systemic lupus erythematosus. The Hong Kong Society for Immunology Annual Scientific Meeting, Hong Kong, March 2000
136. Writing the manuscript: From beginning to end. Workshop on Biomedical Writing. The 9th Asia Pacific League of Associations for Rheumatology Congress, Beijing, China, May 2000
137. The use of low dose methotrexate in ankylosing spondylitis. Concurrent Symposium on Ankylosing Spondylitis. The 9th Asia Pacific League of Associations for Rheumatology Congress, Beijing, China, May 2000
138. Mannose binding lectin and autoimmune disease. Concurrent Symposium on Pathogenesis of Systemic Lupus Erythematosus. The 9th Asia Pacific League of Associations for Rheumatology Congress, Beijing, China, May 2000
139. The need for tools to measure rheumatic disease outcomes in the Asia Pacific region. Concurrent Symposium on the Diagnosis & Measurement for Rheumatic Disease. The

- 9th Asia Pacific League of Associations for Rheumatology Congress, Beijing, China, May 2000
140. Celecoxib in everyday practice – the Asian perspectives. Satellite Symposium. The 9th Asia Pacific League of Associations for Rheumatology Congress, Beijing, China, May 2000
 141. Autoimmune disease in pregnancy. Medical Disease in Pregnancy. Postgraduate Study Day, Department of Obstetrics and Gynaecology, University of Hong Kong, Hong Kong, June 2000
 142. The use of prostacyclin in general medicine. The Shanghai-Hong Kong Medical Forum, Shanghai, China, July 2000
 143. Steroid induced osteoporosis – local perspectives. Hong Kong Medical Forum, Hong Kong, July 2000
 144. Immunomodulatory therapy for rheumatoid arthritis. Hong Kong Medical Technology Association, Hong Kong, September 2000
 145. Crystal induced arthritis. The Hong Kong Society of Rheumatology Annual Meeting, Hong Kong, October 2000
 146. The use of ARAVA in rheumatoid arthritis. Guangzhou-Hong Kong Annual Rheumatology Meeting, Huizhou, China, November 2000
 147. Use of ARAVA: Local experiences and practical issues. Hong Kong Society of Rheumatology Scientific Meeting, Hong Kong, November 2000
 148. Management of inflammatory low back pain. The Hong Kong College of Family Physician, Hong Kong, December 2000
 149. Connective tissue disorders in general practice. The 7th HKDU Sunday Afternoon Symposium on Rheumatology and Orthopaedics for General Practitioners. Hong Kong Doctors' Union, Hong Kong, February 2001
 150. Back pain. Rheumatology One Day Training Course. The Hong Kong Society of Rheumatology, Hong Kong, February 2001
 151. NSAID gastropathy. A worldwide problem & perspectives from Asia. VIOXX launch symposia, Hangzhou, Wuhan, Shanghai, China, March 2001
 152. How to get a paper published in a reputable journal. 4th Workshop in Rheumatology, A Joint Meeting of the Singapore Society of Immunology, Allergy and Rheumatology (SSIAR) and the Malaysian Society of Rheumatology (MSR), Singapore, September 2001

153. Pathogenesis and treatment of scleroderma. International Joint Congress of the Royal College of Pathologists of Australia, The Hong Kong College of Pathologists and the Hong Kong Division of the International Academy of Pathology “Challenges and Opportunities in Pathology”, Hong Kong, October 2001
154. Immunopathogenesis & treatment of systemic sclerosis. The Hong Kong College of Pathologists, Hong Kong, October 2001
155. Immunotherapy in rheumatic diseases. Union Hospital. 19 October 2001
156. Immunopathogenesis of systemic lupus erythematosus. Hong Kong Medical Technology Association, Hong Kong, November 2001
157. The use of rofecoxib in rheumatoid arthritis. Satellite Symposium, Second Huaxia Congress on the Diagnosis and Management of Rheumatic Diseases, Guangzhou, China, December 2001
158. Advances in rheumatoid arthritis. Federation of Medical Societies of Hong Kong, Hong Kong, January 2002
159. Autoimmune disorders and antiphospholipid syndrome – Management issues in pregnancy. Perinatal Medicine in the 21st Century, Perinatal Symposium, Hong Kong, January 2002
160. Thunder god vine and rheumatoid arthritis. Eddie Wang Chinese Medicine Symposium 2002, TWGHs-HKU, Faculty of Medicine, University of Hong Kong, Hong Kong, February 2002
161. Common rheumatic emergencies. Hong Kong Medical Forum, Department of Medicine, Faculty of Medicine, University of Hong Kong, Hong Kong, July 2002
162. Contemporary approach to managing musculoskeletal pain. Hong Kong College of Physicians, Hong Kong, July 2002
163. Preliminary in vitro studies of TCM in rheumatoid arthritis. Symposium on TCM and Immunology, Hong Kong Society for Immunology, Hong Kong, September 2002
164. SLE & connective tissue diseases. Certificate Course on Rheumatology, The Federation of Medical Societies of Hong Kong, Hong Kong, September 2002
165. Office Rheumatology: soft tissue rheumatism. Annual Scientific Meeting, Hong Kong Society of Rheumatology, Hong Kong, November 2002
166. Lupus nephritis: assessing disease activity and severity. Meet the Professor, 10th Asia Pacific League of Association for Rheumatology (APLAR) Congress of Rheumatology, Bangkok, December 2002

167. Clinical manifestations of neuropsychiatric lupus syndromes. 10th Asia Pacific League of Association for Rheumatology (APLAR) Congress of Rheumatology, Bangkok, December 2002
168. Practical aspects of clinical trial methodology: recruitment of patients and formulating a budget. 10th Asia Pacific League of Association for Rheumatology (APLAR) Congress of Rheumatology, Bangkok, December 2002
169. Novel therapies for osteoarthritis. Hong Kong Medical Forum, Department of Medicine, Faculty of Medicine, University of Hong Kong, Hong Kong, July 2003
170. Approach to connective tissue diseases. Hong Kong Doctors' Union CME Programme, Hong Kong, July 2003
171. Diagnosis and early treatment of common arthritis. Solar-Med Limited and Genzyme Corporation Limited, Hong Kong, September 2003
172. Rheumatological emergencies. 16th Annual Scientific Meeting, Hong Kong Society of Rheumatology, Hong Kong, November 2003
173. International perspective and HKU – Assessment: UK perspective similarities and differences with the HKU curriculum, Frontiers in Biomedical Research, Faculty of Medicine, University of Hong Kong, Hong Kong, December 2003
174. Rheumatic disease and the eye. Annual Scientific Meeting, Hong Kong Ophthalmological Symposium, Hong Kong, December 2003
175. Current status in the medical treatment of osteoarthritis. The First Hong Kong International Orthopaedic Forum, Hong Kong, April 2004
176. Treatment options for common rheumatic disorders. 6th Malaysia/Singapore Workshop in Rheumatology, Penang, Malaysia, July 2004
177. Treatment of difficult SLE. Systemic Lupus Erythematosus Special Interest Group Workshop. 11th APLAR Bi-annual Congress, Jeju Island, Korea, September 2004
178. Novel disease modifying anti-rheumatic drugs and biologic agents for rheumatoid arthritis. Symposium on Advancement of Rheumatoid Arthritis, School of Chinese Medicine of Hong Kong Baptist University, Hong Kong, September 2004
179. Constructing examination questions – Asia Medical Education Association Meeting, Hong Kong, October 2004
180. A new approach in the management of joint disease. Blackmores Symposium, Hong Kong, January 2005
181. Recent advances in medical treatment of rheumatoid arthritis. 2005 Annual Congress of the Hong Kong Society for Surgery of the Hand, Hong Kong, May 2005

182. The rheumatologist's perspective on recent coxibs' story: weighing the risks and benefits of coxibs and NSAIDs? CME Meeting for Physicians, St Teresa's Hospital, Hong Kong, June 2005
183. Targeted therapies in autoimmune diseases. Hong Kong Medical Forum, Department of Medicine, Faculty of Medicine, University of Hong Kong, Hong Kong, July 2005
184. Evidence-based pain management: How to balance the benefits and risks of COX-2 inhibitors? Hong King Medical Association, Hong Kong, July 2005
185. Short cases in Rheumatology. MRCP Teach-in Course, Hong Kong Society of Rheumatology, Hong Kong, October 2005
186. Osteoporosis in rheumatic diseases. Hong Kong Society of Rheumatology Annual Scientific Meeting, Hong Kong, October 2005
187. Research in systemic lupus erythematosus in Hong Kong. Foshan First People's Hospital, Foshan, Guangdong, China, November 2005
188. Management of systemic lupus erythematosus. Shenzhen Continued Medical Education Programme in Rheumatology, Shenzhen, November 2005
189. Is there still a role for COX-II inhibitors in the management of rheumatic diseases? Hong Kong Medical Association, Hong Kong, December 2005
190. Evidence based medicine in pain management: how to balance the risk and benefits of COX-2 specific inhibitors. Chinese Medical Association, Macau, February 2006
191. Use of intravenous gamma-globulin in the management of rheumatic diseases. Asia Autoimmunity Forum, Hong Kong, March 2006
192. Who's afraid of the big bad wolf? The University of Dundee, Dundee, April 2006
193. Rational application of recent advances in rheumatoid arthritis treatment. Hong Kong Medical Forum, Hong Kong, June 2006
194. Living in the shadow of systemic lupus erythematosus. Aspreva Symposium. Asia Pacific League of Associations for Rheumatology Congress, Kuala Lumpur, August 2006
195. It's time clinicians should adopt alternative medicine in the treatment of rheumatic diseases. Asia Pacific League of Associations for Rheumatology Congress, Kuala Lumpur, August 2006
196. Sports medicine and rheumatology. Chinese University of Hong Kong, Hong Kong, February 2007

197. Sports medicine and rheumatology. Chinese University of Hong Kong, Hong Kong, February 2007
198. The MEDAL Programme. Macau Orthopaedic Association, Macau, March 2007
199. Clinical Year in Review: Rheumatology. Hong Kong Society of Physicians, Hong Kong, March 2007
200. Gastrointestinal safety and cardiovascular risk of COX-II selective inhibitors. Macau Orthopaedic Association, Macau, March 2007
201. When to refer a patient to the rheumatologist? Hong, Kong Doctors' Union, Hong Kong, March 2007
202. Rheumatology clinical year in review. Hong Kong Society of Physicians, Hong Kong, March 2007
203. Gastrointestinal benefits vs cardiovascular risks of NSAIDs and COXII inhibitors. Macau Orthopaedic Associations, Macau, March 2007
204. The MEDAL programme. Macau Society of Physicians, Macau, March 2007
205. Update on the treatment of rheumatoid arthritis. Guangzhou Rheumatology Association, Guangzhou, China, April, 2007
206. Update on the treatment of osteoarthritis. Guangzhou Rheumatology Association, Guangzhou, China, April 2007
207. Cyclo-oxygenase II inhibitors – Safety and risk consideration. Shenzhen Rheumatology Association, Shenzhen, China, April 2007
208. Update on systemic arthritis. Hong Kong College of Orthopaedic Surgeons, Hong Kong, May 2007
209. Assessment of cerebral lupus. Australian Rheumatology Association Annual Scientific Meeting, Sydney, Australia, June 2007
210. Treatment of difficult systemic lupus erythematosus. Australian Rheumatology Association Annual Scientific Meeting, Sydney, Australia, June 2007
211. Management of lupus nephritis. Division of Rheumatology Seminar. University of Aberdeen, Aberdeen, September 2007
212. Life after Hong Kong. Huaxia Congress on the Diagnosis and Management of Rheumatic Diseases, Hong Kong, December 2007
213. Medical curriculum across the globe: United Kingdom. Frontiers in Medical Education, University of Hong Kong, Hong Kong, December 2007

214. An update on the immunopathogenesis of systemic lupus erythematosus. TMRC Conference, Glasgow, United Kingdom, February 2008
215. Scottish lupus exchange. Scottish Society for Rheumatology Meeting, Greenock, Scotland, March 2008
216. Thrombosis and SLE. Ten Topics in Rheumatology, Singapore, July 2008
217. APLAR news-update. Ten Topics in Rheumatology, Singapore, July 2008
218. Impact of xerostomia and its treatment. 13th APLAR Congress, Yokohama, Japan, September 2008
219. Pharmaceuticals versus biologics in the treatment of rheumatoid arthritis. 13th APLAR Congress, Yokohama, Japan, September 2008
220. Update on the treatment of lupus nephritis. Centre for Rheumatic Disease, Glasgow Royal Infirmary, Glasgow, United Kingdom, September 2008
221. Rheumatology context: Health issues and rheumatic disease. Scottish Occupational Therapy Association Annual Meeting, Perth, Scotland, October 2008
222. Burden of musculoskeletal disorders. Postgraduate lecture programme, Chang Gung Hospital, Kaohsiung, Taiwan, December 2008
223. Designing clinical research. First APLAR Review Course, Manila, Philippines, October 2009
224. Endothelial dysfunction is associated with decreased circulating endothelial progenitor cells in patients with systemic sclerosis. The 2009 ACR/ARHP Annual Scientific Meeting, Philadelphia, PA., 16-21 October 2009.
225. Role of biologics in rheumatoid arthritis treatment. Macau Orthopaedic Association, Macau, May 2010
226. The role of bone marrow and peripheral dendritic cells in SLE. 14th Congress of Asia Pacific League of Associations for Rheumatology (APLAR), Hong Kong, July 2010
227. Study on myeloid dendritic cells in patients of systemic lupus erythematosus. The 14th Congress of Asia Pacific League of Associations for Rheumatology, Hong Kong, China, 11-15 July 2010. DOI: <http://dx.doi.org/10.1111/j.1756-185X.2010.01492.x>
228. Studies on the function of plasmacytoid dendritic cells in healthy and systemic lupus erythematosus. The 14th Congress of Asia Pacific League of Associations for Rheumatology, Hong Kong, China, 11-15 July 2010. DOI: <http://dx.doi.org/10.1111/j.1756-185X.2010.01492.x>

229. Novel therapeutic targets in autoimmune rheumatic diseases. Hong Kong College of Physicians Annual Scientific Meeting, Hong Kong, October 2010
230. Current issues in the management of ankylosing spondylitis and rheumatoid arthritis in Asia. Asia Rheumatology Expert Advisory Council for Health (Asia REACH), Hong Kong, January 2011
231. Rheumatic diseases. Health Talk, Hong Kong, March 2011
232. Screening and diagnosis of common rheumatological disease – for young and late onset. Health Talk, Hong Kong, March 2011
233. Rheumatological or immunological diseases. “Explore the World of Medicine” Public Lecture Series, Hong Kong, April 2011
234. How to submit your paper, from the editor’s view. Envision Publication Workshop, Shanghai, China, April 2011
235. Rheumatoid Arthritis (RA). 1st Symposium of the Asia Pacific League of Associations for Rheumatology (APLAR), Taipei, Taiwan, April 2011
236. Current issues on the management of ankylosing spondylitis and rheumatoid arthritis in Asia. Asia Rheumatology Expert Advisory Council for Health (Asia REACH), Phuket, Thailand, May 2011
237. The Asian perspective on geographical/ethnic variation. Fostamatinib in SLE Scientific Advisory Board Meeting, London, United Kingdom, June 2011
238. Trial and registry data on TNF inhibitors and their implications for clinical practice in Asia. Pfizer Asia REACH Symposium: Targeting the future, Singapore, July 2011
239. Option 2: Case study: Optimizing management of ankylosing spondylitis. Pfizer Asia REACH Symposium: Targeting the future, Singapore, July 2011
240. Cardiovascular Complications of Rheumatic Diseases. Shenzhen, Dongguan, Huizhou Rheumatology Scientific Forum, Shenzhen, China, September 2011
241. Managing musculoskeletal diseases in Asia. MSD Musculoskeletal Scientific Symposium, Hong Kong, March 2012
242. Pathogenesis of systemic lupus erythematosus update. Pathology Update, The Royal College Pathologists of Australasia (RCPA), Sydney, March 2012
243. Neuropsychiatric lupus – how much do we know? Pathology Update, The Royal College Pathologists of Australasia (RCPA), Sydney, March 2012
244. Cardiovascular disease in systemic lupus erythematosus. Pathology Update, The Royal College Pathologists of Australasia (RCPA), Sydney, March 2012

245. Cardiovascular complications in rheumatic diseases. 2012 Annual Scientific Conference of Jiangsu Society for Rheumatology, Xuzhou, China, April 2012
246. Dendritic cells and autoimmune diseases. HKU & Chinese Academy of Medical Sciences 1st Joint Symposium in Translational Medicine, Beijing, China, April 2012
247. Major trends and issues in medical education and system in Hong Kong. U21 Health Sciences Group Meeting, Auckland, New Zealand, Sept 2012
248. Reducing cardiovascular risk in SLE patients. The 15th Congress of Asia Pacific League of Associations for Rheumatology, Advancing Rheumatology in the Asian Pacific Region, Dead Sea, Jordan, September 2012
249. Differentiating flare from infection. Asian Lupus Summit, Manila, Philippines, November 2012
250. Predictors of maternal-fetal outcome. Asian Lupus Summit, Manila, Philippines, November 2012
251. New insights into signal transduction: A promising target for treatment. Annual Meeting of Thai Rheumatism Association (TRA), Huahin, Thailand, March 2013
252. Credentialing: Perspectives from the Academy. Hospital Authority Convention 2013, Hong Kong, May 2013
253. The ACR guidelines on the management of lupus nephritis. Shenzhen Continuing Education Program: The First-Shenzhen-Hong Kong Cooperation Rheumatology Symposium. Shenzhen, China, May 2013
254. Contemporary approach in the management of common inflammatory arthritis. BMA (HK) Therapeutics Course – Chronic Diseases, Hong Kong, May 2013
255. Consensus definition of a low disease activity state in systemic lupus erythematosus. The Annual European Congress of Rheumatology (EULAR), Madrid, Spain, June 2013
256. Evolving paradigm of SLE management. Centro Januarío Hospital, Macau, August 2013
257. Interrelationship between pregnancy and autoimmune rheumatic disease. Symposium of Asia Pacific League of Associations for Rheumatology (APLAR), Bali, Indonesia, August 2013
258. Highlight of APLAR 2013 symposium and 2nd IJREF. Symposium of Asia Pacific League of Associations for Rheumatology (APLAR), Bali, Indonesia, August 2013
259. Update on systemic lupus erythematosus - Pathogenesis and treatment, The International Symposium for Rheumatic Disease in Asia, Japan, August 2013

260. Rheumatoid arthritis: Western medicine perspectives. Seminar on Research and Development in Chinese Medicine, Hong Kong, September 2013
261. Who are the tocilizumab patients? Actemra Symposium, Vietnam, September 2013
262. Training in rheumatology in Hong Kong. 5th International Forum on Rheumatoid Arthritis, Beijing, China, September 2013
263. Evaluation of the flipped classroom in undergraduate medical teaching. Frontiers in Medical and Health Sciences Education – HKU 2013, Hong Kong, December 2013
264. The use of anti-IL6 in patients with rheumatoid arthritis. Centro Januario Hospital, Macau, January 2014
265. Systemic lupus erythematosus. Chief Pharmacist's Office, Hospital Authority, Hong Kong, January 2014
266. The JAK pathway and tofacitinib mechanism of action. ASIA Reach Symposium, Hong Kong, February 2014
267. An update in the management of ankylosing spondylitis. Pfizer India International Speaker Program, India, June 2014
268. Treating to target in SLE: a new concept. 15th Malaysian Society for Rheumatology / Singapore Society for Rheumatology Annual Meeting, Kuala Lumpur, August 2014
269. Update on the treatment of SLE. 15th Malaysian Society for Rheumatology / Singapore Society for Rheumatology Annual Meeting, Kuala Lumpur, August 2014
270. Treating to target in lupus: A new concept. The Chinese Rheumatic Disease Database and Chinese Systemic Lupus Erythematosus Treatment and Research (CSTAR) 4th Annual Scientific Meeting, Beijing, October 2014
271. How to set up a rheumatology service? HKARF Rheumatology education for Mainland medical and allied health professionals, Qingyuen Hospital, China, April 2015
272. Management of systemic lupus erythematosus. HKARF Rheumatology education for Mainland medical and allied health professionals, Qingyuen Hospital, China, April 2015
273. APLAR rheumatoid arthritis treatment recommendations. Annual European Congress of Rheumatology EULAR 2015, Rome, Italy, June 2015.
274. To prepare a competent doctor. " International Forum on Quality & Safety in Healthcare, Asia, Hong Kong Convention and Exhibition Centre, September 2015

275. Training future doctors' surgical safety. Hong Kong Surgical Forum, Li Ka Shing Faculty of Medicine, October 2015
276. Treat to target in systemic lupus erythematosus: What target(s)? 粵港京风湿免疫研讨会暨第四届港大风湿论坛, Hong Kong University Shenzhen Hospital, August 2016
277. Treating to target in systemic lupus erythematosus: What target(s)? The 18th Asia Pacific League of Associations for Rheumatology (APLAR) Congress, Shanghai, China, September 2016
278. How similar is biosimilar in the perspective of our patients? Lecture for Rheumatology and GI nurses arranged by Abbvie, Sheraton Hong Kong, October 2016
279. Diagnosis of inflammatory arthritis. The 12th Rehabilitation Symposium cum the 5th Sir Harry Fang Oration of the Hong Kong College of Orthopaedic Surgeons, Prince of Wales Hospital, October 2016
280. Updates on medical treatment of inflammatory arthritis. The 12th Rehabilitation Symposium cum the 5th Sir Harry Fang Oration of the Hong Kong College of Orthopaedic Surgeons, Prince of Wales Hospital, October 2016
281. Treating-to-target in SLE: What targets? International Conference of Chinese Rheumatologists (ICCR) cum Hong Kong Society of Rheumatology Annual Scientific Meeting cum Guangdong-Hong Kong Rheumatology Seminar, Regal Kowloon Hotel, November 2016
282. Introduction on postgraduate specialist training. Career Talk on the Resident Training Program in Hospital Authority, HAHO Building, Hong Kong, January 2017
283. What if the workplace is away from home? Medical Education Conference. The Chinese University of Hong Kong, March 2017
284. Lupus nephritis: assessing disease activity and severity. Meet the Professor Session. LUPUS 2017 and ACA 2017 Congress, Melbourne, Australia, March 2017
285. A career in lupus/research: tips and inspiration. Meet the Professor Session. LUPUS 2017 and ACA 2017 Congress, Melbourne, Australia, March 2017
286. East meets West: Difficult Lupus. Meet the Professor Session. LUPUS 2017 and ACA 2017 Congress, Melbourne, Australia, March 2017
287. Validation of the lupus low disease activity score. LUPUS 2017 and ACA 2017 Congress, Melbourne, Australia, March 2017

288. What has shaped workforce strategy in Hong Kong? IGHPE 2017 Shanghai Conference: Innovative Strategies for Developing the Future Healthcare Workforce, Shanghai, 5-7 April, 2017
289. Biologic therapies in rheumatoid arthritis: Are they worth it? Public Lecture Series 2017. Lecture Theatre, The Hong Kong Central Library, June 2017
290. Lupus nephritis and rheumatoid arthritis. Faculty of Medicine Public Lecture Series 2017, Hong Kong Central Library, June 2017
291. From common core curriculum to the 130th MBBS curriculum reform. General Education Conference 2017: Evolution and Transformation. The Hong Kong Polytechnic University June 2017
292. Meeting the challenges of healthcare delivery in 21st Century. MPS Conference, Kowloon Shangri-La, June 2017
293. Rheumatoid arthritis treatment guideline update. Sofitel Macau at Ponte 16, Rua do Visconde Paco de Arcos, Macau, June 2017
294. Overview of the graduate medical education in Hong Kong. Summit forum of standardized residency training. Zhongzhan Hospital, Fudan University, Shanghai, July 2017
295. Perspectives from Hong Kong: Training the future physicians. 51st Malaysia-Singapore Congress of Medicine, Singapore, July 2017
296. Novel therapies for spondyloarthritis. 5th Rheumatology Conference of the Hong Kong University Shenzhen Hospital, Shenzhen, July 2017
297. How to build a culture of reflection in medical training programmes? 2017 IAMRA Symposium on Continued Competence, London, October 2017
298. The future of rheumatology in Asia. International Conference of Chinese Rheumatologists (ICCR 2017), Regal Kowloon Hotel, Hong Kong, November 2017
299. 住院医师能力评价和反馈. Dr Sun Yat Sen Medical University, Guangzhou, December 2017
300. Introduction on postgraduate specialist training. Career Talk on 2018/19 HA Resident Training Program, Hong Kong Academy of Medicine Jockey Club Building, January 2018
301. An introduction to the Hong Kong Academy of Medicine. Bangladesh College of Physicians and Surgeons, Dhaka, January 2018
302. Training of medical specialists in Hong Kong. Second China-Pakistan Medical Association Conference, Beijing, January 2018

303. 从亚洲角度看医学教育师资培养. 中山医学教育国际论坛, 粤港澳大湾区医学教育论坛, 广东省医师协会毕业后医学教育工作委员会年会. Guangzhou, March 2018
304. APLAR rheumatoid arthritis treatment recommendations. Pfizer Dinner Symposium, Renaissance Hong Kong Harbour View Hotel, April 2018
305. Revised RA treatment recommendations. 22nd Annual International Conference, Pakistan Society for Rheumatology, Lahore, Pakistan, April 2018
306. Social determinants of health. American College of Physician's International Medicine Meeting, New Orleans, USA, April, 2018
307. Recent progress in the treatment of systemic lupus erythematosus. 23rd Annual Scientific Meeting China Rheumatology Association, Fuzhou, China, May 2018
308. Model of university governance: The University of Hong Kong. Vietnam Leadership Course, Ho Chi Minh City, June 2018
309. Introduction to change management. Vietnam Leadership Course, Ho Chi Minh City, June 2018
310. The role of a leader. Vietnam Leadership Course, Ho Chi Minh City, June 2018
311. Presidents' round table discussion – Maintenance of competency. 52nd Malaysia-Singapore Congress of Medicine, Kuala Lumpur, July 2018
312. 大湾区医疗机构发展暨医疗人才培养研讨会 - 全科医生培训. Guangzhou, August 2018
313. Revised APLAR rheumatoid arthritis treatment recommendations. 20th Asia Pacific League of Associations for Rheumatology, Kaohsiung, September 2018
314. IgG4 related disease case series: Experience in Hong Kong. 20th Asia Pacific League of Associations for Rheumatology, Kaohsiung, September 2018
315. APLAR spondyloarthritis treatment recommendations. SpA Forum and Workshop. HKU-SZN Hospital, Shenzhen, September, 2018
316. Training in medical ethics and morality. World Health Conference, The Chinese Medical Association, Hangzhou, October 2018.
317. Disruptions in medicine: what are the impacts? The Society of Physicians of HK Annual Scientific Meeting, Langham Hotel, Nov 2018

318. Improving outcomes of lupus related recurrent abortion. 6th World Congress on Controversies, Debates & Consensus in Bone, Muscle & Joint Diseases (BMJD), Bangkok, Thailand, November 2018
319. Update on management of painful arthritis. Annual Scientific Meeting in Anaesthesiology 2018, Hong Kong Convention and Exhibition Centre, November 2018
320. The development of treatment recommendations for rheumatoid arthritis in the Asia Pacific region”? International Conference of Chinese Rheumatologists (ICCR 2018), November 2018
321. Application to leadership in the East Asian Context. Executive Leadership Course, Leading Change in Health Professional Education in Vietnam, Da Lat, Vietnam, 15-16 January, 2019
322. Case illustration in how to create and sustain a culture of innovation, creativity and diversity. Executive Leadership Course, Leading Change in Health Professional Education in Vietnam, Da Lat, Vietnam, 15-16 January, 2019
323. JAK inhibitors review and consensus statement. 2019 Asia REACH Summit on Inflammation and Immunology. Le Meridien Hotel, Chiang Mai, Thailand, 26–27 January, 2019
324. What’s new with APLAR? 2019 Asia REACH Summit on Inflammation and Immunology. Le Meridien Hotel, Chiang Mai, Thailand, 26–27 January, 2019
325. Treating Rheumatoid Arthritis in Asia. Philippine Rheumatology Association (PRA) Annual Meeting 2019, SMX Convention Center, Lanang, Davao City, Philippines, 7-9 March 2019
326. Janus Kinase review. What does the latest Asia guidelines say? JAK inhibitors review & Hong Kong consensus statement. Dinner Symposium arranged by Pfizer, Macau, 4 April 2019
327. 香港畢業後醫學模擬訓練與教員發展(Simulation training and faculty development). 廣東省醫師協會畢業後醫學教育工作委員會年會 深圳 (20-21 April 2019)
328. Disruptions in medicine: Impact on specialist training. Hong Kong Hospital Authority Convention 2019, Hong Kong Convention & Exhibition Centre, 14-15 May 2019
329. Treatment of rheumatoid arthritis: The “orally available biologics”! The British Medical Association (HK) Advance in Therapeutics Course 2019, Hong Kong 27 May 2019

330. 香港醫學專科學院在提升大灣區醫療水平上的關鍵角色 - 廣東省醫師協會 2019 年粵港澳大灣區住院醫師規範化培訓高峰論壇, 深圳 (2 June 2019)
331. Introduction of HKAM and collaboration opportunities. 18th Academic Conference of Korean Academy of Medical Sciences. 9-11 October 2019
332. Training doctors in Hong Kong. 2019 Hong Kong-Beijing-Kunming Medical Forum, 26 October 2019.
333. Quality Assurance in Postgraduate medical education in Hong Kong. 2019 Greater Bay Area Residency Forum, HKU Shenzhen Hospital, 7 December 2019
334. SLE 的診斷治療進展 – 2019 香港大學深圳醫院風濕論壇, 22 December 2019
335. Sharing from Associate Dean's perspective for undergraduate health professions education, and also medicine perspective as front-line teacher for interns and residents. HKU Med(HPE), 11 March 2020
336. What Makes a Good Rheumatologist? Focus on Rheumatoid Arthritis. Macau Society of Clinical Internal Medicine Scientific Meeting, 20 September 2020
337. Round table discussion on: Promoting the value and measuring the impact of international standards for substantive equivalency, Cologne Consensus Conference, September 2020
338. To love and heal. Gerald Choa Memorial Lecture, Hong Kong College of Physicians, 17 October 2020
339. Medical students as educators – Practical teaching tips sharing by experienced teachers. Faculty of Medicine, The University of Hong Kong, 22 December 2020
340. "Shedding light on the pandemic - Advancements in COVID-19 vaccines. The Hong Kong Science Museum, The Joseph Needham Foundation for Science and Civilisation and The Hong Kong Academy of Sciences jointly organised online public lecture. 27 February 2021
341. Case sharing – lupus nephritis. Hong Kong Lupus Nephritis (LN) Virtual Scientific Workshop, 8 April 2021
342. Review of Tofacitinib clinical data and real world evidences. 21st Singapore Society of Rheumatology-Malaysian Society of Rheumatology Workshops in Rheumatology 2021 virtual symposium. 31 July 2021
343. JAK Inhibitors for the treatment of RA and PsA: Clinical and real world data of Tofacitinib. 21st Singapore Society of Rheumatology-Malaysian Society of Rheumatology Workshops in Rheumatology 2021 virtual symposium. 31 July 2021

344. 香港畢業后醫學教育探索與實踐 – The 3rd Postgraduate Medical Education Forum in Guangdong-Hong Kong-Macao Greater Bay Area, 4 December 2021
345. Is it possible to strive for remission in rheumatoid arthritis? Meeting of Macao Physician Society and Macau Diabetes Association 2021, 5 December 2021
346. Achieving the best outcome in rheumatoid arthritis. Professorial Symposium What's New in Medicine: Hong Kong Chinese Medical Association Ltd. 9 January 2022

VII. SUPPORT FOR RESEARCH AND CLINICAL DEVELOPMENT

Support from University / Hospital Authority / Charitable Funding Bodies

1. The Nuffield Foundation – Oliver Bird Fund for Research into Rheumatism (1991)
A study to investigate the mechanisms of thrombosis in patients with anti-phospholipid syndrome
(as principal investigator) (£10,326)
2. Scottish Hospital Endowments Research Trust (1991)
The investigation of plasma fibrinolysis and the fibrinolytic potential of patients with rheumatoid vasculitis
(as principal investigator) (£11,298)
3. Committee on Research and Conference Grants, University of Hong Kong (1993)
A study to investigate the monocyte bcl-2 proto-oncogene expression and the use of plasma factor VIII von Willebrand factor antigen measurement in monitoring disease progress in patients with system lupus erythematosus
(as principal investigator) (HK\$117,750)
4. Committee on Research and Conference Grants, University of Hong Kong (1994)
Cytokine receptor expression in systemic lupus erythematosus
(as principal investigator) (HK\$100,000)
5. Committee on Research and Conference Grants, University of Hong Kong (1994)
Development of a Western blot assay to study anti-ENA antibodies in patients with systemic lupus erythematosus
(as co-investigator) (HK\$60,000)
6. Croucher Research Grants (1994)
A study to investigate the pathogenetic role of CD5+ B-lymphocyte subset in systemic lupus erythematosus
(as principal investigator) (HK\$587,833)
7. Committee on Research and Conference Grants, University of Hong Kong (1995)
The use of anti-ribosomal protein antibodies, anti-neuronal antibodies and factor VIII von Willebrand factor antigen in the diagnosis and monitoring of major neurological manifestations of SLE
(as principal investigator) (HK\$116,000)
8. Committee on Research and Conference Grants, University of Hong Kong (1995)
The chemistry and biology of anti-rheumatic drugs bucillamine and D-penicillamine
(as co-investigator) (HK\$80,000)
9. Committee on Research and Conference Grants, University of Hong Kong (1996)
The study of genetic influence on disease susceptibility and severity in patients with rheumatoid arthritis in Hong Kong
(as principal investigator) (HK\$80,000)

10. Earmarked Grant for Research, Research Grants Council (1996)
Investigation of anti-rheumatic drugs: triptolide, bucillamine and their analogues
(as principal investigator) (HK\$692,000)
11. Post-doctoral research fellowship grant for Dr KK Tong for 3 years, University of Hong Kong (1996)
as supervisor) (HK\$828,000)
12. Committee on Research and Conference Grants, University of Hong Kong (1997)
the elucidation of the roles of regulatory suppressor T-lymphocytes in rheumatoid arthritis
as principal investigator) (HK 135,000)
13. University of Hong Kong Teaching Development Grants (1997)
establishment of a computerised archival system for teaching materials
(as co-principal investigator) (HK\$246,300)
14. Central Fund of Hong Kong Polytechnic University (1998)
An evaluation of combined psychological treatment and occupational therapy in the
management of patients with rheumatoid arthritis in Hong Kong
(as co-investigator) (HK\$110,000)
15. Committee on Research and Conference Grants, University of Hong Kong (1998)
The role of interleukin-15 in the pathogenesis of rheumatoid arthritis
(as principal investigator) (HK\$106,000)
16. Health Services Promotion Fund (1999)
Translation and validation of Arthritis Impact Measurement Scale-2 (AIMS-2) into
Chinese
(as co-principal investigator) (HK\$88,600)
17. Committee on Research and Conference Grants, University of Hong Kong (1999)
Elucidation of the mechanism of impaired mannose binding lectin production in
systemic lupus erythematosus
(as principal investigator) (HK\$88,600)
18. Post-doctoral fellowship grant for Dr Y Ren for 2 years, University of Hong Kong (1999)
(as supervisor) (HK\$588,000)
19. Vice-Chancellor's Development Fund on Chinese Medicine, School of Traditional Chinese Medicine, University of Hong Kong (1999)
Elucidation of the effects of triptolide & its analogues on immunomodulatory cell &
synovial fibroblast function in rheumatoid arthritis
(as principal investigator) (HK\$175,000)

20. Merck Educational Grant (1999)
A study of the socio-economic impact of rheumatoid arthritis and osteoarthritis and their treatment side-effects in Hong Kong
(as principal investigator) (HK\$76,000)
21. Research Grants Council Earmarked Grant (1999)
The role of adrenomedullin in inflammation
(as co-investigator) (HK\$763,200)
22. Research Grants Council Earmarked Grant (1999)
B cell apoptosis in systemic lupus erythematosus
(as co-investigator) (HK\$690,000)
23. University Research Grants (2000)
Towards a better understanding of the role of nitric oxide in the pathogenesis of systemic sclerosis
(as principal investigator) (HK\$120,000)
24. University Research Grants (2001)
A study to investigate the handling of apoptotic cells by phagocytes in systemic lupus erythematosus
(as principal investigator) (HK\$60,000)
25. Earmarked Research Grant, Research Grants Council (2002)
A randomised double-blind, placebo-controlled crossover clinical study of the efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome
(as co-investigator) (HK\$423,010)
26. Small Project Funding Programme, Committee on Research and Conference Grants (CRCG) (2002)
Effects of sex hormones on lymphocyte function in systemic lupus erythematosus
(as principal investigator) (HK\$87,900)
27. Department of Medicine, University of Hong Kong (2002)
Expression of cyclooxygenase iso-enzymes in the salivary gland of patients with primary Sjögren's syndrome
(as principal investigator) (HK\$100,000)
28. Vice-Chancellor's SARS Research Fund, University of Hong Kong (2003)
A study to evaluate the immunopathology of severe acute respiratory syndrome
(as principal investigator) (HK\$100,000)

29. Small Project Funding Programme, Committee on Research and Conference Grants (CRCG), University of Hong Kong (2003)
Evaluation of the effects of sex hormones on neutrophils and macrophage apoptosis and macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus
(as principal investigator) (HK\$68,000)
30. Earmarked Research Grant, Research Grants Council (2003)
Complement deficiency and dendritic cell function in the pathogenesis of systemic lupus erythematosus
(as principal investigator) (HK\$939,968 + HK\$50,000 University of Hong Kong Matching Grant = HK\$989,968)
31. Integrated Chinese Medicine Holdings (2003)
Evaluation of the effects of Lingzhi and Huangqi on rheumatoid arthritis
(as principal Investigator) (HK\$265,166)
32. Janssen & Cilag Research Fund (2005)
Socio-economic costs of rheumatoid arthritis in Hong Kong
(as principal Investigator) (HK\$50,000)
33. Small Project Funding Programme, Committee on Research and Conference Grants (CRCG), University of Hong Kong (2005) – Dendritic cell function and their effects on B cell activation in systemic lupus erythematosus
(as principal investigator) (HK\$66,150)
34. Small Project Funding Programme, Committee on Research and Conference Grants (CRCG), University of Hong Kong (2005)
p21 gene polymorphism with systemic lupus erythematosus and rheumatoid arthritis
(as co-investigator) (HK\$ 66,150)
35. Small Project Funding Programme, Committee on Research and Conference Grants (CRCG), University of Hong Kong (2006)
Association of B Lymphocyte Stimulator (BLyS) gene polymorphisms with systemic lupus erythematosus (SLE)
(as co-investigator) (HK\$70,000)
36. Croucher Foundation Conference Organising Grant (2006)
Asia Autoimmunity Forum
(as **Chairman** of organising committee) (HK\$76,000 + HK\$28,500 HK SAR Government matching grant = HK\$105,000)
37. Aspreva Investigator Research Grant (2006)
(as co-principal investigator) (US\$100,000 + US\$50,000 HK SAR Government matching grant = US\$150,000)

38. The Institute of Cardiovascular Research (2007)
Pathogenesis of inflammatory autoimmune diseases
(as principal investigator) (£25,000)
39. Tenovus (2008)
Early atherosclerosis in young patients with systemic lupus erythematosus: Utilization of a novel ex-vivo model of endothelial dysfunction
(as co-principal investigator) (£10,000)
40. Tenovus (2008)
A multi-user Machine: the Radox RX Daytona clinical chemistry system
(as co-investigator) (£10,000)
41. Anonymous Trust (2008)
Effects of high dose UVA1 phototherapy on cutaneous fibrosis and endothelial cell function in patients with systemic sclerosis
(as co-principal investigator) (£9,900)
42. Tenovus (2009)
An investigation of the level of immune cell activity and its regulation in patients with systemic lupus erythematosus
(as principal investigator) (£10,000)
43. Lupus UK (2009)
Lupus UK East of Scotland Nurse
(as co-principal investigator) (£155,830)
44. Seed Fund Scheme, Stem Cell and Regenerative Medicine Consortium (2010)
Immunogenicity of hESC and iPSC-derived grafts using a humanized mouse model
(as co-principal investigator) (~HK\$716,410)
45. Seed Funding Programme for Basic Research, University of Hong Kong (2010)
Characterisation of the features and functional changes of bone marrow dendritic cells in systemic lupus erythematosus
(as principal investigator) (HK\$100,000)
46. Seed Funding Programme for Basic Research, University of Hong Kong (2010)
The effect of adrenomedullin on gene and protein expression in macrophages stimulated by tumour necrosis factor-alpha
(as co-investigator) (HK\$67,000)
47. Educational Activities to set-up a Musculoskeletal Radioimaging Training centre in Queen Mary Hospital, Pfizer (2010)
(HK\$200,000)

48. Educational Activities to set-up a Musculoskeletal Radioimaging Training centre in Queen Mary Hospital, Pfizer (2011)
(HK\$180,000)
49. The Shun Tak District Min Yuen Tong of Hong Kong (2011-2013)
Pathogenic studies of autoimmune rheumatic disease.
(as principal investigator) (HK\$1,500,000)
50. General Research Fund (2011-2014)
Functional characterization of the novel C-type lectin-like receptor CLEC16A and its expression association in systemic lupus erythematosus.
(as co-investigator) (HK\$980,000)
51. Seed Funding Programme for Basic Research, University of Hong Kong (2012)
Does adrenomedullin reduce the inflammatory response caused by advanced glycation endproducts?
(as co-investigator) (HK\$72,300)
52. Seed Funding Programme for Basic Research, University of Hong Kong (2012)
Interactions between plasmacytoid dendritic cells and T regulatory / interleukin-17 producing T-helper cells in systemic lupus erythematosus
(as principal investigator) (HK\$61,100)
53. Small Project Funding Programme, Committee on Research and Conference Grants (CRCG), University of Hong Kong (2013)
The role of plasmacytoid dendritic cells in systemic lupus erythematosus
(as principal investigator) (HK\$77,119)
54. General Research Fund (GRF) (2013-2015)
The role of regulatory microRNAs in plasmacytoid dendritic cell functions in systemic lupus erythematosus immunopathogenesis
(as principal investigator) (HK\$692,826)
55. General Research Fund (GRF) (2013-2016)
Relationship between matrix Gla protein and osteogenic endothelial progenitor cells with vascular and valvular calcification in patients with rheumatoid arthritis: Potential therapeutic role of vitamin K
(as Co- investigator) (HK\$649,524)
56. Brian and Catherine Lau unrestricted grants.
Improving the outcome of ankylosing spondylitis in Hong Kong (2014 – 2017)
(HK\$1,000,000)
57. General Research Fund (GRF). (2014-2016)
The role of IL-33 in the modulation of macrophage differentiation and immunoregulatory functions in systemic lupus erythematosus
(as Co- investigator) (HK\$866,032)

58. University Grants Committee Funding Scheme for Teaching and Learning Related Proposal (2014-2017)
Interprofessional Team-based Learning for Health Professional Students
(as Co- investigator) (HK\$5,069,000)
59. Croucher Foundation (2014-2018)
Advances in Immunology in Health and Disease (Croucher Summer Course 2014-2018)
(as **Summer Course Director**) (HK\$1,800,000)
60. Health and Medical Research Fund (2015 – 2017)
Validation of a new definition of lupus low disease activity state (LLDAS): Clinical and management implications
(as principal investigator) (HK\$476,120.00)
61. Roche Investigator-initiated Study (2016 – 2019)
A real world study comparing the efficacy and safety of tocilizumab in monotherapy and in combination with conventional synthetic disease modifying anti-rheumatic drugs
(as principal investigator) (HK\$642,369)
62. University Grants Committee Funding Scheme for Teaching and Learning Related Proposals (2016 – 2019)
Beyond the E-portfolio: Connectivity and Communities of Learning in a Virtual Environment
(as Co-investigator of the project 2014 – 2017) (HK\$5,699,225)
63. University Grants Committee Theme-based Research Scheme
Centre for Research into Circulating Fetal Nucleic Acids
(as Co-principal investigator of the project 2016-2020) (HK\$2,500,000 to HKU)
64. General Research Fund (GRF) (2017-2020)
Regulation of inflammasome activation in systemic lupus erythematosus
(as Co-investigator of the project) (HK\$1,229,089)
65. Mr M Hui and Family Donation (2018)
Drug allergy testing and desensitization
(as Co-principal investigator) (HK\$1,200,000)
66. Health and Medical Research Fund (2019 – 2020)
Dysregulation of interleukin-18 receptor accessory protein in neutrophils of lupus nephritis patients – a pilot study
(as principal investigator of the project) (HK\$100,000)
67. Innovation and Technology Commission (ITC) (2020-2025)
Health@InnoHK (ITC), Centre for Translational Stem Cell Biology (CTSCB)
(as Co- principal investigator) (HK\$ 284.6M)

68. RGC Collaborative Research Fund COVID-19 and Novel Infectious Disease Exercise
(Ref: C7154-20G) 2021-2024)
A multinational big data Covid-19 Epidemiological Study on post-infection Outcomes
(ACESO)
(as Co- principal investigator) (HK\$9,691,060)
69. Health and Medical Research Fund Commissioned Grant (2021 – 2026)
The long term spill-over impact of COVID-19 on health and healthcare of patients with
non-communicable diseases: an in-depth outcome and health economic evaluation
(as Co-investigator) (HK\$9,334,600)
70. Health and Medical Research Fund Commissioned Grant (2021 – 2024)
COVID-19 vaccines adverse events response and evaluation (CARE) programme
(as Co-investigator of the project (HK\$10,000,000)

Support through Pharmaceutical Industry Sponsored Clinical Studies (all as principal investigator)

1. Merck & Co, Inc (1999) – A double-blind randomised, stratified, parallel-group study to assess the incidence of PUBs during chronic treatment with MK-0966 or naproxen in patients with rheumatoid arthritis (HK\$782,640)
2. GD Searle and Co. (1999) – A multicentre, double-blind, parallel group study comparing the efficacy and incidence of gastroduodenal ulcer associated with SC-58635 100mg bid with that of diclofenac 50mg bid taken for 12 weeks in patients with osteoarthritis or rheumatoid arthritis in Hong Kong (US\$25,226)
3. Merck & Co, Inc (1999) – An active comparator- and placebo-controlled, parallel-group, double-blind, 52-week study to assess the safety and efficacy of 25 mg and 50 mg MK-0966 daily in rheumatoid arthritis patients (HK\$280,000)
4. Hoechst Marion Roussel China Limited (1999) – Evaluation of the efficacy and safety of leflunomide 20 mg tablets once daily vs methotrexate 7.5 – 10 mg tablets weekly in adult patients with active rheumatoid arthritis (HK\$280,000)
5. Pharmalink International Limited (2001) – Treatment of knee and hip osteoarthritis with lyprinol (US\$90,000)
6. Serono International SA (2002) – A multicentre, randomised, double-blind, placebo-controlled phase II study of subcutaneously administered oncept in the treatment of patients with active psoriasis and psoriatic arthritis (HK\$187,735)
7. Merck & Co, Inc (2002) – A randomised, double-blind, active-comparator-controlled, parallel-group study to evaluate the safety of etoricoxib in patients with osteoarthritis or rheumatoid arthritis (HK\$385,610)
8. Novartis Pharmaceuticals Ltd (2004) – A multinational, multicenter, randomized, double-blind, double-dummy, stratified, active controlled parallel group study comparing the efficacy and safety of intravenous zoledronic acid, 5 mg once yearly, and oral risedronate, 5 mg daily, in the prevention and treatment of corticosteroid induced osteoporosis (HK\$356,318)
9. Roche Ltd (2005) – A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy (HK\$361,345)
10. Roche Ltd (2005) – A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with methotrexate in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current methotrexate therapy (HK\$361,345)

11. Roche Ltd (2005) – Extension study of the safety and efficacy of MRA in combination with traditional DMARD therapy in patients with rheumatoid arthritis (HK\$666,000)
12. Roche Ltd (2005) – Extension study of the safety and efficacy of MRA in combination with methotrexate in patients with rheumatoid arthritis (HK\$1,110,000)
13. La Jolla Pharmaceutical Company (2006) – A randomized, double-blind, placebo-controlled, four-arm, parallel group, multi-center, multi-national, safety and efficacy trial of 100 mg, 300 mg, and 900 mg of abetimus sodium in systemic lupus erythematosus patients with a history of renal disease (HK\$217,194)
14. Roche Product Limited (2008) – International open-label study to evaluate the safety, tolerability and efficacy of tocilizumab in patients with active rheumatoid arthritis on background non-biologic DMARDs who have an inadequate response to current non-biologic DMARD or anti-TNF therapy.
15. Roche Product Limited (2010) – A randomized, double-blind, parallel group study of the safety and effect on clinical outcome of tocilizumab SC versus tocilizumab IV, in combination with traditional disease modifying anti-rheumatoid arthritis drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis (\$276,472)
16. Anthera Pharmaceuticals, Incorporated (2011) – A randomized, double-blind phase 2b study to evaluate the efficacy, safety, and tolerability of A-623 administration in subjects with systemic lupus erythematosus (\$1,286,334)
17. AstraZeneca Limited (2011) - A multi-centre, randomised, double-blind, placebo controlled, parallel group dose ranging study in Asia evaluating efficacy and safety of fostamatinib in patients with active rheumatoid arthritis who are inadequate responders to methotrexate therapy. (\$548,478)
18. AstraZeneca Limited (2011) - A long-term study to assess the safety of fostamatinib in the treatment of rheumatoid arthritis in Asia (\$457,612)
19. MedImmune, LLC (2012) – A phase 2, randomized study to evaluate the efficacy and safety of MEDI-546 in subjects with systemic lupus erythematosus (\$1,409,741)
20. Pfizer Corporation Hong Kong Limited (2012) - A randomized, double-blind, placebo-controlled study of the safety and efficacy of etanercept in subjects with rheumatoid arthritis who have had an inadequate response to adalimumab or infliximab plus methotrexate (\$160,746)
21. Sanofi-Aventis Hong Kong Limited (2012) - A randomized, double-blind, parallel, placebo-controlled study assessing the efficacy and safety of sarilumab added to non-biologic DMARD therapy in patients with rheumatoid arthritis who are inadequate responders to or intolerant of TNF- α antagonists (\$277,983)

22. Sanofi-Aventis Hong Kong Limited (2013) - A multi-center, uncontrolled extension study evaluating efficacy and safety of SAR153191 on top of DMARDs in patients with active Rheumatoid Arthritis (RA). (\$405,622)
23. Pfizer Inc (2014 - 2021) - Phase 3B/4 randomized safety endpoint study of 2 doses of tofacitinib in comparison to a tumor necrosis factor (TNF) inhibitor in subjects with rheumatoid arthritis. (as Co-I) (HK\$ 372,650.53)
24. AbbVie (2016-present) - A phase 3, randomized, double-blind study comparing upadacitinib (ABT-494) to placebo and to adalimumab in subjects with moderately to severely active rheumatoid arthritis who are on a stable background of methotrexate (MTX) and who have an inadequate response to MTX (MTX-IR). (as Co-I) (2016-present) (HK\$ 884,809.91)
25. Gilead Sciences Inc (2016 - 2019) - A randomized, double-blind, placebo- and active-controlled, multicenter, phase 3 study to assess the efficacy and safety of Filgotinib administered for 52 weeks alone and in combination with Methotrexate (MTX) to subjects with moderately to severely active rheumatoid arthritis who are naïve to MTX therapy. (as Co-I) (HK\$ 393,410.47)
26. Gilead Sciences Inc (2016 - 2019) - A randomized, double-blind, placebo- and active-controlled, multicenter, phase 3 study to assess the efficacy and safety of filgotinib administered for 52 weeks in combination with methotrexate to subjects with moderately to severely active rheumatoid arthritis who have an inadequate response to Methotrexate. (as Co-I) (HK\$ 437,349.43)
27. AstraZeneca Limited – (2021) A multicentre, randomised, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of anifrolumab in Asian participants with active systemic lupus erythematosus. (as co-PI) (HK\$ 433,060.13)
28. Janssen Pharmaceuticals – (2022) Dissecting leukocyte heterogeneity in association with functional response in the development of nephritis in systemic lupus erythematosus (Immunology) (as co-PI). (HK\$3.81M)
29. J & J – (2022) – A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus. (as PI) [Study no: 80202135SLE2001 / CTC no: 2201HKU1 / Study budget in clinical trial agreement: under preparation]
30. J & J – (2022) – A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Nipocalimab in Adult Participants with Active Lupus Nephritis. (as PI) [Study no: 80202135LUN2001 / CTC no: 2202HKU1 / Study budget in clinical trial agreement: under preparation]
31. Provention – (2022) – Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 Evaluation In Lupus (PREVAIL-2). (as PI) [Study no: PRV-3279-2a / CTC no: 2273HKU1 / Study budget in clinical trial agreement: under preparation]

VIII. TEACHING DUTIES

Key Undergraduate Curriculum Positions

1. Staff in charge of all undergraduate teaching in clinical immunology and rheumatology
2. Deputy Co-ordinator of the Musculoskeletal System Block (1997 – 2007)
3. Member of the Faculty Admissions Committee (1998)
4. **Co-chairman** of the Scientific Foundation for Clinical Practice Group (1999 – 2000).
5. Co-staff in charge of the Train the Trainers Workshops (1999 – 2007).
6. Faculty Deputy Coordinator of Phase II Block C (2000 – 2002).
7. **Chairman**, Assessment Sub-committee, Faculty Undergraduate Education Committee (2003 – 2007).
8. **Programme Director** (Professional Development of Educators and Clinicians), Institute of Health and Medical Sciences Education (2004 – 2007)
9. Deputy Chairman, Faculty Undergraduate Education Committee (2005 – 2007)
10. Assistant Dean, Education and Student Affairs (2005 – 2007)
11. Deputy Chairman, Undergraduate Curriculum Committee (2010 – 2012)
12. Integrated Block Departmental Coordinator, Year 3 Coordinating Sub-committee (2010 – 2012)
13. Departmental Coordinator, Year 3 Integrated Block Planning Group (2010 – 2012)
14. Member, Special Study Modules Sub-committee (2010 – 2012)
15. **Chairman**, Working Group on Review of Discipline-based Teaching for MBBS (2010 – 2012)
16. Member, Department Undergraduate Teaching Committee (2010 – 2013)
17. **Director**, Bau Institute of Health and Medical Sciences Education (2010 – 2018)
18. **Co-chairman**, Curriculum Review Sub-committee (2010 – 2018)
19. Member, Faculty Internship Sub-committee (2010 – 2018)
20. Member, Faculty Curriculum Development Committee (2010 – present)
21. Member, Faculty Curriculum Development Committee (FCDC) (2011)
22. MSS CS Coordinator, Clinical Skills Sub-committee (2011 – 2012)
23. Clinical Skills Coordinator, MBBS II Musculoskeletal System Block Planning Group (2011 – 2012)
24. Departmental Representative, MBBS II Musculoskeletal System Block Planning Group (2011 – 2012)
25. Integrated Block Departmental Coordinator, MBBS III Integrated Block Planning Group (5 year)/MBBS III/IV Integrated Block Planning Group (6-year) (2012 – 2013)
26. Integrated Block Departmental Coordinator, MBBS III/IV Coordinating Sub-committee (2012 – 2014)
27. Member, Special Study Modules (“SSM”) and Elective Sub-committee (2012 – 2014)
28. **Associate Dean** (Teaching and Learning) (2013 – 2018)
29. **Senior Advisor to the Associate Dean** (Teaching and Learning) (2018 – present)
30. Member of the Panel of Judges for the CHEST Delegation Prize (2020-21)
31. Member of the Panel of Judges for the Avery Chan Prize in Dermatology (2020-21)

As lecturer of the following undergraduate / postgraduate courses from other universities:

1. Napier BSC (Immunology), Hong Kong University SPACE
2. Undergraduate course in Occupational Therapy, Hong Kong Polytechnic University
3. Master in Sports Medicine, The Chinese University of Hong Kong

As external examiner of local / overseas medical schools

1. National University of Singapore, Singapore (May 2006) – Final MB examination (Medicine)
2. Jalan University, Malaysia (Aug 2014) – Final MB examination (Medicine)
3. International Medical University, Malaysia (August 2014) – Semester 9 End of Posting Examination
4. External Examiner, Final MB, The Chinese University of Hong Kong (16 April 2020)

IX. OTHER ACADEMIC ADMINISTRATIVE DUTIES

Many of my administrative duties within the Faculty and Department are reflected in my research and teaching activities above. Below are my other academic administrative duties:

Membership of Key Department and Faculty Committees

Department of Medicine

1. Staff-in-charge of audio-visual equipment
2. Member of the Clinical Management Committee
3. Co-opted member of the Committee for Selection of Lecturers (Clinical Immunology) (ad hoc)
4. Member of the Advanced Internal Medicine Training Committee
5. Member of the Accommodation Committee
6. Member of the Research Postgraduate Committee
7. Vice-chairman, Organising Committee, Medical Forum (2000, 2001, 2003 [as **Chairman**], 2012)
8. **Chairman**, Organising Committee, Medical Research Conference (2005)
9. Member, Human Resources Committee (2010 – present)
10. **Head** of Department (2019 – present)

Faculty of Medicine

1. Member of the Library Committee, Faculty of Medicine (1996 – 1997)
2. Co-opted member of the Committee on Re-titling of Honorary Senior Clinical Teachers (ad hoc)
3. Editor of the Faculty Newsletter (2004 – 2007)
4. Member of the Wong Ching Yee Medical Scholarships Committee
5. Member, Summer Course for Secondary School Students
6. Assistant Dean, Information Technology & Planning (2001 – 2004)
7. Member of the Committee of Management of the HKU/China Medical Board Grants
8. Board of Directors of the Clinical Trials Centre (2004 – 2007)
9. Member, Faculty Higher Degrees Committee (2003 – 2007)
10. Member, Faculty Research Committee (2003 – 2007)
11. Member, Well-being Committee of the Programme for Effective Transition and Student Support (PETSS) (2004 – 2007)
12. Member, Organising Committee, HKU-Mayo Symposium on MRI (ad hoc)
13. Member, Faculty Outside Practice Subcommittee (2005 – present)
14. Two clinical professors of the Faculty appointed by the Dean, with a term of service of 2 years, Committee of Management on the Li Shu Pui Medical Foundation Clinical Fellowship Scheme (2010)
15. Member, Management Committee of the Stem Cell and Regenerative Medicine Consortium (2010-2012)
16. Member, Organising Committee of the Frontiers in Biomedical Research, HKU 2011 (2011)

17. MC Member, Clinical Affairs, Stem Cell & Regenerative Medicine Consortium (SCRMC) (2011)
18. Member, Task Force in Medical Humanities (2011)
19. Member, Promotion and Tenure Panel, Faculty of Medicine (2011 – 2014)
20. **Chairman**, Faculty-based Internship Committee (2012 – 2018)
21. Member, Committee of Management of Dr Cheng Yu Tung Fellowships (2012 – 2014)
22. Member, Faculty Human Resources Committee (2013 – 2018)
23. **Director**, Bau Institute of Medical and Health Sciences Education, Li Ka Shing Faculty of Medicine, University of Hong Kong (2013-2018)
24. **Chairman**, Faculty Board, Li Ka Shing Faculty of Medicine, The University of Hong Kong (11/2019 – present)

The University of Hong Kong

1. Advisor, Academic Advisory Committee for Diploma in Medical Nursing, HKU SPACE (1998 – 2000)
2. Co-opted Member, Research Panel for Medicine, University's Committee on Research and Conference Grants (2002 – 2006)
3. Member, Committee for the Review of the Faculty of Dentistry (2011)
4. Member, Working Group on Massive Open Online Courses (2013 – 2018)
5. Member, Curriculum Development Committee (2014 – 2018)
6. Member, Search Committee for the Dean of Medicine (2012 – 2013)
7. Member, University Admissions Committee (2013 – 2018)
8. Member, The University's Teaching and Learning Quality Committee, University of Hong Kong (07/14 – 2018)
9. Member, Working Group on the Undergraduate Research Fellowship Programme, University Research Committee, The University of Hong Kong (11/2015 – 2018)
10. Member, Senate, The University of Hong Kong (2016-2022)
11. Member, Disciplinary Committee, The University of Hong Kong (2017 – present)
12. Member, the Court, The University of Hong Kong (2017 – present)
13. Member, Search Committee for President (Vice-chancellor), The University of Hong Kong (2017)
14. Member, Panel on the Review of the Faculty of Engineering, The University of Hong Kong (2018)
15. **Chairman**, Review Committee of the Science Majors Curriculum of the Faculty of Science, The University of Hong Kong (2018)
16. Co-opted member, Committee on Higher Doctorates, The University of Hong Kong (2018 - 2020)
17. Internal member, Review Panel, Taught Postgraduate Curricula of the Faculty of Dentistry (2018 – 2019)
18. Member, Research Support and Grants Sub-Committee, The University of Hong Kong (1 December 2019 – 30 November 2021)
19. Member, Conference, Fellowship and Other Travel Sub-Group, The University of Hong Kong (1 December 2019 – 30 November 2021)
20. **Chairman**, Committee on Higher Doctorates, The University of Hong Kong (1 July 2020 – 30 June 2022)
21. **Chairman**, Review Panel for the Institute for Advanced Dentistry, Faculty of Dentistry, The University of Hong Kong (2020 – present)

22. Panel Member, Committee of Inquiry into Possible Good Cause, The University of Hong Kong (1 July 2020 – 30 June 2022)
23. Member, Staff Grievances Panel, The University of Hong Kong (March 2020 – present)

X. KNOWLEDGE EXCHANGE AND PUBLIC SERVICES

Membership of Non-Government Organisations

- 1989 – 1992** Honorary Advisor
Dundee Rheumatoid Arthritis Self Help Group
- 1992 – present** Honorary Advisor
Hong Kong Rheumatoid Arthritis Association
- 1992 – present** Honorary Advisor
Hong Kong Lupus Association
- 1993 – present** Professional Advisor
Hong Kong Society for Rehabilitation
- 1993 – present** Honorary Advisor
Alliance for Patients' Mutual Help Organisation, Hong Kong
- 1995 – present** Honorary Advisor
B27 Association, Hong Kong
- 1996 – present** Honorary Consultant
Regeneration Society, Hong Kong
- 2001 – 2007** **Founding Chairman** (2001 – 2007)
Honorary President (2007 – present)
Hong Kong Arthritis and Rheumatism Foundation
- 2012 – 2018** Advisor of the Medicine Annual Quiz
Liberal Studies Cup on Medicine
- 2013 – Present** Honorary Advisor
Hong Kong Alliance of Patients' Organizations Limited
- 2018 – 2020** Honorary Advisor
Hong Kong Museum of Medical Sciences Society
- 2021 - present** Honorary Clinical Supervisor
The Hong Kong College of Family Physicians

Membership of Government and Public Service Organisations

- 1999 – present** Member
Subspecialty Services Development Working Group in Rheumatology
Hospital Authority
- 2000 – 2007** Subspecialty (Rheumatology) co-ordinator
E-Knowledge Gateway
Hong Kong Hospital Authority E-Knowledge Gateway
- 2000 – 2010** Member
Working Party on COX-2 inhibitors
Hospital Authority
- 2000 – 2018** Member
Internship Sub-committee of the Licentiate Committee
Medical Council of Hong Kong
- 2001 – 2007** Member
Advisory Board for Research & Development Committee
MacLehose Medical Rehabilitation Centre
- 2010 – 2018** Member
Central Internship Committee
Hospital Authority
- 2010 – 2020** Member
Credentials Sub-Committee of the Licentiate Committee
Medical Council of Hong Kong
- 2012 – 2016** Member
Education and Accreditation Committee
Medical Council of Hong Kong
- 2013 – 2018** Member
Working Group on Intern Allocation and Training
Hospital Authority
- 2013 – 2018** Co-Opted Member
Working Group on Defining High-Risk Medical Procedures/Practices
Performed in Ambulatory Setting
Department of Health
- 2014 – 2018** Member
Working Group on Medical Student Clinical Attachment
Hospital Authority

- 2014 – present** Vice-Chairman
Hong Kong Jockey Club Disaster Preparedness and Response Institute
- 2014 – present** Permanent Expert Panel Member
Central Research Working Group (CRWG) for Hospital Authority
(HA) Chinese Medicine Research
Hospital Authority
- 2015** Advisory Panel Member
Clinical Services Plan for the New Territories East Cluster, Strategy
and Planning Division
Hospital Authority
- 2015 – 2018** Member
Project Steering Committee on Standards for Ambulatory Facilities
Department of Health
- 2016 – 2020** Member
High-Level Steering Committee on Antimicrobial Resistance, Food
and Health Bureau
The Government of the Hong Kong Special Administrative Region
- 2017 – 2020** **Academic Lead**
*Medical Council of Hong Kong Licensing Examination Information
Portal*
- 2018** Member
Consultative Group on Voluntary Health Insurance Scheme
Food and Health Bureau
- 2018 – 2020** Honorary Advisor
The Hong Kong Academy of Nursing
- 2018 – 2021** Co-opted Member
Community Care Fund Task Force
- 2018 – 2022** Member
Committee on Promotion of Organ Donation
- 2018 - 2021** Member
Centralized Organ Donation Register
Department of Health
- 2018 – present** Non-official Member
Health and Medical Research Fund – Research Fellowship Assessment
Panel
Food and Health Bureau

- 2018 – present** Member
Assessment Panel for Commissioned Study on Healthcare Manpower
Planning and Projection (Extended Study)
Food and Health Bureau
- 2018 – present** Member
Assessment Panel for the Commissioned Study on Regulatory
Framework for Healthcare Professionals (Extended Study)
Food and Health Bureau
- 2018 – present** Member
Task Force on Limited Registration Scheme
Hospital Authority
- 2018 – 2020** Member
Forum on Training Collaboration between HA and HKAM
Hospital Authority
- 2018 – present** Member
Stakeholder Group, Hong Kong Report Card on Physical Activity for
Children and Youth
Active Healthy Kids Global Alliance
- 2018 – present** Member
Continued Competency Working Group
International Association of Medical Regulatory Authorities
- 2018 – 2020** **Chairman**
Task Force on Regulation of Advanced Therapy Products
Department of Health
- 2018 – present** Justice of the Peace
The Government of the Hong Kong Special Administrative Region
- 2018 – present** Board Member
The Hospital Authority, Hong Kong
- 2019** 副主任委員
廣東省本科高校臨床教學基地教學指導委員會
- 2019** Member
Task Group on sustainability of Hospital Authority
- 2019 – 2020** **Chairman**
External Review Panel
Macao Academy of Medicine

- 2019 – present** Full Member
The Hospital Authority, Board Alumni
- 2019 – present** **Chairman** (2019-2020), member (2021-present)
Shenzhen-Hong Kong Medical Specialist Training Centre
- 2019 - present** Director
Hong Kong Tuberculosis, Chest and Heart Diseases Association
- 2020** **Team Leader**
COVID-19 Community Testing Scheme
- 2020 – 2021** Member
Health Promotion Committee, Grantham Hospital
- 2020 – 2021** Member
Staff Training Committee, Grantham Hospital
- 2020 - present** Member
Hospital Governing Committee, Grantham Hospital
- 2020 – present** Hong Kong Convention Ambassador
Hong Kong Tourism Board
- 2020 – present** Director
Board of Directors
Hong Kong Genome Institute
- 2020 – present** Member
Scientific Advisory Committee, Hong Kong Genome Institute
- 2020 – present** **Convenor**
Advisory Panel on COVID-19 Vaccines
Hong Kong Special Administrative Region of the People's Republic of China

I have also been interviewed by many radio and tele-broadcasting agencies, including the CNN, on many occasions and contributed numerous newspaper and periodical articles on rheumatic conditions.